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Inflammatory diseases and multiple human cancers are associated with increased cyclooxygenase-2 (COX-2)
expression together with decreased expression of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). This
has been hypothesized to lead to a milieu of bioactive lipids modulating angiogenesis and cellular
proliferation. Further insight into these processes were gained by traditional cell and molecular biology
approaches, which were combined with cutting edge liquid chromatography mass spectrometry (LC-MS)
methods to elucidate the function, disposition, and metabolism of a major COX-2/15-PGDH derived
metabolite, 11-oxo-eicosatetraenoic acid (11-oxo-ETE). 11-oxo-ETE was found to possess significant anti-
proliferative activity (IC50 2 microM) in human umbilical endothelial cells (HUVECS), which was 5 times
more potent than isomeric 15-oxo-ETE. The corresponding methyl ester derivatives were even more potently
anti-proliferative than the free acids. The gold standard method of quantification, stable isotope dilution
(SID) LC-MS, was applied to determine the absolute intra- and extra- cellular levels of oxo-ETEs in multiple
cell lines. Maximal intracellular concentrations of 11-oxo-ETE were 0.02 ng/4x10^5 cells in human colon
adenocarcinoma (LoVo) cells versus 0.58 ng/4x10^5 cells in HUVECs. Its methyl ester derivative increased
the intracellular concentration of free 11-oxo-ETE 3-fold. Pharmacological inhibition of relevant transporter
proteins increased anti-proliferative activity and the intracellular pool of 11-oxo-ETE. Consistent with an
observed structural homology to other bioactive fatty acids, 11-oxo-ETE reduced canonical nuclear factor-
kappa B signaling activity. LC-MS revealed a mechanistic explanation of this activity via adduction to critical
cysteine or histidine residues of the p50 subunit of the p50/p65 transcription factor. LC- high-resolution MS/
MS approaches revealed that the oxo-ETEs underwent substantial intracellular metabolism. Two of the
double bonds were reduced and novel coenzyme A (CoA) thioesters were formed followed by reduction of all
four of their double bonds. The identification of novel CoA thioester metabolites could have important
implications to detection and function of the oxo-ETEs as well as other electrophilic polyunsaturated fatty
acids in normal physiology as well as in inflammation and cancer.
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ABSTRACT 
 
INVESTIGATIONS OF BIOACTIVITY, DISPOSITION, AND METABOLISM OF LIPIDS 
THROUGH LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY 
 Nathaniel W. Snyder 
Ian A. Blair 
Inflammatory diseases and multiple human cancers are associated with increased 
cyclooxygenase-2 (COX-2) expression together with decreased expression of 15-
hydroxyprostaglandin dehydrogenase (15-PGDH).  This has been hypothesized to lead to a 
milieu of bioactive lipids modulating angiogenesis and cellular proliferation.  Further insight into 
these processes were gained by traditional cell and molecular biology approaches, which were 
combined with cutting edge liquid chromatography mass spectrometry (LC-MS) methods to 
elucidate the function, disposition, and metabolism of a major COX-2/15-PGDH derived 
metabolite, 11-oxo-eicosatetraenoic acid (11-oxo-ETE). 11-oxo-ETE was found to possess 
significant anti-proliferative activity (IC50 2 μM) in human umbilical endothelial cells (HUVECS), 
which was 5 times more potent than isomeric 15-oxo-ETE.  The corresponding methyl ester 
derivatives were even more potently anti-proliferative than the free acids.  The gold standard 
method of quantification, stable isotope dilution (SID) LC-MS, was applied to determine the 
absolute intra- and extra- cellular levels of oxo-ETEs in multiple cell lines.  Maximal intracellular 
concentrations of 11-oxo-ETE were 0.02 ng/4x10
5
 cells in human colon adenocarcinoma (LoVo) 
cells versus 0.58 ng/4x10
5
 cells in HUVECs.  Its methyl ester derivative increased the intracellular 
concentration of free 11-oxo-ETE 3-fold.  Pharmacological inhibition of relevant transporter 
proteins increased anti-proliferative activity and the intracellular pool of 11-oxo-ETE.  Consistent 
with an observed structural homology to other bioactive fatty acids, 11-oxo-ETE reduced 
canonical nuclear factor-kappa B signaling activity.  LC-MS revealed a mechanistic explanation of 
this activity via adduction to critical cysteine or histidine residues of the p50 subunit of the 
p50/p65 transcription factor. LC- high-resolution MS/MS approaches revealed that the oxo-ETEs 
vii 
underwent substantial intracellular metabolism.  Two of the double bonds were reduced and 
novel coenzyme A (CoA) thioesters were formed followed by reduction of all four of their double 
bonds.  The identification of novel CoA thioester metabolites could have important implications to 
detection and function of the oxo-ETEs as well as other electrophilic polyunsaturated fatty acids 
in normal physiology as well as in inflammation and cancer. 
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1 
Chapter 1: Introduction 
 This thesis describes the application of liquid chromatography-mass spectrometry (LC-
MS) to study the bioactivity, disposition, and metabolism of lipids.  Thus, a brief introduction to 
lipids with a focus on one of the most abundant endogenous lipids, arachidonic acid (AA), is 
provided in order to provide a framework for the research presented in this thesis.  The relevant 
nomenclature, structure, metabolism, roles of AA metabolites in disease, and methods for the 
quantification of AA metabolites are discussed.  The history of the scientific study of lipids is 
storied and important to our understanding of human health and disease.  Likewise, a primer on 
the analytical methods and technologies used in this thesis provides an introduction to the novel 
studies that have been conducted.  As a central methodological theme of this thesis, the theory of 
LC-MS has also been provided. 
1.1 Lipids and Nomenclature 
Lipids can be been defined as fatty or waxy organic compounds that are readily soluble in 
nonpolar solvents such as ether but poorly in polar solvents such as water.  This definition covers 
a range of diverse molecules, and can be further refined by a multi-functional nomenclature of 
lipids proposed by Fahy, et al.  The nomenclature classifies lipids into eight categories; fatty acyls 
(FAs), glycerolipids (GLs), glycerophospholipids (GPs), sphingolipids (SPs), sterol lipids, prenol 
lipids, saccharolipids, and polyketides (5).  This thesis covers mostly investigations into the first 
group, the FAs (Chapter 1-7), but GLs, GPs and SLs are also discussed (Chapter 6-7). 
FAs are structurally simple lipids that form the building blocks of more complex lipids and 
can be classified as unsaturated or saturated based on the presence or absence, respectively, of 
double bonds.  FAs can be further described by number of carbons, number of double bonds, and 
by position of the double bonds.  Subcategories of FAs can be grouped by distinct 
physiochemical properties, emergent from chemical moieties present in the structures.  For 
example, polyunsaturated fatty acids (PUFAs) are subject to oxidation by reactive oxygen and 
2 
nitrogen species as well as oxygenase enzymes.  The resulting oxidized lipids function as a 
diverse array of signaling molecules (6).  When more than one double bond is present in a FA, 
the connecting group is often a methylene moiety termed a bis-allylic configuration, and the 
abstraction of a bis-allylic hydrogen is an important initiating step in enzymatic oxidation and lipid 
peroxidation (7).   
3 
As shown in Figure 1.1.A, the application of the above nomenclature can describe many 
important elements about the FA being described.  AA has 20 carbon atoms and 4 double bonds, 
so it can be abbreviated as 20:4-6 or 20:4n-6, where the notation -6 derives from the double 
bond at C14-C15 being five carbons away from the terminal carbon at C-20 (which is designated 
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Figure 1.1. Struture of AA, 1-stearoyl-2-arachidonoyl phosphatidylinositol, and 
arachidonoyl-coenzyme A. (A) The structure of AA.   Double bond positions indicated 
by carbon number.  The omega () and omega (-6) carbons are also labeled.  Bis-allylic 
hydrogens are indicated.  (B) The structure of a glycerophospholipid with stearic acid at the 
sn-1 position, AA at the sn-2 position, and a polar phosphoinositol head group at the sn-3 
position. (C) The structure of arachidonoyl-Coenzyme A.  The arachidonoyl acyl group is 
linked to the coenzyme A molecule through a thioester bond in the carbonyl of AA. 
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by convention as ).  Additionally, the FAs include the subgroup of acyl-coenzyme A (CoA) 
thioesters (8), a topic covered in Chapter 7 and 8.  In the case of the acyl-CoA species, the FA is 
esterified through a thioester linkage to a bulkier CoA molecule. 
Another class of lipids, the phospholipids, are ubiquitous and major components of all cell 
membranes where they form lipid bilayers (9).  Phospholipids can also serve as precursors for 
bioactive products, or engage in signaling activities directly (Fig. 1.2).  Phospholipids are a 
diverse class of biomolecules, but the structure of a typical GP, 1-stearoyl-2-arachidonoyl-
phosphatidylinositol is shown in Figure 1.1.B. In this representative structure, glycerol is esterified 
with stearic acid (18:0) at the sn-1 position, and it is esterified with AA at sn-2 position with a polar 
phosphoinositol head group at the sn-3 position.  The esterification of AA to yield more complex 
lipids is an important part of the regulation of AA metabolism and physiology. 
1.2 Arachidonic Acid Metabolism and Disease 
Metabolism of AA is an active area of study because it involves the generation of diverse 
biologically active lipid mediators, the eicosanoids (10).  The eicosanoids derived from AA act via 
G-protein coupled receptor (GPCR) agonism or potentially as nuclear transcription factor ligands 
(6,11,12).  They are involved in inflammation (13), cancer (14), and other physiological processes 
by modulating signaling pathways (15), transcription factor activity (16), and gene expression 
(17).  The diverse roles of various eicosanoids in inflammation, cancer, and other processes are 
described in more detail in Chapters 2, 3, 4, and 7.   
In most animals, AA is a non-essential fatty acid because it can be synthesized from 
linoleic acid  (3).  Free AA in mammals is tightly regulated and exists primarily as the esterified 
form in PLs, GPs, and SLs (Figures 1.1 and 1.2).  Release of AA by hydrolysis from esterified 
lipid stores is an important step in AA metabolism, and critical in the physiological role of AA 
metabolites.  Esterified AA at the sn-2 position on phosphatidylinositol can be directly released 
through hydrolysis of the PL by phospholipase A2 enzyme (18).  Alternatively, phospholipase C-
mediated hydrolysis of phospholipids can first occur at the sn-3 position.  The polar 
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phosphoinositol head group is thereby removed, forming a diacylglycerol (DAG) which is acted on 
by DAG lipase to release free AA (19,20). In the brain, arachidonylethanolamide (AEA) is an 
endogenous cannabinoid neurotransmitter, and the substrate for fatty acid amide hydrolase, 
which converts AEA into ethanolamine and AA (21).  As shown in Figure 1.2, the tight control of 
AA directly impacts the generation of eicosanoids in physiologically important pathways. 
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Figure 1.2: Simplified scheme of AA metabolism.  The metabolism of AA 
starting with release from esterification at the sn-2 position of 1-stearoyl-2-
arachidonoyl phosphatidylinositol.  The release of AA from esterification allows 
cyclooxygenase mediated metabolism to downstream products.  Not shown: 15-
Lipoxygenase can also act on the esterified form of AA.  R1: stearoyl (18:0); DAG: 
diacylglycerol; DAGL: DAG lipase; PI: phosphatidylinositol; PLA2: phospholipase 
A2; PLC: phospholipase C; AEA: arachidonoylethanolamide (anandamide); FAAH: 
fatty acid amide hydrolase; AA: arachidonic acid; POX: peroxidase; HETE, 
hydroxyeicosatetreanoic acid; HPETE, hydroperoxyeicosatetreanoic acid; PG, 
prostaglandin; TX, thromboxane. 
 
7 
1.3 Enzymatic and Non-enzymatic Biotransformation of AA 
Transformation of AA through the cyclooxygenases (COXs) is one of the primary routes 
of AA metabolism into potent lipid signaling mediators (Figure 1.2).  COX exists as two 
isoenzymes, COX-1 and COX-2 (22).  COX-1 is constitutively expressed in many cells and is 
considered to function as a house-keeping enzyme where its products help to maintain normal 
biological processes. COX-2 was identified independently by three groups as a COX isoenzyme 
that is induced in response to cytokines, growth factors, bacterial endotoxin, and certain other 
stimuli (23-25). 
COXs are membrane bound proteins located on the inner and outer membrane of the 
nuclear envelope, as well as the surface of the endoplasmic reticulum lumen (26). The enzymes 
possess dual catalytic functions, containing both COX and peroxidase (POX) active sites. The 
COX site converts AA into PGG2 and 11(R)- and 15-HPETEs, while the peroxidase site reduces 
the hydroperoxide groups in PGG2 or HPETEs to the corresponding hydroxyl groups (Figure 1.2).  
This results in the generation of PGH2 as well as 11(R)- and 15-HETEs (27). 
The generally accepted mechanism of COX action involves a tyrosine protein radical 
(10). The COX catalytic cycle begins when an alkyl hydroperoxide binds to heme in the POX site.  
The hydroperoxide is reduced to the corresponding alkyl hydroxyl.  The heme is thereby oxidized 
to the oxyferryl Fe
4+
=O and a protoporphyrin radical cation (Fe
4+
=O
.
) is formed. This unstable 
intermediate abstracts hydrogen from the 
385
Tyr side chain, resulting in the formation of 
385
Tyr 
radical and an oxyferryl. The 
385
Tyr radical then abstracts the pro-S hydrogen at C13 of AA bound 
in the COX active site. 
385
Tyr is adds a proton, while an allylic radical is formed at C13 of AA. The 
C11-C12 double bond of AA relocates to C12-C13 and forms a conjugated double bond with 
C14-C15 and the C13 radical is transferred to C11. Then oxygen is inserted at the C11 position. 
The radical is transferred to oxygen, which rapidly attacks the C8-C9 double bond. This attack 
forms a dioxygen (endoperoxide) bridge between C11 and C9, along with a C8 radical. This is 
followed by a C8 radical attack of the C12-C13 double bond and formation of a C8-C12 single 
bond, together with a C13 radical. After translocation of the C13 radical and C14-C15 double 
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bond, a C15 radical is formed and followed by oxygen attachment to C15. Finally, this PGG2 
precursor abstracts a hydrogen atom and forms the final PGG2. PGG2 can then function as the 
initial alkyl hydroperoxide and enter the POX site, where it is reduced to PGH2. After several 
cycles, COX will usually lose activity via a mechanism that may be related with the quenching of 
tyrosine radicals or damage to the COX protein by free radicals (28).  The mechanism leading to 
HETE formation is less clear, but notably from the above mechanism, oxygen insertion in the 
normal catalytic COX cycle occurs at C11 and C15, which would lead to the formation of 11- and 
15-H(P)ETE. 
COX is a target for the class of therapeutics known as non-steroidal anti-inflammatory 
drugs (NSAIDs). Aspirin was the first described NSAID and differs mechanistically from other 
NSAIDs, in that it converts COX-2 into a 15(R)-lipoxygenase (LOX) via covalent modification, 
instead of completely inhibiting COX-2 activity.  Acetylation of COX-1 via aspirin inactivates the 
enzyme.  Other NSAIDs can be referred to as traditional NSAIDs (tNSAIDs) and include 
ibuprofen, diclofenac, naproxen, and many others.  These tNSAIDs are usually competitive 
inhibitors of COX and ultimately inhibit prostaglandin (PG) biosynthesis with a variety of effects 
depending on the drug, dose, timing, co-administration, and selectivity of binding for COX-1/COX-
2 (29,30).  For example, low dose aspirin will selectively inactivate platelet COX-1 for the life of 
the platelet, but fail to achieve systemic effects of COX inhibition, resulting in an anti-thrombotic 
effect while sparing the irritation of gastric mucosa due to inhibition of PG biosynthesis (31).  
COX-2 specific inhibitors have been developed with the hope of reducing the side effect of gastric 
irritation, although they have been associated with significant PG/thromboxane dependent 
adverse cardiovascular events (29,32).  
 Aside from COXs, AA can also be metabolized by the lipoxygenase (LOX) family.  LOXs 
catalyze a dioxygenase type reaction, as opposed to the PG producing di-oxygen insertion and 
cyclization of the COXs.  The catalytic product of LOXs from AA is a n-6 hydroperoxy fatty acid 
with a conjugated Z,E-diene system.  Similar to the COX reaction, the unstable hydroperoxy 
moiety is then reduced by cellular POXs to the corresponding hydroxyl group.  The nomenclature 
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for LOXs is based on the specificity of the enzyme for the carbon where molecular oxygen is 
inserted.  Humans possess at least five lipoxygenases.  Of these five, two are pure 15-LOXs.  
The other human LOXs, namely 5-LOX, 8-LOX, and 12-LOXs are reviewed elsewhere (33).  The 
non-human (and non-animal) lipoxygenases are beyond the scope of this thesis. 
15-LOX-1 also termed reticulocyte 15-LOX, has been purified from human eosinophils and 
leukocytes (34,35).  15-LOX-2 has been isolated and described from human skin.  Expression of 
15-LOX-2 was also observed in prostate, lung, and cornea (36).  The specific reduced products of 
15-LOX-1 from AA include 15(S)-HETE and 12(S)-HETE because of some 12-LOX-type activity.  
15-LOX-2 produces pure 15(S)-HETE.  Unlike COXs, LOXs do not have an absolute requirement 
for acting on free AA.  Thus, the possibility of oxidation followed by release by phospholipases 
must always be considered for lipoxygenase products (33).  15-LOX-1 rapidly inactivates in a 
turnover dependent mechanism, but 15-LOX-2 is catalytically stable.  The role of 15-LOXs in 
humans is complex and animal models give conflicting results, but an excellent review is 
available (37).  The Brash group at Vanderbilt University describes the possible functions of LOXs 
as generators of signaling mediators (directly or through intermediates), peroxidation, or as 
enzymes for lipid mobilization.  Ongoing research into these roles is discussed in Chapters 2, 3, 
4, and 7. 
Besides enzymatic pathways, AA is also subject to autoxidation both in vitro and in vivo. 
AA has four double bonds and three pairs of bis-allylic hydrogen atoms (Figures 1.1 and 1.2); 
therefore, it is readily oxidized when it is exposed to air, free radicals, or heat (38).  This instability 
requires careful control of parameters to avoid or control for artifact formation during an 
experiment.  While enzymatically produced AA metabolites are formed with enantiomeric 
specificity, autooxidation of AA results in the formation of racemic products.  The use of chiral 
chromatography to separate the two enatiomers, discussed below, can differentiate these two 
pathways of formation in simple systems (39).  Thus, both enzymatic and non-enzymatic 
generation of eicosanoids, can generate a diverse array of products from the parent AA.  The 
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initial composition of this complex mixture of eicosanoids depends upon the enzymatic machinery 
present and the physiochemical environment. 
1.4 Further Metabolism of Eicosanoids 
Total eicosanoid levels are controlled not only via COX/LOX dependent generation, but 
also by eicosanoid catabolism (40).  Among the eicosanoid catabolism enzymes, 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) has been studied the most intensively.  15-
PGDH is strongly down-regulated in numerous cancer cell lines and human cancers resulting in 
the accumulation of pro-proliferative PGs, such as PGE2 (41).  Increasing 15-PGDH levels 
reduces PGE2 and results in anti-proliferative effects in cell and mouse models (42,43). 
Additionally, COX-2 inhibitor therapy alone fails in some patients who are 15-PGDH deficient, 
suggesting that a combination of COX-2 inhibitors and inducers of 15-PGDH provide a better 
chemoprevention approach (44).  
15-PGDH preferentially converts the 15(S)-hydroxyl group on eicosanoids to a keto group 
(45). For example, PGE2 undergoes 15-PGDH-mediated conversion to 15-keto-PGE2 which can 
be further metabolized to 13,14-dihydro-15-keto-PGE2 by a specific reductase.  The primary 
cofactor of 15-PGDH is NAD
+
.  A different type II 15-PGDH uses NADP
+
 as its cofactor, but has a 
Km value two orders of magnitude higher than NAD
+
 dependent 15-PGDH when PGE2 is the 
substrate (46).  Molecules with a -6 hydroxyl group, such as the LOX-type product 15(S)-HETE, 
are also readily oxidized by 15-PGDH (47). This suggests that 15-PGDH could also play an 
important role in the metabolism of different oxidized fatty acids, which is a topic explored in 
Chapter 2.   
After being reduced, these α,β-unsaturated ketone containing fatty acids can undergo 
glutathione S-transferase (GST)-mediated conjugation with glutathione (GSH) (48). The GSH 
conjugates have higher polarity than their precursors, and they can be excreted out of cells 
through relevant transporters (49).  The interconnected metabolism and function of 15-PGDH 
products are discussed in more detail in Chapters 2, 3, and 4. 
11 
 The localization of eicosanoids is also important to their function and metabolism.  In the 
setting of cancer, the generation, signaling, and metabolism of eicosanoids is partly controlled via 
dysregulation of eicosanoid transporters (50).  This is consistent with the intracellular 
biotransformation of eicosanoids such as PGE2 and action via GCPRs with binding pockets 
facing the extracellular space.  The transporters thought to be important to eicosanoids include 
members of the family of Organic 
Anion Transporters (OATs) and 
the Multidrug Resistance Proteins 
(MRPs) of the ATP-Binding 
Cassette family (ABC).  
Specifically, the PG transporter 
(PGT) and OATP-D  provide 
carrier mediated transport for 
efflux of the eicosanoids (51).  
MRP4 has also been shown to 
efflux eicosanoids, notably PGE2 
(52).  MRP1 mediates efflux of 
GSH-conjugates, including LOX 
products (49).  Studies into the 
effect of eicosanoids may need to 
take into account the state and 
relevance of transporters to any 
bioactivity, potency, or 
metabolism under investigation 
as is further discussed in Chapter 
3. 
 
Table 1.1: The van Deemter equation for departure 
from ideal chromatography. Simplified to H = A + B/ 
+ C* from the original h= 2 dp + (2 Dm / ) + (8/^2) 
(/ (1+)
2
)(df
2
/D1 )  Where A= Eddy diffusion term, 
B=coefficient of longitudinal diffusion, C=coefficient of 
mass transfer, D= coefficient of molecular diffusion 
(m=mobile phase, l=liquid stationary phase), d= 
diameter (p=particle, f=film), k=column capacity ratio, 
=proportionality factor, h= plate height, =linear 
velocity.  The C term has been expanded to include 
modern chromatographic instrumentation, and some 
modern treatments have re-written the fundamental 
equation. Adapted from (3,4). 
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1.5 Liquid Chromatography-Mass Spectrometry for Metabolite 
Measurements 
LC uses the differential partition of a molecule of interest to a mobile phase (solvent) and 
a stationary phase (column) to separate compounds from a complex sample.  Thus, LC adds a 
dimension, termed retention time, to the identity of the molecule being studied (an analyte).  
Retention time reflects the physical interaction of the liquid chromatography separation (53).  The 
underlying factors of liquid chromatography can be expressed by the Van Deemter equation 
(Table 1.1).  In this equation, the resolving power in height equivalents of a theoretical plate is 
explained by departure from the ideal chromatography caused by molecular diffusion, eddy 
diffusion, and mass transfer coefficient (4).  This equation explains how the characteristics of a 
liquid chromatography method can be tuned to maximize the number of theoretical plates by 
minimizing their theoretical height. This optimization would provide the best separation possible 
between any set of molecules.  Driving improved chromatographic performance is thereby 
dependent on the ideal packing of the column particle material, low dispersion, fit mass transfer 
between phases, and optimum velocity of flow.  Approaches to chromatographic performance in 
metabolite analysis are further discussed in Chapter 6.   
The chemistry of the column can provide varying selectivity for different compounds based on the 
characteristics of the compounds being separated (charge, hydrophobicity and chirality) (39).  
The nature of the solvents can determine the analyte interactions with the column to provide 
reversed phase chromatography, where a polar solvent is transitioned to an increasing non-polar 
solvent, or normal chromatography where a non-polar solvent is transitioned to a more polar 
solvent.  Column chemistries and solvent selection can be optimized to provide differing retention 
times to even closely related compounds, including structural isomers difficult to resolve by other 
methods (54).  However, retention time is often an insufficiently specific dimension for accurate 
analysis of related molecules or complex mixtures, thus additional terms are required for 
identification and quantitation of a given analyte.  This leads to the necessity of coupling LC to 
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another instrument in order to provide additional data to describe molecules from a complex 
mixture. 
A powerful instrument called a mass spectrometer can be attached after the LC to 
provide additional information about an analyte.  The fundamental output of a mass spectrometer 
is the determination of signal intensity for a given mass to charge ratio (m/z).  The m/z is derived 
from the mass of the molecule as well as the number of charges imparted to the molecule.  By 
definition a mass spectrometer must analyze a charged molecule so; mass spectrometers 
actually measure the ions (charged species) of a given analyte. 
A mass spectrometer operates on the principles of: generation of an ion (at the source), 
separation of the ion (via a mass analyzer), and detection (at the detector).  Each of these 
segments of the mass spectrometer will be discussed sequentially in the following paragraphs, 
starting with the ion source.  The source of the mass spectrometer determines the type of ions 
generated, and influences the resulting analysis.  Ion polarity can be either positive (+) or 
negative (-), with the polarity 
mode of detection imparting some 
properties to the resulting data 
based on the specifics of the 
analyte (55).  When coupled with 
LC, the most widely used source 
utilizes atmospheric pressure 
ionization (API) (56).  Analytes in 
the liquid mobile phase are 
desolvated by charged droplet 
collapse (electrospray ionization, 
ESI) (57) or by applying a current 
to a conducting needle under 
atmospheric pressure 
 
Table 1.2: The mass spectrometers employed in 
this thesis.  Mode of detection in terms of ion 
destruction through analysis for each instrument is 
given.  Separation in-time or in-space is given for 
each instrument for better understanding of the 
discussion below and experimental design.  
Operating resolutions used in this thesis are listed. 
R=Resolution, t=time of detection, T= period of 
oscillation.  Adapted from (1). 
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(atmospheric pressure chemical ionization, APCI) (58).  Analytes are charged in solution for ESI 
by adjusting the pH of the mobile phase, or by other techniques (e.g. derivatization).  High 
temperature, nitrogen gas, a spray/source voltage, and/or vacuum at the source of the instrument 
may also assist the desolvation process.  Flow rates from the LC into the source can drastically 
affect the nature and output of the source, and the resulting analysis and detection of ions (59).  
Different analytes are often differentially compatible with ionization by distinct source types; often 
a chemical knowledge or empirical approach is needed to determine the ideal conditions for 
ionization, taking into account prior knowledge of matrix effects, solvent effects, thermal stability, 
propensity for adduction, and stability holding charge (60). 
The mass analyzer is the primary instrument used to distinguish ions with different m/zs, 
given the resolving power of the mass spectrometer.  A functional definition of resolution is the 
m/z divided by the minimum m/z peak separation of ions with the same nominal mass expressed 
in Da. (61).  A larger value of resolution means better separation of peaks, or an isolated peak 
with a smaller width as measured from the full width of the peak at half maximum of the peak 
height (FWHM).  Mass spectrometers featuring different analyzers are highlighted in Table 1.2.  
Low resolution instruments, which typically operate at unit mass resolution, can only distinguish 
two ions that differ in mass by 1 Da.  The TSQ, API4000, and LTQ are the low resolution 
instruments used in this thesis.  High resolution by contrast, could be up to 2,000,000 FWHM (or 
higher) (62), giving neutron encoded mass defect specific information, but more practically runs a 
range of 30,000 to 240,000 FWHM.  An LTQ-Orbitrap XL and a FT-ICR are high resolution 
instruments used in this thesis.  High resolution instruments confer much higher analytical 
specificity than the corresponding low resolution instruments. 
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Figure 1.4: Schematic of tandem MS experiments. (A) Product ion scan for 
generation of a fragment ion spectra. (B) Precursor ion scan for detection of the set of 
parent ions giving rise to a particular fragment. (C) Neutral loss scan for synchronized 
detection of the set of ions that lose a given m/z upon fragmentation. (D) Ion 
monitoring (Single/Multiple Reaction) for detection of a precursor/fragment pair.  
Adapted from (2).  
 
The interplay of the analyzer and detector results in different characteristics of the 
resulting data acquired, such as scan rate (expressed in Hz), dynamic range, instrument specific 
strengths and weaknesses, and an increasing requirement for data management strategies as file 
size increases exponentially.  The detector on mass spectrometers also plays an independent 
role in analysis.  Amplification and interpretation of the signal is an important component of 
detection due to the inherently weak signal generated by a low abundance ion.  For induction 
based detectors, such as utilized in the Orbitrap, Fourier transform is used to convert amplitude to 
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a useable m/z.  Characteristics, utilization, and the future applications of mass analyzers are 
discussed in greater detail in Chapter 6 and the Conclusion.   
Aside from resolution of a mass analyzer, tandem mass analysis (MS/MS or MS
n
) can be used to 
improve sensitivity (increased signal/noise) and specificity and increase the information gained 
from a mass spectrometry experiment (63).  Tandem mass spectrometry can be tandem in space 
where the elements are physically separated across analysis as in a transmission quadrupole 
(e.g. triple quadrupole (64)) or time-of-flight instrument.  Alternatively, tandem in time based 
analysis involves trapping the ions in a confined physical space, with separations occurring over 
time, as in an ion trap (65,66).  The type of analysis determines the type of experiment which can 
be performed on the ions of interest.  Analysis in space allows true precursor ion and neutral loss 
scanning, where the ions are scanned through the first mass analyzer and a product ion is 
scanned through the last mass analyzer.  In the case of the neutral loss scan, the first and last 
mass analyzers are operated at a given offset, so only an ion losing a certain value of m/z is 
detected.  Both analysis in time and analysis in space can perform product ion scans, where a 
given ion is selected in the first stage, fragmented, and then the resulting product ions are 
analyzed in the last stage.  The final type of tandem MS experiments is selected reaction 
monitoring, where the first and last stages are set to a given mass range so a distinct precursor 
and product ion are selected for.  This type of analysis can be used to improve performance for a 
given experiment by tuning sensitivity, specificity, and information gained.  This thesis features 
experiments conducted in all of these analysis modes, where specific instrumentation used for 
such analysis is indicated in Table 1.2. 
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Derivatization 
offers a route to improve 
liquid chromatography-
mass spectrometry 
performance.  Gains in 
sensitivity, specificity, 
ionization efficiency, 
analyte stability, and 
improved 
chromatographic 
characteristics, including 
retention and peak 
shape, can be attained through simple derivatization schemes (54,58).  The application of specific 
derivatization techniques to analytical challenges are discussed in chapters 2 and 3.  In particular, 
this thesis takes advantage of liquid chromatography- electron capture atmospheric pressure 
chemical ionization- mass spectrometry (LC/ECAPCI/MS) via derivatization with 
pentafluorobenzyl bromide (PFB) (58).  This technique can provide increased sensitivity and 
specificity via increasing the ionization efficiency of a target analyte by tagging an electron 
capturing group (PFB in this case) to the analyte of interest.  The process of derivatization and 
ECAPCI is shown in Figure 1.5. 
Ultimately, LC-MS provides a highly sensitive and specific platform to measure a range of 
analytes even from complex matrices (67).  Advancements in high resolution and accurate mass 
MS (68,69) coupled with bioinformatics and software platforms (70-72) have made MS the 
optimal methodology for robust, sensitive, high-throughput metabolomic and proteomic analyses 
(73,74).  Regardless of these advances, a LC-MS system is not truly quantitative, even for 
relative measurements, without the application of additional analytical methodologies.  
Appropriate internal standards are especially critical when measuring analytes in complex and/or 
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Figure 1.5: ECAPCI with a PFB derivative of AA. The 
derivatization and ECAPCI of AA with PFB resulting in the 
formation of a negative ion of AA is shown.  This process improves 
sensitivity and specificity by increasing the efficiency of ion 
formation for a molecule of interest. 
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biological samples, due to possibly systemic bias introduced by matrix effects on analyte stability, 
extraction, and ionization efficiency (75-80).  Internal standards that faithfully reproduce the 
properties of the analytes of interest are ideal.  Stable isotope analogs containing [
15
Nn] [
13
Cn], or 
both isotopes, represent the best internal standards because they have the same chemical 
properties as the analyte of interest, but can still be uniquely distinguished by a mass 
spectrometer (81).  [
2
Hn]-containing stable isotope analogs are much easier to synthesize and 
tend to be used even though there is usually a slight separation between the [
2
Hn]-analog and the 
endogenous analyte.  Therefore the use of [
2
Hn]-containing stable isotope analogs is not quite as 
rigorous as the corresponding [
15
Nn]- or [
13
Cn]-containing stable isotope analogs.  Applying stable 
isotope analogs to a LC-MS experiment allows for quantification based on the observed ratio of 
analyte to internal standard.  This approach is termed stable isotope dilution (SID) LC-MS, and 
represents the gold standard method of analysis because it corrects for many potential sources of 
bias and error introduced by the experimenter and instrumentation (82). 
The power of LC-MS, especially when coupled to other techniques including but not 
limited to derivatization and SID-LC-MS, can be applied to quantitatively and qualitatively study 
metabolism in a rigorous and sensitive manner.  This thesis will apply LC-MS as explained in the 
above paragraphs to the problem of human metabolism, in particular lipid metabolism.  The lipid 
subset of the human metabolic system is particularly interesting because of the incredible 
diversity of known and potential pathways and products.  Lipids are an important element of 
metabolism because of their involvement in a wide variety of disease states.   
Notably, in inflammatory diseases and multiple human cancers, increased COX-2 and 
decreased 15-PGDH are hypothesized to lead to a milieu of bioactive lipids promoting 
angiogenesis and cellular proliferation.  I hypothesized that this pro-proliferative switch is also 
dependent on the loss of generation of anti-proliferative homeostatic lipids.  In chapter 2, through 
LC-MS and other analytical techniques, it has been established that 11-oxo-eicosatetraenoic acid 
(11-oxo-ETE) is a major COX-2/15-PGDH derived metabolite with anti-proliferative function.  
Based on the observation that a cancer model system rapidly exported 11-oxo-ETE, I sought to 
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understand the disposition of 11-oxo-ETE and the related 15-oxo-ETE.  I hypothesize that the 
potency of endogenous anti-proliferative lipids is mediated by the decreased availability of those 
molecules to the intracellular space of cancer cells.  The inadequacies of the available chemical 
tools in this sphere led to a search for new chemical entities to use as probes for future studies.  
In chapter 3, methyl-ester derivatives of both 11-oxo and 15-oxo-ETE were tested.  Using SID-
LC-MS, it was possible to show that the methyl esters potently deliver the oxo-ETE to the 
intracellular space.  In chapters 3 and 4, the signaling and disposition of the oxo-ETEs were 
explored, using the tools that I developed, which are described in chapters 2 and 3.  
In my early work, it was observed that the oxo-ETEs were highly transient.  This led to 
the hypothesis that 11-oxo- and 15-oxo-ETE are subject to further metabolic transformation inside 
the cellular space.  To explore the metabolism of the oxo-ETEs untargeted and targeted 
approaches to biomolecule analysis were developed as described in chapters 5 and 6.  Using 
these untargeted and targeted approaches, limited saturation of the free acids was observed, as 
well as the formation and saturation up to all four double bonds of a novel coenzyme A thioester 
of oxo-ETEs.  The identification of novel metabolites was supported through LC-MS/MS, time 
course studies, stable isotope labeling, and treatments with the methyl-esters of the oxo-ETEs as 
well as isotope labeled 15-oxo-ETE. 
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Chapter 2: 11-Oxo-eicosatetraenoic Acid is a Cyclooxygenase-
2/15-Hydroxyprostaglandin Dehydrogenase-Derived Anti-
Proliferative Eicosanoid 
 
Published as: Liu X, Zhang S, Arora JS, Snyder NW, Shah SJ, Blair IA. 11-Oxoeicosatetraenoic 
acid is a cyclooxygenase-2/15-hydroxyprostaglandin dehydrogenase-derived antiproliferative 
eicosanoid. Chem Res Toxicol. 2011 Dec 19;24(12):2227-36. Epub 2011 Sep 30. PubMed PMID: 
21916491; PubMed Central PMCID: PMC3242474.   NWS contributed to cell proliferation 
studies and elucidation of oxo-ETE-GSH structure, as well as preparation of the manuscript. 
 
2.1 Abstract 
Previously, we established that 11(R)-hydroxy-5,8,12,14-(Z,Z,E,Z)-eicosatetraenoic acid 
(HETE) was a significant cyclooxygenase (COX) -2-derived arachidonic acid (AA) metabolite in 
epithelial cells.  Stable isotope dilution chiral liquid chromatography (LC)-electron capture 
atmospheric pressure chemical ionization (ECAPCI)/mass spectrometry (MS) was used to 
quantify COX-2-derived eicosanoids in the human colorectal adenocarcinoma (LoVo) epithelial 
cell line, which expresses both COX-2 and 15-hydroxy prostaglandin dehydrogenase (15-PGDH).  
11(R)-HETE secretion reached peak concentrations within minutes after AA addition before 
rapidly diminishing, suggesting further metabolism had occurred.  Surprisingly, 15-PGDH, which 
is normally specific for oxidation of eicosanoid 15(S)-hydroxyl groups, was found to convert 
11(R)-HETE to 11-oxo-5,8,12,14-(Z,Z,E,Z)-eicosatetraenoic acid (ETE).  Furthermore, LoVo cell 
lysates converted 11(R)-HETE to 11-oxo-ETE and inhibition of 15-PGDH with 5-[[4-
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ethoxycarbonyl) phenyl]azo]-2-hydroxy-benzeneacetic acid (CAY 10397) (50 M) significantly 
suppressed endogenous 11-oxo-ETE production with a corresponding increase in 11(R)-HETE.  
These data confirmed COX-2 and 15-PGDH as enzymes responsible for 11-oxo-ETE 
biosynthesis.  Finally, addition of AA to the LoVo cells resulted in rapid secretion of 11-oxo-ETE 
into the media, reaching peak levels within 20 min of starting the incubation.  This was followed 
by a sharp decrease in 11-oxo-ETE levels.  Glutathione (GSH)-S-transferase (GST) was found to 
metabolize 11-oxo-ETE to the 11-oxo-ETE-GSH (OEG)-adduct in LoVo cells, as confirmed by 
LC-MS/MS analysis.  Bromodeoxyuridine (BrdU)-based cell proliferation assays in human 
umbilical vein endothelial cells (HUVECs) revealed that the half-maximal inhibitory 
concentration (IC50) of 11-oxo-ETE for inhibition of HUVEC proliferation was 2.1 M.  These 
results show that 11-oxo-ETE is a novel COX-2/15-PGDH-derived eicosanoid, which inhibits 
endothelial cell proliferation with a potency that is similar to that observed for 15d-PGJ2. 
 
 
2.2 Introduction 
In a previous study, we established that 11(R)-HETE was a significant COX-2-derived AA 
metabolite in epithelial cells.(83)  However, the consequences of this finding were not clear at 
that time.  A number of toxic substances including arsenite,(84) dioxin,(85) benz[a]pyrene-diol-
epoxide,(86) and cigarette smoke(87) up-regulate COX-2 expression, which in turn regulates 
numerous intracellular biochemical pathways.  This occurs primarily through the biosynthesis of 
COX-2-derived AA metabolites, which can exert cell-specific effects on inflammation, cell 
growth, and proliferation.  For example COX-2-derived prostaglandin (PG) E2 increases tumor 
proliferation through multiple mechanisms including activation of plasma membrane G-protein-
coupled receptors and the nuclear peroxisome proliferator-activated receptor (PPAR).(13) 
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Steady-state levels of PGE2 are maintained by PGE-synthase-mediated biosynthesis from 
COX-2-derived PGH2 and catabolism by 15-PGDH-mediated inactivation to 15-oxo-PGE2 
(Figure 1).(88,89)  The 15-oxo-PGE2 is then converted to 13,14-dihydro-15-oxo-PGE2 by 15-
oxo-prostaglandin-13 reductase.(90)  Loss of 15-PGDH expression is associated with tumor 
formation in bladder, breast, colon, intestine, kidney, lung, pancreas, stomach, and skin 
cancer.(41,91-96)  Thus, up-regulation of COX-2(13) and down-regulation of 15-PGDH(41) 
provides a switch towards endogenous mediators that are significant contributors to cancer 
progression.(97) 
PGD2, another COX-2-derived metabolite is also metabolized by 15-PGDH to form 15-oxo-
PGD2, which is then converted to the corresponding inactive 13,14-dihydro-derivative (Figure 
1).(98)  Alternatively, PGD2 undergoes albumin-mediated dehydration to give PGJ2, followed by 
a further dehydration to give 15-deoxy-12,14-prostaglandin J2; (15d-PGJ2) (Figure 2).(99)  
Previous studies have shown that 15d-PGJ2 is a PPAR agonist,(100) which inhibits HUVEC 
proliferation in culture.(101)  In addition, 15d-PGJ2 can induce caspase-mediated endothelial cell 
apoptosis(102) and inhibit the nuclear factor B (NFB) pathway.(103,104)  It can also increase 
levels of p53 in HUVECs, activate p53 phosphorylation, and induce p21.(105) 
Studies of purified COX enzymes have shown that 11(R)-HETE, 15(S)-hydroxy-5,8,11,13-
(Z,Z,Z,E)-eicosatetraenoic acid (15(S)-HETE), and 15(R)-HETE are the major HETEs that are 
formed.(106)  The HETEs arise from reduction of the corresponding hydroperoxyeicosatetraenoic 
acids (HPETEs) primarily through the peroxidase (POX) activity of COXs (Figure 1).(107)  
11(R)-HETE was a significant eicosanoid secreted by AA-treated rat intestinal epithelial cells that 
stably express COX-2 (RIES cells) but it was rapidly metabolized.(83)  15(S)-HETE was formed 
in lower abundance and metabolized to 15-oxo-ETE,(54,108) as expected from its 15(S)-
configuration and the substrate specificity of 15-PGDH.  15-Oxo-ETE was also found to inhibit 
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endothelial cell proliferation, although at concentrations higher than 15d-PGJ2.(108)  However, 
there is little evidence that 15d-PGJ2 can be formed in vivo at concentrations commensurate with 
an endogenous anti-proliferative role.(109)  In our earlier study,(110) the metabolic fate of 11(R)-
HETE secreted by the RIES cells was not established.  11-Oxo-ETE has now been synthesized 
and a LC-selected reaction monitoring (SRM)/MS method for its analysis has been developed.  
This has made it possible to determine whether 11-oxo-ETE is secreted by human epithelial cell 
lines with up-regulated COX-2 expression and to identify the dehydrogenase responsible.  The 
ability of 11-oxo-ETE to modulate HUVEC proliferation has also been examined. 
 
2.3 Experimental Procedures 
Chemicals and Reagents. AA (peroxide-free), 11(R,S)-HETE, 15(R,S)-HETE, [
2
H8]-15(S)-
HETE, [
13
C20]-15-oxo-ETE, 15-oxo-ETE, PGE2, [
2
H4]-PGE2, 13,14-dihydro-15-keto-PGE2, [
2
H4]-
13,14-dihydro-15-keto-PGE2, 15d-PGJ2, CAY10397, protease inhibitor cocktail and recombinant 
human 15-PGDH were purchased from Cayman (Ann Harbor, MI).  The Dess-Martin reagent 
[1,1,1-Tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one], 2,3,4,5,6-pentafluorobenzyl 
(PFB) bromide, Trizma-HCl, lipoxidase from Glycine max (soybean), sodium borohydride, and 
NAD
+
 were purchased from Sigma-Aldrich (St. Louis, MO).  Fetal bovine serum (FBS) was from 
Gemini Bioproducts (West Sacramento, CA).  F12K medium, DMEM medium, Medium 200 
(M200), D-glucose, L-glutamine, low-serum growth supplement (LSGS) kit, penicillin, and 
streptomycin were supplied by Invitrogen (Carlsbad, CA).  LC-MS grade water, hexane, 
methanol, isopropanol, acetonitrile and dichloromethane were obtained from Fisher Scientific 
(Pittsburgh, PA).  Gases were supplied by The Linde Group (Munich, Germany).  [
13
C20]-AA was 
obtained from Spectra Stable Isotopes (Columbia, MD). 
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Cell Culture. Human colorectal adenocarcinoma LoVo cells (ATCC, Manassas, VA) were 
cultured in F12K medium supplemented with 10% FBS, 2 mM L-glutamine, 100,000 units/l 
penicillin and 100 mg/l streptomycin.  Human colonic adenocarcinoma HCA-7 Colony 29 cells 
(Sigma-Aldrich, St. Louis, MO) were grown in DMEM supplemented with 10% FBS, 2 mM L-
glutamine, 110 mg/L sodium pyruvate, 100,000 units/l penicillin and 100 mg/l streptomycin. For 
lipidomics analysis, the culture media was replaced with serum-free F12K or DMEM media 
before the treatment.  HUVECs were obtained from Invitrogen (Carlsbad, CA), and cultured on 
collagen I-coated tissue culture dishes in Medium 200 supplemented with LSGS kit.  Cell 
proliferation assays were performed using HUVECs from passage 4. 
Mass Spectrometry. A triple stage quadrupole (TSQ Quantum) mass spectrometer (Thermo 
Electron, San Jose, CA) equipped with an APCI source was used for the quantitative lipidomics 
analyses.  Targeted chiral LC-ECAPCI/SRM/MS analysis was conducted using PFB derivatives 
of 7 lipids and 4 heavy isotope analog internal standards.  For the lipidomics profile, the 
instrument was operated in the negative ion mode, and unit resolution was maintained for both 
precursor and fragment ions.  Operating conditions for the TSQ Quantum were: vaporizer 
temperature at 450°C; heated capillary temperature at 250 °C with the corona discharge needle 
set at 30 µA; nitrogen as sheath (25 psi) and auxiliary (5 arbitrary units) gas.  Collision-induced 
dissociation (CID) was performed using argon as the collision gas at 2.7 mtorr in the RF-only 
quadrupole.  The following SRM transitions were used: 11-oxo-ETE-PFB, m/z 317 → 165 
(collision energy (CE), 25 eV), 15-oxo-ETE-PFB, m/z 317 → 113 (CE, 18 eV), [13C20]-15-oxo-
ETE-PFB, m/z 337 → 120 (CE, 18 eV), 11(R)-HETE-PFB, m/z 319 → 167 (CE, 16 eV), [2H8]-
15(S)-HETE-PFB, m/z 327 → 226 (CE, 13 eV), PGE2-PFB, m/z 351 → 271 (CE, 18 eV), [
2
H4]-
PGE2-PFB, m/z 355 → 275 (CE, 18 eV). 13,14-dihydro-15-keto-PGE2-PFB, m/z 351 → 235 (CE, 
22 eV), [
2
H4]-13,14-dihydro-15-keto-PGE2-PFB, m/z 355 → 239 (CE, 22 eV). 
25 
For GSH adduct analysis, the mass spectrometer was operated in the positive ion mode with 
an electrospray ionization (ESI) source.  The operating conditions were: spray voltage at 4 kV; 
capillary temperature at 350°C; nitrogen as sheath (35 psi) and auxiliary (13 arbitrary units) gas.  
CID was performed using argon as the collision gas at 2.7 mtorr in the Rf-only quadrupole.  The 
following SRM transition (m/z 626 → 497) was monitored for 11-oxo-ETE-GSH (CE, 18 eV).   
Liquid Chromatography. LC separations were conducted using a Waters® Alliance 2690 
HPLC system.  A Chiralpak AD-H column (250 × 4.6 mm inner diameter, 5 µm; Daicel) was 
employed for normal phase separation (flow-rate 1 ml/min) of PFB-derivatives of eicosanoids.  
Gradient 1 was used for separating PFB-derivatives of HETEs and PGE2, whereas gradient 2 was 
used for PFB derivatives of oxo-ETEs.  For gradient 1, solvent A was hexane, and solvent B was 
methanol/isopropanol (1:1; v/v).  Gradient 1 was as follows: 2% B at 0 min, 2% B at 3 min, 3.6% 
B at 11 min, 8% B at 15 min, 8% B at 27 min, 50% B at 30 min, 50% at 35 min, and 2% B at 37 
min.  Separations were performed at 30°C using a linear gradient.  For gradient 2, solvent A was 
hexane, and solvent B was isopropanol/hexane (6:4; v/v).  Gradient 2 was as follows: 2% B at 0 
min, 2% B at 14.5 min, 12% B at 15 min, 23% B at 19 min, 90% B at 19.5 min, 90% B at 23.5 
min, and 2% B at 24 min. 
A Chiralpak AD-RH column (150 × 4.6 mm inner diameter, 5 µm; Daicel) was used for 
reverse phase (isocratic method 1, flow-rate 0.5 ml/min) separation of the un-derivatized 11-oxo-
ETE.  The mobile phase for isocratic separations was methanol/water/formic acid (95:5:0.1; v/v). 
Chemically synthesized 11-oxo-ETE was purified by normal-phase (isocratic method 2) 
preparative LC (Ultrasphere™ 250 × 10 mm, inner diameter, 5 µm; Beckman) using Waters® 
Alliance 2690 HPLC system by monitoring the UV absorbance at 236 nm.  The mobile phase for 
isocratic method 2 (flow-rate 2.5 ml/min) was hexane/isopropanol/acetic acid (98.5:1.5:0.1 ; v/v). 
GSH adducts were separated by reverse phase using gradient 3 on Waters® Alliance 2690 
HPLC system.  The separation employed a Phenomenex Synergi Hydro-RP column (150 × 4.6 
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mm inner diameters, 5 µm).  Solvent A was 0.1% aqueous formic acid, and solvent B was 
methanol/acetonitrile (50:50; v/v).  Gradient 3 was as follows: 2% B at 0 min, 2% B at 14 min, 
30% B at 20 min, 42% B at 21 min, 65% B at 27 min, 80% B at 29 min, 90% B at 33 min, 90% B 
at 34 min, 2% B at 35 min.  The flow rate was 0.4 ml/min.  The separation was performed at 
ambient temperature using a linear gradient. 
PFB Derivatization. Eicosanoids were dissolved in 100 µl of acetonitrile, and then reacted 
with 100 µl of PFB bromide in acetonitrile (1:19; v/v) and 100 µl of diisopropylethylamine in 
acetonitrile (1:9; v/v) at room temperature for 30 min.  The derivatives were evaporated to 
dryness, dissolved in 100 µl of hexane/ethanol (95:5; v/v) and analyzed by chiral LC-
ECAPCI/SRM/MS. 
Enzymatic Conversion of 11(R)-HETE by 15-PGDH. Various concentrations of 11(R)-
HETE (0, 2.3 M, 4.6 M, 6.9 M, 9.2 M and 23 M) were incubated with 4 nM of 
recombinant human 15-PGDH (50 ng, 1.8 pmol) and cofactor NAD
+
 (400 M) in 50 mM Tris-Cl 
(pH 7.9) for 3.5 min at 37 
o
C.  Each total reaction volume was 200 l.  After a 3.5 min 
incubation, the enzymatic reaction was quenched with 400 l of ice cold methanol and [13C20]-15-
oxo-ETE (8 ng) added as the internal standard.  Eicosanoids were extracted with 1.2 ml of 
dichloromethane/methanol (8:1; v/v).  The lower organic layer was then evaporated to dryness 
under nitrogen and reconstituted in methanol (100 l).  An aliquot (25 µl) was separated using 
isocratic method 1 and analyzed by LC-ESI/MS as described above.  The retention time for 11-
oxo-ETE was 8.7 min.  In separate experiments, the formation of 11-oxo-ETE was found to be 
linear for the first 5 min.  Eicosanoids were quantified by interpolation from a standard curve 
prepared with 11-oxo-ETE using [
13
C20]-15-oxo-ETE as the internal standard. 
Chemical Synthesis and Purification of 11-Oxo-ETE. The Dess-Martin reagent (5 mg, 12.0 
mol) was added to a solution of 11(R,S)-HETE (10 mg, 31.0 µmol) in dichloromethane (0.5 ml) 
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and stirred for 2 h at room temperature.  The reaction was monitored by LC-MS using gradient 1 
as described above, after PFB derivatization until there was no starting material left.  There was 
only one major product, which corresponded to 11-oxo-ETE.  The reaction mixture was 
centrifuged twice at 3,400 rpm (10 min) and the supernatant was evaporated.  The residue was 
dissolved in the mobile phase (800 l) and purified by isocratic method 2 as described above.  
The retention time for 11-oxo-ETE was 13.1 min.  High resolution accurate mass measurements 
were obtained using electrospray ionization on a Thermo LTQ-FT mass spectrometer at a 
resolution of 100,000 (data not shown).  NMR spectra were obtained on a Bruker 500 MHz NMR 
instrument. 
15-PGDH inhibition in LoVo or HCA-7 Cell Lysates by CAY10397.LoVo or HCA-7 cells 
were grown to 90% confluence, washed with 10 ml of phosphate-buffered saline (PBS) buffer (2 
times), and then gently scraped in 600 µl of lysis buffer containing 0.1 M Tris-HCl (pH 7.9) and 
the protease inhibitor.  Cell suspension was transferred to 2 ml Eppendorf tubes, and sonicated for 
60 seconds on ice (power 5).  Cell lysate was then incubated with or without the selective 15-
PGDH inhibitor (CAY10397, 50 M) and its co-factor (NAD+, 500 µM) for 10 min at 37°C.  The 
pH was then adjusted to 4 with 10% aqueous acetic acid (10 µl) followed by addition of the 
internal standard mix, [
13
C20]-15-oxo-ETE, [
2
H8]-15(S)-HETE and [
2
H4]-PGE2 (50 pg/µl, 20 µl).  
Diethyl ether (600 µl) was added, and samples were vortex-mixed and centrifuged (15000 rpm×2 
min).  The organic layer was evaporated under nitrogen, and then the eicosanoids were 
derivatized with PFB bromide as mentioned above.  Finally, samples were re-dissolved in 
hexane/ethanol (95:5; v/v, 100 µl), and analyzed (20 µl) by normal phase LC-ECAPCI/MS.  The 
amounts of eicosanoids were normalized by protein concentrations of each lysate, which were 
determined by BCA assay. 
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Metabolism of AA by LoVo or HCA-7 Cells. LoVo or HCA-7 cells were grown to 90% 
confluence in 6-well plates as described above, and then fed fresh serum-free F-12K or DMEM 
medium.  Cells were then incubated with AA (10 µM) for 0, 5, 10 and 30 min, 1 and 2.5 h at 
37°C.  At each time point, 0.6 ml medium was taken out, 20 µl 10% aqueous acetic acid was 
added to adjust pH to 3-4, together with 20 µl internal standards mixture (50 pg/ µl [
12
C20]-15-
oxo-ETE, [
2
H8]-15(S)-HETE, [
2
H4]-PGE2 and [
2
H4]-13,14-dihydro-15-keto-PGE2-PFB).  Then 
diethyl ether (1 ml) was added, and the mixture was vortex-mixed and centrifuged (15000 rpm × 
2 min).  The upper ether layer was evaporated under nitrogen, and PFB derivatives were 
synthesized as described above and analyzed by normal phase LC-ECAPCI/MS. 
Standard curves for Eicosanoid Quantification. To quantify eicosanoids excreted in the 
medium, Eppendorf tubes containing 0.6 ml F12K medium were spiked with lipid standards, 
together with internal standards for ([
12
C20]-15-oxo-ETE, [
2
H8]-15(S)-HETE ,[
2
H4]-PGE2 and 
[
2
H4]-13,14-dihydro-15-keto-PGE2-PFB 1 ng each).  To quantify eicosanoids in the cell lysate, 
lipids standards and internal standards mixture were spiked into 0.2 ml Tris-HCl buffer.  The 
extraction and PFB derivatization methods are the same as mentioned above. 
Analysis of 11-OEG adducts in LoVo cell lysate. LoVo cells were grown to 90% confluence 
and then washed with PBS (10 ml).  Cells were gently scraped in 600 µl Tris-HCl buffer (0.1 M, 
pH=7.9), containing protease inhibitor.  Cell lysates were transferred to 2 ml Eppendorf tubes, 
and sonicated for 60 seconds on ice (power 5).  11-oxo-ETE (20 ng in ethanol) was added to the 
lysate together with 1 mM GSH.  After incubation for 25 min at 37°C, 10 µl of 10% acetic acid 
was added, and the sample was loaded onto SPE column (oasis HLB, 30 mg) pre-conditioned 
with methanol and then 0.1% formic acid.  The column was washed with 1 ml water and eluted 
with 250 µl methanol, and then 20 µl was analyzed by reverse phase LC-ESI/MS using gradient 
3, as described above. 
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Cell proliferation assay. BrdU incorporation in HUVECs was used to assess the effects of 
11-oxo-ETE on cell proliferation.  The BrdU assay was performed in a 96-well format using a 
commercially available colorimetric enzyme-linked immunosorbent assay (ELISA) kit (Roche), 
and also by immunofluorescence microscopy.  Equal numbers of HUVECs in passage 4 were 
plated in either, collagen-I coated 96-well plates (2000 cells/well), or collagen-I coated 8-
chamber tissue culture glass slides (10000 cells/chamber).  Cells were allowed to attach overnight 
in 0.25% DMSO containing media.  Eicosanoids were dissolved in DMSO, such that the final 
concentration of DMSO in cell media was always 0.25% or lower.  Cells were then treated for 24 
h with either vehicle (0.25% DMSO), 11-oxo-ETE (1 nM-100 M), or 15d-PGJ2 (1 nM-100 M).  
After 18 h of treatment, BrdU (final concentration, 10 M in 0.25% DMSO) was added to each 
treatment group for an additional 6 h. 
For the colorimetric ELISA, the manufacturer’s protocol was followed to perform the assay.  
The absorbance at λ = 370 nm obtained from the assay was transformed to the cell numbers using 
a standard curve constructed by plating known number of HUVECs in triplicate.  The IC50 values 
for eicosanoid inhibition of HUVEC proliferation were defined as the half maximal inhibitory 
concentration for endothelial cell proliferation over 24 h when compared with vehicle-treated 
cells.  They were determined from the regression lines of the log inhibitor vs. response curves 
using a least squares fit. 
For the immunofluorescence staining, cells were fixed with neutral buffered formalin for 10 
min, permeabilized with methanol for 20 min, and then DNA was denatured by pressure cooking 
the slides in 10 mM citric acid buffer, pH 6 for 1 h.  Cells were then incubated overnight with rat 
anti-BrdU antibody (1:1000, Accurate Chemical & Scientific Corp.) at 4°C, followed by 30 min 
incubation at 37 °C with Cy3-conjugated donkey anti-rat secondary antibody (1:600, Jackson 
Immuno Research).  Cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI, 
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Invitrogen) and visualized using a Nikon E600 microscope equipped with differential interference 
contrast (Nomarski) optics and photographed (x200 magnification) with a Fast 1394 QICam 
(QImaging).  Positive BrdU staining was quantified by image analysis using IVision Analysis 
Software (Biovision).  The percentage of proliferating cells was
 
determined by counting the 
BrdU-positive cells versus the total
 
number of cells in randomly selected microscopic fields 
(10/replicate) for each treatment group. 
Statistical Analyses. All experiments were conducted in triplicate, unless otherwise indicated.  
Statistical significance (p value < 0.05) was determined using a two-tailed unpaired t-test 
employing GraphPad® Prism software (v 5.01). 
 
2.4 Results 
Biosynthesis of 11-oxo-ETE by 15-PGDH. Various concentrations of 11(R)-HETE were 
incubated with recombinant human 15-PGDH and NAD
+
 at 37
o
C.  A Michaelis-Menton kinetic 
analysis of 11-oxo-ETE formation revealed that the Vmax (296 nmol/min/mg), Km (3.42 M), and 
kcat (8.6 min
-1
) values for oxidation of 11(R)-HETE (Figure 3) were similar to those for 15(S)-
HETE (Km = 1.65 M, kcat =8.6 min
-1
; Supplementary Figure 1).  Therefore, the catalytic 
efficiency (Kcat/Km) for 15-PGDH-mediated oxidation of 11(R)-HETE (2513 min
-1
mM
-1
, Figure 
3) was similar to that for 15(S)-HETE (7091 min
-1
mM
-1
; Supplementary Figure 1). 
Chemical Synthesis of Authentic 11-Oxo-ETE. 11-Oxo-ETE was synthesized chemically 
by oxidizing racemic 11(R,S)-HETE using the Dess-Martin reagent, and then purified using 
chromatographic separation.  A combined total of 10 mg of the racemic 11(R,S)-HETE resulted in 
the isolation of 4.9 mg of pure 11-oxo-ETE (overall yield of 49%).  High resolution electrospray 
ionization-MS of 11-oxo-ETE revealed accurate masses of m/z 319.2263 and m/z 341.2079 for 
the protonated and sodiated molecules, respectively [calculated accurate mass for protonated 
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(C20H31O3) and sodiated (C20H30O3Na) molecules, m/z 319.2273 and m/z 341.2093, respectively].  
500 MHz 
1
H-NMR (H, CDCl3; Supplementary Figure 2) 7.55 (dd, J1 = 11.5 Hz, J2 =15.5, 1H), 
6.21(d, J =15.5Hz, 1H),  6.15-6.11 (m, 1H), 5.97-5.92 (m, 1H), 5.60-5.58 (m, 2H), 5.41-5.38 (m, 
2H), 3.35 (d, J =4.5Hz , 2H), 2.83-2.81 (m, 2H), 2.38-2.31 (m, 4H), 2.17-2.12 (m, 2H), 1.74-1.25 
(m, 8H), 0.89 (t, J = 7.0 Hz, 3H).  Analysis of purified 11-oxo-ETE as its PFB derivative by LC-
ECAPCI/MS (Figure 4a) revealed an intense negative ion at m/z 317 corresponding to [M-PFB]
-
.  
CID of [M-PFB]
-
 (m/z 317) and MS/MS analysis revealed major product ions at m/z 273, 219, 
165, 149, and 123.  The UV spectrum was consistent with the presence of a conjugated dienone 
with a UV max at 279 nm and molecular extinction coefficient () of 18,985 M
-1
cm
-1
.  
Confirmation of 11-oxo-ETE Identity by LC-MS and MS/MS Analyses. The LoVo cell 
line is known to express both COX-2 and 15-PGDH and only trace amounts of COX-1,(41,111) 
this was confirmed by Western blot analysis (data not shown).  Cell lysates were incubated with 
100 nM 11(R)-HETE in the presence of 500 M NAD+ for 10 min.  LC-MS analysis of PFB 
derivatives of eicosanoids extracted from the LoVo cell lysate showed that there was a single 
major metabolite, which eluted at 12.8 min (data not shown).  The full scan mass spectrum of this 
metabolite had only one major ion at m/z 317 corresponding to [M-PFB]
-
 (Figure 4b).  CID and 
MS/MS analysis revealed the formation of intense product ions at m/z 123, 149, 165, 219, and 
273 (Figure 4b).  The product ion spectrum was identical with that obtained from authentic 
synthetic 11-oxo-ETE-PFB (Fig. 4a), which confirmed the identity of 11-oxo-ETE from LoVo 
cells.  The product ion at m/z 165 in LoVo cell-derived and synthetic 11-oxo-ETE-PFB 
corresponded to cleavage between C-9 and C-10 and m/z 123 was formed from cleavage between 
C-11 and C-12 (Fig. 4).   
Separation of Eicosanoids by Chiral LC-ECAPCI/SRM/MS. Lysates from LoVo cells 
were extracted for the eicosanoids, which were then analyzed (after PFB derivatization) by LC-
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ECAPCI/SRM/MS.  A representative chromatogram (Figure 5) reveals the separation of 11-oxo-
ETE (retention time 12.8 min) and 15-oxo-ETE (retention time 12.0 min) that were formed in the 
LoVo cell lysate.  Additional eicosanoids that were observed (Figure 5) include, 13,14-dihydro-
15-keto-PGE2 (retention time, 33.6 min), 11(R)-HETE (retention time, 10.0 min), and PGE2 
(retention time, 29.4 min). 
Inhibition of 15-PGDH by CAY10397 in LoVo and HCA-7 cell lysates. In contrast to 
LoVo cells, the HCA-7 cell line is known to express COX-2 and only trace amounts of COX-1 
and 15-PGDH.(41,112)  This was confirmed by Western blot analysis (data not shown).  LoVo 
(Figure 6a) or HCA-7 (Figure 6b) cell lysates were incubated with 500 mM NAD+, with or 
without the 15-PGDH-inhibitor, CAY10397 (50 µM) for 10 min.  Inhibition of 15-PGDH 
significantly abolished the formation of endogenous 11-oxo-ETE (Figure 6a) by 92%, along with 
the diminished formation of 15-oxo-ETE as well as 13,14-dihydro-15-oxo-PGE2 (Figure 6a) in 
the LoVo cell lysate.  However, since the oxo-ETEs and 13,14-dihydro-15-oxo-PGE2 were 
undetectable in HCA-7 cell lysate, their precursors were quantified instead, and CAY10397 had 
no effect on their levels (Figure 6b). 
Secretion of eicosanoids from LoVo and HCA-7 cells following AA addition. Time-course 
analyses for the amount of different eicosanoids secreted by LoVo and HCA-7 cells following 
AA incubation for 0-2.5 h are shown in Figure 7a and Figure 7b, respectively.  11-Oxo-ETE was 
secreted into the cell media by LoVo cells along with 15-oxo-ETE and 13,14-dihydro-15-oxo-
PGE2 (Figure 7a).  Interestingly, both 11-oxo-ETE and 15-oxo-ETE reached maximum 
concentrations 10 min after the addition of AA to the cells.  This was followed by a decline of 
both eicosanoids to steady-state levels after 2.5 h (Figure 7a) in LoVo cells.  In contrast, 13,14-
dihydro-15-oxo-PGE2 levels did not peak until 1 h after the addition of AA (Figure 7a) and 
remained constant throughout the remainder of the incubation period.  In contrast, none of the 
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eicosanoids resulting from 15-PGDH-mediated metabolism were detected in the media of HCA-7 
cells incubated with AA (Figure 7b). 
Formation of 11-OEG in LoVo Cell Lysates. Biosynthesis of 11-OEG was monitored in the 
cell lysate after the addition of 100 nM 11-oxo-ETE and 1 mM GSH to the LoVo cell lysate.  11-
OEG formation was detected and confirmed by LC-MS/MS monitoring of the major metabolite 
formed after a 30 min incubation.  OEG (retention time, 32.2 min, data not shown) was observed 
as an intense peak in the LC-ESI/MS chromatogram when analyzed by gradient 3 (as described 
above).  CID and MS/MS analysis revealed the formation of intense product ions at m/z 497, 319, 
308, and 179 (Figure 8). 
Effects of Eicosanoids on HUVEC Proliferation. Proliferation by HUVECs was assessed by 
quantifying the BrdU incorporation into the cells actively synthesizing new DNA.  The BrdU 
assay was performed using a quantitative colorimetric 96-well format ELISA as well as by 
immunofluorescence microscopy for observing the morphological effects of eicosanoids in 
HUVECs.  For the BrdU ELISA, HUVECs (2000 cells/well) were treated with different doses (0-
100 M) of 11-oxo-ETE and 15d-PGJ2 for a period of 24h.  The cell numbers corresponding to 
each treatment dose were computed and used to calculate cell proliferation (%) as compared to 
the vehicle-treated controls.  11-Oxo-ETE (IC50 = 2.1 M) was equipotent with 15d-PGJ2 (IC50 = 
2.3 M), a known potent inhibitor of endothelial cell proliferation (Figure 9a).  For the 
immunofluorescence analysis, HUVECs (8000 cells/chamber) were treated with 2 M of either 
11-oxo-ETE or 15d-PGJ2 for 24 h.  BrdU incorporation was assessed by counting the BrdU-
positive cells as compared to the total number of cells counted in randomly selected microscopic 
fields (10 fields/treatment).  The photomicrographs clearly show that treatment with 11-oxo-ETE 
as well as 15d-PGJ2 remarkably reduced the total number of BrdU-positive cells (stained red) as 
compared to vehicle-treated controls (Figure 9b).  Moreover, there was a distinct change in the 
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morphological appearance of the DAPI-stained (stained blue) cells in the eicosanoid-treated 
slides that failed to incorporate BrdU (Figure 9b). 
 
2.5 Discussion 
15-PGDH catalyzes NAD
+
-mediated oxidation of the 15(S)-hydroxyl moiety of PGs and other 
eicosanoids (Fig 1).(41,98,108)  Our previous studies had established that 15-PGDH is also 
responsible for metabolizing the 15-lipoxygenase-derived 15(S)-HETE in macrophages and 
monocytes to 15-oxo-ETE.(108)  Surprisingly, we have now found that 11(R)-HETE is also 
metabolized by 15-PGDH to a novel eicosanoid, that was identified as 11-oxo-ETE (Fig 2).  
Moreover, the catalytic activity of human 15-PGDH for oxidation of 11(R)-HETE (Figure 2) was 
very similar to that observed for 15(S)-HETE (Supplementary Figure 1).  These results were very 
surprising in view of the lack of a 15(S)-hydroxyl group on 11(R)-HETE as well as the incorrect 
11(R)-stereochemistry.  The structure of 11-oxo-ETE metabolite was established by chemically 
synthesizing authentic 11-oxo-ETE from racemic 11-HETE.  11-Oxo-ETE was formed in both 
LoVo cell lysates (Figure 6a) and secreted from intact cells (Figure 7a); whereas 11-oxo-ETE was 
not formed by HCA-7 cell lysates (Figure 6b) or secreted from intact cells (Figure 7b).  Since 
LoVo cells express COX-2 as well as 15-PGDH, whereas HCA-7 cells express COX-2 but not 
15-PGDH,(41,111,112) these data convincingly prove that 11-oxo-ETE is an endogenous product 
formed enzymatically by a combination of COX-2 and 15-PGDH. 
11-oxo-ETE is isomeric with 15-oxo-ETE (Figure 2) and also has very similar LC properties.  
Therefore, a reversed phase LC-SRM/MS method was developed to separate the un-derivatized 
oxo-ETEs, and normal phase was implemented to separate their PFB derivatives.  This made it 
possible to readily analyze the two oxo-ETEs.  Endogenous eicosanoids formed by LoVo and 
HCA-7 epithelial cells and cell lysates as well as those formed after the addition of AA were 
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analyzed as PFB derivatives by chiral LC-ECAPCI/MS.(110,113)  Representative 
chromatograms of the eicosanoids produced endogenously in the LoVo cell lysates are shown in 
Figure 5.  Inhibition of 15-PGDH enzyme by CAY10397 significantly diminished the formation 
of endogenous 11-oxo-ETE in LoVo cell lysates (Figure 6a).  In addition, the formation of 15-
oxo-ETE as well as 13,14-dihydro-15-oxo-PGE2, the other two 15-PGDH-dependent metabolites, 
were also significantly reduced in LoVo cell lysates treated with CAY10397 (Figure 6a).  In 
contrast, the three 15-PGDH products, namely, 11-, 15-oxo-ETE and 13,14-dihydro-15-oxo-
PGE2, were undetectable in HCA-7 cells as these cells do not express any 15-PGDH.(41,111)  
Instead, the corresponding precursors for these three metabolites were observed in the lysates.  
Furthermore, treatment with CAY10397 had no effect on levels of 11(R)-HETE, 15(S)-HETE or 
PGE2 (Figure 6b).  Intact LoVo cells also secreted 11-oxo-ETE, 15-oxo-ETE as well as 13,14-
dihydro-15-oxo-PGE2.  However, the 11-oxo-ETE was cleared very rapidly (Figure 7a), 
suggesting that further metabolism was occurring.  Subsequently, it was observed that 11-oxo-
ETE underwent GST-mediated metabolism to 11-OEG, similar to the formation of 15-OEG in 
RIES cells (Figure 8).(110) 
We realized that 11-oxo-ETE, is very similar in structure to 15d-PGJ2.  It only differs in the 
lack of a C-8 to C-12 bond, in having a cis-8,9- rather than cis-9,10-double bond, and a cis- rather 
than trans-14,15-double bond (Figure 2).  This suggested that 11-oxo-ETE might be a more 
effective inhibitor of HUVEC proliferation than 15-oxo-ETE(108) with a potency similar to that 
observed for 15d-PGJ2.(101)  In fact, 11-oxo-ETE was six times more potent than 15-oxo-ETE 
(data not shown) and equipotent with 15d-PGJ2 at inhibition of HUVEC proliferation (Figure 9).  
Dose-response studies revealed that its IC50 was 2.1 M compared to an IC50 value of 2.3 M for 
15d-PGJ2 (Figure 9a).  Moreover, immunofluorescence microscopy revealed that 11-oxo-ETE not 
only inhibited BrdU incorporation into the HUVECs but it also caused a dramatic change in the 
shape and morphology of these cells (Figure 9b).  Although the total number of cells counted in 
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the eicosanoid-treated groups were quite similar to the vehicle-treated group, the BrdU-negative 
cells were significantly distorted (Figure 9b).  Typically, if the cells are undergoing death by 
apoptosis, they would appear more compact and round.  However, 11-oxo-treated cells were 
elongated and stretched (Figure 9b), which could be indicative of extensive cytoskeletal 
remodeling, cell cycle arrest and/or differentiation.  Interestingly, 11-oxo-ETE formation could 
not be detected in HUVEC lysate that was incubated with 11(R)-HETE (data not shown).  
Finally, immunoblot analysis of HUVEC cell lysate failed to detect COX-2 protein (data not 
shown).  Taken together, these data suggest a paracrine role for 11-oxo-ETE on endothelial cell 
proliferation.   
As noted above, inhibition of 15-PGDH resulted in significant decreases in 11-oxo-ETE 
formation in LoVo cells (Figure 6).  15-PGDH is down-regulated in numerous cancers 
types,(41,91,92,94-96) which would cause a decrease in 11-oxo-ETE biosynthesis by preventing 
the in vivo conversion of 11(R)-HETE to 11-oxo-ETE (Figure 1).  This could be particularly 
devastating as COX-2 becomes up-regulated during tumorigenesis, which would result in 
elevated PGE2 biosynthesis along with decreased 15-PGDH-mediated inactivation to 15-oxo-
PGE2 (Figure 1).  Ultimately, this would result in an increase in PGE2-mediated pro-proliferative 
activity(13,97) without the counter effect of anti-proliferative oxo-ETEs.  Increased PGE2 activity 
can also arise through down-regulation of the influx PG transporter - the organic anion transporter 
polypeptide (OATP) 2A1 (Figure 1).(50,114) 
There is some evidence that 11-oxo-ETE can activate nuclear PPAR.(16)  PPAR is a ligand-
dependent transcription factor responsible for the regulation of a number of cellular events 
ranging from lipid metabolism to apoptosis.(115)  15d-PGJ2 is a PPAR agonist, which might 
account for its ability to inhibit endothelial cell proliferation.(100,101)  However, this effect is 
only observed with pharmacological amounts of 15d-PGJ2 rather than endogenous 
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concentrations.(109)  Besides PPAR agonistic activity, 15d-PGJ2 is also known to be an 
inhibitor of NFB signaling, a pathway critical to cell proliferation as well as 
tumorigenesis.(116,117)  In view of the ability of COX-2/15-PGDH to rapidly metabolize AA to 
nM amounts of oxo-ETEs, together with the structural similarity of oxo-ETEs and 15d-PGJ2 
(Figure 2), it will be important to determine which of these activities are shared by both classes of 
eicosanoids.  It is noteworthy that docosahexaenoic acid and docosapentaenoic acid can be 
metabolized by the sequential action of COX-2 and dehydrogenises into oxo-eicosanoids that 
modulate the antioxidant response.(118)  Similarly 5-lipoxygenase-drived 5(S)-HETE is 
metabolized by 5-hydroxyeicosanoid dehydrogenase into the chemoattractant 5-oxo-ETE.
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(119)(118)(118)(117)(117)(116)(116)(116)  Therefore, the oxo-eicosanoids represent a family of 
oxidized lipids with diverse biological activities. 
In summary, our studies have revealed that down-regulation of 15-PGDH inhibits the 
formation of endogenous anti-proliferative eicosanoid, 11-oxo-ETE.  Therefore, 15-PGDH has 
two quite distinct properties; it can either inactivate PGs or activate HETEs to oxo-ETEs that 
exert a paracrine effect on endothelial cells (Figure 1).  11-Oxo-ETE, a member of the oxo-ETE 
family,(119-121) was observed previously as an endogenously-derived lipid in human 
atherosclerotic plaques.(122)  However, the biosynthesis of 11-oxo-ETE and its biological 
activity were not evaluated in that study.  Furthermore, there does not appear to be any 
subsequent report of its formation either, in vitro or in vivo.  We have now shown that in fact 11-
oxo-ETE is derived from COX-2/15-PGDH-mediated AA metabolism and that it inhibits 
endothelial cell proliferation with an IC50 that is very similar to that of 15d-PGJ2. 
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Figure 2.1. Formation and action of COX-2-derived eicosanoids in epithelial cell 
models.  
AA is released from membrane phospholipids by calcium-dependent cytosolic phospholipase A2 
(cPLA2).  The released AA undergoes COX-2-medaited metabolism to PGs or forms the lipid 
hydroperoxides, 15(S)-hydroperoxyeicosatetraenoic acid; (HPETE), 15(R)-HPETE and 11(R)-
HPETE, which are reduced to the corresponding HETEs.  PGD2 and PGE2 are inactivated by 15-
PGDH-mediated conversion to their 15-oxo-metabolites.  Both 15-oxo-PGD2 and 15-oxo-PGE2 
are converted to 13,14-dihydro-5-oxo-PG metabolites.  Intact PGD2 secreted by the epithelial 
epithelial cell membrane
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cells can undergo albumin-mediated dehydration to 15d-PGJ2.  PGE2 secreted from the epithelial 
cells by the ABCC4 transporter is pro-proliferative for tumor cells.  Re-uptake of PGE2 by 
OATP2A1 into the epithelial cells leads to further 15-PGDH-mediated inactivation.  In contrast to 
PGE2 and PGD2, 15(S)-HETE and 11(R)-HETE are activated by 15-PGDH-mediated oxidation to 
15-oxo-ETE and 11-oxo-ETE, respectively.  The oxo-ETEs are further conjugated to form OEGs.  
Secreted 15- and 11-oxo-ETE that escape further metabolism can then inhibit endothelial cell 
proliferation.  Therefore, down-regulation of 15-PGDH and OATP2A1 would result in increased 
PGE2-mediated tumor and endothelial cell proliferation. 
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Figure 2.2.  Chemical structures of COX-2 derived eicosanoids. 
 
 
Figure 2.3. Kinetic plot of the formation of 11-oxo-ETE by 15-PGDH.  Various  
concentrations of 11(R)-HETE (0- -PGDH and cofactor NAD+.   
Determinations for 11-oxo-ETE were conducted in triplicate (means ± S.E.M.) by stable isotope  
dilution LC-ESI/MS analyses.  
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Figure 2.4. Confirmation of 11-oxo-ETE formation by LC-MS/MS analysis.   
Specific product ions observed by CID and MS/MS analysis of [M-PFB]
∙
 (m/z 317), corresponding  
to 11-oxo-ETE are shown on the relevant chemical structures.  (a) Synthetic 11-oxo-ETE-PFB  
standard; (b) 15-PGDH-derived 11-oxo-ETE-PFB from LoVo cell lysate to which 100 nM 11(R)- 
HETE had been added.  
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Figure 2.5. Targeted chiral lipidomics of COX-2 derived eicosanoids from LoVo 
cells.   
LoVo cells were lysed; eicosanoids were extracted, derivatized with PFB bromide, and analyzed by  
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LC-ECAPCI/SRM/MS.  LoVo cell lysates were pre-treated with 50 µM CAY10397 to inhibit 15- 
PGDH to be able to detect the 11-, 15-HETEs and PGE2.  Representative chromatograms are shown  
for (a) 11(R)-HETE-PFB (m/z 319  167), (b) [2H8]-15(S)-HETE-PFB internal standard (m/z 327   
226), (c) 11-oxo-ETE-PFB (m/z 317  165), (c) 15-oxo-ETE-PFB (m/z 317  165), (d) [13C20]- 15- 
oxo-ETE-PFB internal standard (m/z 337  120), (e) PGE2-PFB (m/z 351  271), (f) [
2
H4]-PGE2- 
PFB (m/z 355  275), (g) 13,14-dihydro-15-oxo-PGE2-PFB (m/z 351  235), (h) [
2
H4]-13,14- 
dihydro-15-oxo-PGE2-PFB (m/z 355  239).   
 
 
Figure 2.6. Inhibition of 15-PGDH in LoVo and HCA-7 cell lysates by CAY10397.  (a)  
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LoVo or (b) HCA-7 cell lysate (1x10
6
 cells/treatment group) was incubated with or without  
CAY10397 (50 µM, to inhibit 15-PGDH).  Eicosanoids were extracted from the lysates and their  
levels were determined by chiral LC-ECAPCI/SRM/MS.  Analyses were performed in triplicates,  
and error bars show S.E.M. 
 
Figure 2.7. Time course for eicosanoids secreted from LoVo and HCA-7 cells.   
(a) LoVo or (b) HCA-7 cells were incubated with 10 M AA for 0-6 h.  The different eicosanoids  
secreted into the media at various time-points were extracted and their levels were determined by  
stable isotope dilution LC-ECAPCI/SRM/MS analysis of their PFB derivatives.  Determinations  
were conducted in triplicate (means + S.E.M.), and the quantitation was performed using the  
standard curves generated for these eicosanoids.  
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Figure 2.8. LC-MS/MS analysis of 11-OEG adduct.  11-OEG was synthesized by reacting 200  
nM 11-oxo-ETE and 1 mM GSH in LoVo cell lysate for 25 min at 37°C.  The product was extracted  
by solid-phase extraction and analyzed by LC-ESI/MS/MS.  Specific product ions observed by CID  
of [MH]
+ 
(m/z 626) are shown with their relevant chemical structures in the MS/MS analysis of 11- 
OEG.  
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Figure 2.9. Effect of eicosanoids on cell proliferation of HUVECs.  (a) For BrdU ELISA,  
HUVECs (2000 cells/well) were treated with various doses of 11-oxo-ETE and 15d-PGJ2 for a  
period of 24 h.  Cell proliferation (means + S.E.M.) was assessed by measuring absorbance at 370  
nm and converting it to cell numbers using a standard curve and thereby used to construct the IC50  
plots.  All experiments were conducted three times in triplicate.  Representative data from one  
experiment conducted in triplicate are shown as means ± S.E.M.  (b) For immunofluorescence,  
HUVECs (8000/chamber) were treated with 2 M of 15d-PGJ2 or 11-oxo-ETE for 24 h and then  
stained for BrdU and counterstained with DAPI (cells stained blue).  Photomicrographs were taken at  
x200 magnification, and BrdU-positive (stained purple) cells were counted in randomly selected  
microscopic fields (10/replicate) as compared to the total number of cells in these fields.  All  
experiments were conducted in triplicate.  Representative photomicrographs from one set of  
replicates are shown. 
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Figure 2.10. Kinetic plot of the formation of 15-oxo-ETE by 15-PGDH.  Various  
concentrations of 15(S)-HETE were incubated with 4 nM 15-PGDH and cofactor NAD
+
.  
Determinations were conducted in triplicate (means ± S.E.M.) by stable isotope dilution LC-ESI-
SRM/MS analyses.   
 
 
 
 
Figure 2.11. 500 MHz 1H NMR spectrum of 11-oxo-ETE in CDCl3. 
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Chapter 3: Cellular Uptake and Anti-proliferative Effects of 11-
oxo-eicosatetraenoic Acid 
 
Published as: Snyder, Nathaniel W., et al. "Cellular uptake and anti-proliferative effects of 11-
oxo-eicosatetraenoic acid." Journal of lipid research (2013). 
 
3.1 Abstract 
Cyclooxygenases (COXs) metabolize arachidonic acid (AA) to 
hydroxyeicosatetraenoic acids (HETEs), which can then be oxidized by dehydrogenases 
such as 15-hydroxyprostaglandin dehydrogenase (15-PGDH) to oxo-eicosatetraenoic 
acids (ETEs).  We have previously established that 11-oxo-eicosatetraenoic acid (oxo-
ETE) and 15-oxo-ETE are COX-2/15-PGDH-derived metabolites.  Stable isotope dilution 
chiral liquid chromatography coupled with electron capture atmospheric pressure 
chemical ionization/mass spectrometry has now been used to quantify uptake of 11-oxo-
ETE and 15-oxo-ETE in both and LoVo cells and human umbilical vein endothelial cells 
(HUVECs).  Intracellular 11-oxo- and 15-oxo-ETE concentrations reached maximum 
levels within 1 h and declined rapidly, with significant quantitative differences in uptake 
between the LoVo cells and the HUVECs.  Maximal intracellular concentrations of 11-
oxo-ETE were 0.02 ng/4x105 cells in the LoVo cells and 0.58 ng/4x105 cells in the 
HUVECs.  Conversely, maximal levels of 15-oxo-ETE were 0.21 ng/4x105 in the LoVo 
cells and 0.01 ng/4x105 in the HUVECs.  The methyl-esters of both 11-oxo- and 15-oxo-
ETE increased the intracellular concentrations of the corresponding free oxo-ETEs by 3-
8-fold.  11-oxo-ETE, 15-oxo-ETE, and their methyl esters inhibited proliferation in both 
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HUVECs and LoVo cells at concentrations of 2-10 M, with 11-oxo-ETE methyl ester 
being the most potent inhibitor.  Co-treatment with probenecid, an inhibitor of multiple 
drug resistance transporters (MRPs) 1 and 4, increased anti-proliferative effect of 11-
oxo-ETE methyl ester in LoVo cells and increased the intracellular concentrations of 11-
oxo-ETE from 0.05 ng/4x105 cells to 0.18 ng/4x105 cells. Therefore, the present study 
has established that the COX-2/15-PGDH derived eicosanoids 11-oxo- and 15-oxo-ETE 
enter target cells, that they inhibit cellular proliferation, and that their inhibitory effects are 
modulated by MRP exporters. 
3.2 Introduction 
AA metabolism is implicated in cellular and physiologic regulation, inflammatory 
diseases, and cancer (123).  In colon cancers, COX-2 expression is increased and 
conversely 15-PGDH is down-regulated (41).  There is also evidence for COX-2/15-
PGDH counter-regulation in gastric, breast, and lung cancers (88,95,124).  The 
magnitude of the up-regulation/down-regulation may even serve as an independent 
predictor of progression and survival (125,126).  This “proliferative switch” is 
hypothesized to increase tumorigenesis and angiogenesis via increased prostaglandin 
(PG) E2 formation (Fig. 1A) and a feed forward loop for COX-2 (127,128).  However, 
COX-2 mediated AA metabolism also generates other eicosanoids including 11- and 15-
hydroperoxyeicosatetraenoic acids (HPETEs) and after reductive metabolism, the more 
stable 11- and 15-HETEs (27,83) (Figs. 1A, 1B).  15-HPETE is also a major product of 
the lipoxygenase pathway, through various 15- or 12/15-lipoxygenases (LOXs; Fig. 1B) 
(33).  15-PGDH then oxidizes 11- or 15-HETE to the ,-unsaturated ketone-containing 
oxo-ETEs (108,129).  Confirmation of the dehydrogenase pathway has been obtained 
using numerous experimental paradigms.  15-oxo-ETE was found as a major product of 
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15-PGDH-mediated oxidation of 15(S)-HETE in rabbit lung, as a major product of AA 
from mast cells, and as a major product of stenosed canine coronary arteries (130-132).  
In addition, either COX/15-PGDH or LOX/15-PGDH mediated metabolic pathways are 
involved in the formation of 15-oxo-ETE (Fig. 1B) (83,108).  Furthermore, 11-oxo- and 
15-oxo-ETE have been detected in advanced human atherosclerotic lesions, although its 
route of formation was not examined in that study (122).  Finally, we have demonstrated 
recently that 11-oxo-ETE is generated by COX/15-PGDH mediated metabolism (129). 
In spite of significant evidence for the formation of 11- and 15-oxo-ETEs in vivo, 
the pharmacology of these endogenous metabolites has not been examined in detail.  In 
contrast, the structurally related PG analog, 15-deoxy-12,14-PGJ2 (15d-PGJ2; Fig. 1A) 
has been very extensively studied as an endogenous PPAR ligand, NF-B modulator, 
and redox signaling mediator (12,133,134).  Anti-proliferative and anti-inflammatory 
properties have also been examined for similar bioactive lipids including: 15-oxo-ETE 
(108), linoleic acid metabolites (135), a series of long-chain electrophilic fatty acids 
termed the EFOXs (118), and nitro-fatty acids (136).  In the absence of a known G-
protein coupled receptor, such as that activated by 5-oxo-ETE,(121) these bioactive 
lipids are hypothesized to rely on intra-cellular targets.  Therefore, understanding the 
availability of these compounds to the cytoplasmic space is of critical importance.  This 
study was designed to test the cellular uptake, metabolism, and anti-proliferative effects 
of 11-oxo-ETE in multiple cell models.  We examined differential uptake of both 11-oxo- 
and 15-oxo-ETE between HUVECs and the LoVo colon cancer cell line.  Using methyl-
ester derivatives of 11-oxo-ETE and 15-oxo-ETE, we studied targeted intracellular 
delivery to HUVECs and LoVo cells. Finally, we investigated whether there was 
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potentiation of the anti-proliferative action of oxo-ETEs through targeted delivery or by 
pharmacological blockade of MRP exporters. 
3.3 Materials and Methods 
Chemicals and Reagents.  LC-MS Optima grade hexanes, methanol, acetonitrile, 
isopropanol, protease inhibitor, and BCA protein quantification kit were obtained from 
Fisher Scientific (San Jose, CA).  Dichloromethane, N,N-diisopropylethylamine (DIPEA), 
dimethyl sulfoxide (DMSO), and pentafluorobenzyl bromide (PFB) were from Sigma-
Aldrich (St. Louis, MI).  Probenecid was obtained from Enzo Life Sciences (Farmingdale, 
NY). Phosphate buffered saline (PBS) and 3-(N-morpholino) propanesulfonic acid 
(MOPS) were from Invitrogen (Carlsbad, CA). 11-oxo-ETE, 15-oxo-ETE, [13C20]-15-oxo-
ETE, as well as the methyl esters of 11-oxo-ETE (11-oxo-ETE-ME) and 15-oxo-ETE (15-
oxo-ETE-ME) were prepared in house with standard procedures (129).  Western 
Lightning ECL was obtained from Perkin Elmer (Waltham, MA).  Fetal bovine serum 
(FBS) was obtained from Gemini Bioproducts (West Sacramento, CA).  HUVECs, 
human arterial endothelial cells (HAECs), Medium 200, Low Serum Growth Supplement 
(LSGS), penicillin, streptomycin, F-12K media, and DMEM media were obtained from 
Invitrogen (Carlsbad, CA).  LoVo, MCF-7, A549, and HCA-7 cell lines were obtained 
from American Type Culture Collection (ATCC) (Manassas, VA). 
Cell culture.  LoVo and adenocarcinoma human alveolar epithelial (A549) cells were 
maintained in F-12K media supplemented with 2% FBS and 100,000 units/L penicillin 
and 100mg/L streptomycin.  HUVECs and human arterial endothelial cells (HAECs) 
were maintained in Medium 200 (Invitrogen, Carlsbad, CA ) supplemented with the 
LSGS Kit on Collagen I-coated tissue culture dishes  (Becton Dickinson, Bedford, MA).  
Human colonic adenocarcinoma (HCA-7) cells and the MCF-7 breast cancer cells were 
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maintained in DMEM supplemented with 2% FBS and 100,000 units/L penicillin and 
100mg/L streptomycin.  The relevant maintenance media was used for treatment unless 
otherwise indicated. 
Quantification of cellular uptake.  LoVo cells and HUVECs were plated at 4x105 cells / 
well in a 6-well tissue culture plate (Corning, Corning, NY) or a 6-well collagen coated 6-
well plate (Becton Dickinson, Bedford, MA) and allowed to attach for 12 h.  11-oxo-ETE, 
15-oxo-ETE, or the respective methyl ester stocks were re-suspended in media 
containing 0.25% DMSO at indicated concentrations.  Either LoVo cells or HUVECs 
were treated for indicated time-points with indicated compounds.  Media was pipetted 
off; a 3 mL aliquot was spiked with 1 ng [13C20]-15-oxo-ETE internal standard, and taken 
for analysis.  The cells were rinsed 4 times with cold PBS, gently scraped into 3 mL of 
cold PBS, and spiked with 1 ng [13C20]-15-oxo-ETE internal standard.  The final rinse of 
cold PBS was taken and sampled as a control for residual 11-oxo- or 15-oxo-ETE.  
Extraction and derivatization has been described in detail elsewhere (137).  Briefly, 
media was extracted with diethyl ether with 0.5% acetic acid with vigorous shaking and 
the organic phase was separated and evaporated under nitrogen gas.  Cells were 
extracted with dichloromethane/methanol (2:1,v/v, with 0.5% acetic acid) with vigorous 
shaking and one freeze-thaw cycle, the organic phase was then removed and 
evaporated under nitrogen gas.  After evaporation of the organic phases to dryness, 
samples were suspended in 100 µL DIPEA in acetonitrile (1:9; v/v) and 200 µL of PFB 
bromide in acetonitrile (1:19; v/v) and kept at room temperature for 30 min.  The 
derivatized samples were dried down again under nitrogen, and then re-suspended in 
100 µL of hexane/ethanol (95:5; v/v) for stable isotope dilution chiral LC-selected 
reaction monitoring (SRM)/ECAPCI/MS analysis. 
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Treatment of cells with [13C20]-15-oxo-ETE. LoVo cells (5x10
6) were cultured as 
described above and then treated with 10 mM [13C20]-15-oxo-ETE.  Cell and media 
fractions were pooled, and derivatization and analysis were performed as described 
above except the internal standard was omitted. 
Liquid Chromatography.  A Water’s Alliance 2690 HPLC system (Waters Ltd, Watford, 
Hertfordshire, UK) was used for liquid chromatography separations. The PFB derivatives 
of 11-oxo-ETE and 15-oxo-ETE were separated using normal phase Chiralpak AD-H 
column (250x4.6mm, 5µm; Daicel Chiral Technologies, Westchester, PA) with a 1 
mL/min flow rate. Solvent A was hexanes and solvent B was isopropanol/hexane (6:4; 
v/v). Gradient composition was: 2% B at 0 min, 2% B at 14.5 min, 12% B at 15 min, 90% 
B at 17 min, 90% B at 22 min, 2% B at 22.5 min, and 2% B at 29 min. 
Mass Spectrometry.  A Thermo Triple Stage Quadrupole (TSQ Quantum) mass 
spectrometer (Thermo Scientific) with an APCI source was operated in negative ion 
mode.  The following transitions corresponding to each compound were monitored; 11-
oxo-ETE-PFB, m/z 317165 [collision energy (CE), 25 eV] 15-oxo-ETE-PFB, m/z 
317113 (CE, 18 eV); [13C20]-15-oxo-ETE-PFB, m/z 337120 (CE, 18 eV).  For 
absolute quantification of 15-oxo-ETE and 11-oxo-ETE, standard curves ranging from 0 
to 2 ng and 0 to 4 ng, respectively, were generated in the same matrix under identical 
extraction conditions with pure compounds.  Data analysis was performed using Xcalibur 
software (Thermo Scientific). 
BrdU Incorporation Assays.  HUVECs, LoVo, HCA-7, and A549 cells were plated at 
2000 cells/well and allowed to attach for 12 h.  Treatment media was prepared at 
indicated concentrations by serial dilution from the most concentrated stock, keeping 
constant 0.25% DMSO.  Cells were treated for 24 h, and then spiked with BrdU for 6 h to 
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allow incorporation into newly synthesized DNA.  The assay was developed using a 
BrdU cell proliferation kit (Roche Diagnostics) according to the manufacturer’s directions, 
and a UV-Vis plate reader (BioRad). 
Western Blots.  Cells were collected from pre-confluent cultures and lysed in RIPA 
buffer containing 1x protease inhibitor cocktail.  Protein was quantified with a BCA kit.  
30 g of protein lysate in reducing conditions was loaded into 4-12% gradient gel and 
ran in MOPS buffer for 50 min at 200V.  Proteins were transferred onto a nitrocellulose 
membrane overnight on ice at 30V.  After blocking with 5% BSA in TBS/T, primary 
antibody was incubated overnight in blocking buffer.  Primary antibodies for MRP1, 
MRP4, and GAPDH were respectively, Abcam (ab32574-100), (ab56675), and (ab8245).  
Secondary antibody was HRP-conjugated sheep anti-mouse from GE Life Sciences 
(NA9310).  All antibodies were diluted in blocking buffer at 1:1000.  Visualization was 
accomplished with Western Lightning ECL in a digital developer (GE Healthcare). 
MTT Proliferation Assays.  LoVo cells were plated at 2000 cells/well and allowed to 
attach for 12 h.  Treatment media was prepared at indicated concentrations by serial 
dilution from the most concentrated stock, keeping constant 0.25% DMSO.  Probenecid 
was added from a concentrated stock to 1mM treatment concentration.  After indicated 
time-points, media was replaced with fresh base media containing no FBS or Pen/Strep, 
and MTT was added to a final concentration of 2 mg/mL and allowed to incubate for 4 h.  
After incubation, all of the media was removed and the MTT was eluted using pure 
isopropanol.  The resulting absorbance was read at 565 nm in a 96-well plate using a 
UV-Vis plate reader (BioRad). 
Statistical analysis.  All statistical analyses were carried out using the GraphPad Prism 
(5) software package. 
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3.4 Results 
Intracellular 11-oxo-ETE was reduced in LoVo colon cancer cells versus human 
umbilical vein endothelial cells.  To study the uptake and metabolism of 11-oxo-ETE, 
LoVo cells or HUVECs were incubated with 10 M of 11-oxo-ETE, 10 M of 15-oxo-
ETE, or media with 0.25% DMSO vehicle for 4 h.  Media and cells were collected at 
various time-points.  Quantification of the free 11-oxo- and 15-oxo-ETE was performed 
by stable isotope dilution chiral LC-SRM/ECAPI/MS with [13C20]-15-oxo-ETE as the 
internal standard.  Cells were carefully normalized to cell count used in the experiments, 
and only allowed a minimum of time to attach in order to avoid excess growth.  Cell 
volume determination would require lifting of the cells which, especially in the case of the 
collagen attached, elongated HUVECs, could result in a cell volume change. 
Intracellular concentrations of 11-oxo-ETE were reduced in the LoVo cells (Fig. 
2A) as when compared with the HUVECs (Fig. 2B) at all time-points examined.  15-oxo-
ETE demonstrated the opposite trend, with greater intracellular amounts in LoVo cells 
(Fig. 2A) versus HUVECs (Fig. 2B).  Maximal uptake of 11-oxo-ETE was achieved for 
LoVo cells and HUVECs at 30 min and 60 min, respectively.  15-oxo-ETE maximal 
uptake occurred at 30 min for both cell types.  Clearance of the free 11-oxo-ETE 
occurred completely in both cell lines by 4 h, whereas 15-oxo-ETE was still detectable at 
that time.  Treatment of the LoVo cells with [13C20]-15-oxo-ETE did not cause the 
generation of endogenous 11-oxo-ETE or 15-oxo ETE as judged by comparison of the 
LC-MS chromatogram that was obtained from the cell suspension (Supplementary Fig. 
3) with that obtained from the internal standard alone (Supplementary Fig. 1).  This 
conclusively demonstrated that 11-oxo-ETE uptake and metabolism was significantly 
different between the LoVo cells (Fig. 2A) and HUVECs (Fig. 2B). 
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11-oxo-ETE inhibited BrdU incorporation across multiple cell lines with varying 
potency.  BrdU incorporation assays were used to measure the anti-proliferative effects 
of treatments with increasing doses of 11-oxo-ETE.  The value obtained for vehicle 
treatment 0.25% DMSO was arbitrarily set at 100%.  Multiple cancer cell lines were used 
including LoVo, HCA-7 and A549 from colon, colon, and lung cancer respectively. The 
same assay was conducted with HUVECs to allow comparison to our earlier work on 11-
oxo- and 15-oxo-ETE (108,129).  Increasing doses showed a dose-dependent reduction 
in proliferation.  HUVECs were the most sensitive to treatment (Fig. 3A) followed by the 
colon cancer lines LoVo (Fig. 3B) and HCA-7 (Fig. 3C).  A549 lung cancer cells showed 
no significant response to treatment until higher doses of 11-oxo-ETE were used (Fig. 
3D). 
11-oxo-ETE-ME and 15-oxo-ETE-ME preferentially target the intracellular space.  In 
order to test the targeting of oxo-ETEs to the intracellular environment, 11-oxo-ETE-ME, 
15-oxo-ETE-ME, 11-oxo-ETE, 15-oxo-ETE, and a vehicle control were incubated with 
LoVo cells and HUVECs for 60 min.  Media and cells were then extracted and free oxo-
ETEs were quantified by LC-MS.  The methyl esters significantly increased the levels of 
free oxo-ETEs in the cell over the amount in the media in both LoVo cells (Fig. 4A) and 
HUVECs (Fig. 4B).  The free 15-oxo-ETE reached a higher intracellular concentration in 
the LoVo cell (Fig 4A).  In contrast the 11-oxo-ETE was higher in the HUVECs (Fig. 4B).  
Essentially no 11-oxo-ETE or 15-oxo-ETE was detected in the LC-MS chromatogram 
from the fourth wash of the LoVo cells treated with 11-oxo-ETE, 15-oxo-ETE, 11-oxo-
ETE-ME or 15-oxo-ETE-ME (Supplementary Fig. 3) when compared with a control 
internal standard alone (Supplementary Fig. 2).  Similar results were obtained from 
HUVECs (data not shown).  Furthermore, there was no detectable 11-oxo-ETE-ME or 
15-oxo-ETE-ME in the fourth wash of the cells (data not shown).  This confirmed that 
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none of the 11-oxo-ETE or 15-oxo-ETE could have arisen from material left on the cell 
surface and suggested that the methyl ester derivatives could provide a useful delivery 
strategy to target the intracellular environment for both 11-oxo- and 15-oxo-ETE. 
MTT assays over multiple days demonstrate anti-proliferative effects for 11-oxo-
ETE and 11-oxo-ETE-ME.  To observe the anti-proliferative effects of 11-oxo-ETE, 15-
oxo-ETE and their methyl esters, MTT assays were carried out over 72 h.  Every 24 h, 
samples were collected, and the media was refreshed.  Values obtained for vehicle 
treatment 0.25% DMSO was arbitrarily set at 100%.  15d-PGJ2 was included as a 
reference compound.  11-oxo-ETE dose dependently inhibited growth over multiple days 
(Fig. 5A).  Furthermore, 11-oxo-ETE-ME reached significance for inhibition before the 
free 11-oxo-ETE (Fig. 5A).  In all cases, by 72 h, significant anti-proliferative effects were 
observed versus the vehicle control (Figs. 5A, 5B).  Interestingly, 11-oxo-ETE-ME (Fig. 
5B) was more potent than 11-oxo-ETE (Fig. 5A), causing a significant antiproliferative 
effect at all three time points. 
The transporter proteins MRP1/MRP4 were expressed in the more resistant cell 
lines.  In order to help understand why there were differences in the intracellular 11-oxo-
ETE concentrations the expression of MRP1 and MRP4 membrane transporters was 
examined.  MRP4 expression was robust in the A549 lung cells and significant in the two 
endothelial lines tested (HUVEC, HAEC); whereas expression of MRP 1 was robust in 
all cancer lines (LoVo, HCA-7, MCF-7, and A549) when compared with the two 
endothelial lines (Fig. 6).  This suggested that increased MRP1 expression could have 
been a major determinant of the reduced cellular 11-oxo-ETE levels in LoVo cells (Fig. 
2A) when compared with the HUVECs (Fig. 2B).  MRP1 has previously been implicated 
in PG export, especially in the context of cancer cell dependent up-regulation of tumor 
microenvironment PGE2 (138). 
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Anti-proliferative effects of 11-oxo-ETE-ME are increased with co-treatment of the 
drug transport inhibitor probenecid.  To test the possibility of blocking the drug 
transporters to increase anti-proliferative effects, a MTT assay over multiple days using 
the LoVo cell line was carried out.  Treatments with probenecid, 11-oxo-ETE-ME, or the 
combination of both were compared to vehicle control arbitrarily set at 100%.  At both 48 
and 72 h, significantly increased anti-proliferative effects were observed for the 
combination treatment versus either treatment alone (Fig. 7).  Pretreatment with 
probenecid increased the recovery of 11-oxo-ETE from the 11-oxo-ETE-ME treated 
LoVo cells (Fig. 8).  This suggests that increased intracellular 11-oxo-ETE was the 
mechanism for the synergistic action of probenecid on 11-oxo-ETE-ME anti-proliferative 
action. 
 
3.5 Discussion 
The involvement of COX-2 and 15-PGDH in cancer progression has been well 
documented (14,40,41,139-142).  Pro-proliferative AA metabolites derived from COX-2, 
such as PGE2 acting via the G-protein coupled PGE receptors (EP)1, EP2, and EP4, 
induce proliferation and angiogenesis (15,143,144).  Autocrine and paracrine signaling 
of PGE2 in cancer leads to a feed forward loop modulating local immune responses and 
increasing angiogenesis and proliferation (139,141).  A decrease in catabolic 15-PGDH 
leads to increased activity of PGE2 due to its reduced metabolic clearance (41).  
However, AA metabolism leads to a plethora of metabolites with distinct and sometimes 
opposing functions (6).  Considerable work on the anti-proliferative effects of AA 
metabolites have focused primarily on 15d-PGJ2 (17).  These studies have been 
complicated by contradictory results (118,145,146), uncertainty over the actual 
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physiological relevance of the tested compounds (109), and a lack of dysregulation in 
disease states(11).  Other cyclopentenone PGs such as PGA2 have been linked to anti-
proliferative action via inhibition of the cell cycle through cyclin D1 at 100M (147). 
11-oxo-ETE and 15-oxo-ETE are known endogenous compounds isolated from 
clinical specimens, and major metabolites of AA via COX/15-PGDH 
(83,108,122,129,132).  In this study, measurable anti-proliferative effects were seen in 
three of four tested cell lines at 2 M and all four cell lines at 10 M (Fig. 4).  Although 
11-oxo-ETE was clearly more potent than 15-oxo-ETE, the effect of both eicosanoids 
was significant, and their effects could be modulated by targeted intracellular delivery or 
pharmacological blockade of transporters (Figs. 5, 6, 7). The amounts of 11-oxo-ETE 
and 15-oxo-ETE that were detected in the LoVo cells and HUVECs represented only a 
small fraction of the total amount of each oxo-ETE or oxo-ETE-ME that was added to the 
cells.  From our previous work, we suspect that major amounts of the oxo-ETEs are 
conjugated to GSH, exported, and cleaved to the cysteinyl-glycine adduct (83).  We are 
also actively investigating other biotransformation pathways that contribute to metabolic 
clearance.  The finding that intracellular delivery of 11-oxo-ETE through use of the 
methyl ester derivative increased the anti-proliferative effects in LoVo cells (Figs. 4, 5, 7) 
lends support to the hypothesis that a plausible mechanism of action may be through 
intracellular targets.  This was particularly evident in the increased anti-proliferative 
activity of 11-oxo-ETE-ME (Fig. 5B) when compared with the free 11-oxo-ETE (Fig. 5A).  
The amplification of anti-proliferative effects and increased recovery of 11-oxo-ETE with 
probenecid co-treatment (Fig. 7) also supports this hypothesis.  This is in agreement 
with an expanding body of work supporting a hypothesis for the mechanism of action for 
certain bioactive lipids through intracellular signaling mediators (12,118,135,136).  These 
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findings, along with our previous work on the GSH-mediated metabolism of 11-oxo- and 
15-oxo-ETE may implicate intracellular uptake as a rate-limiting factor in bioactivity and 
metabolism of these compounds (83). 
During tumorigenesis, significant up-regualtion of COX-2 occurs, which would 
increase the production of pro-proliferative PGE2, (13,141) as well as the antiproliferative 
oxo-ETEs.  However, there is also signficant down-regualtion of 15-PGDH, 
(41,92,95,96,148) which would result in increased activity of PGE2 due to its decreased 
catobolism coupled with a decrease in the formation of the oxo-ETEs (Fig. 1B)  (129).  
Increased expression of MRP4, (138,149,150) the transporter involved in the efflux of 
PGE2 (151,152) also occurs during tumorigenesis.  This would further prevent the 15-
PGDH-mediated metabolism of PGE2 in epithelial cells and so further facilitate an 
increase in its activity at relevant membrane EPs.  In contrast, increased efflux of oxo-
ETEs mediated by MRP4 would result in reduced activity because (as described above) 
they have intracelluar targets.  Finally, the up-regulation of glutathione biosynthesis and 
increased glutathione-S-transferase expression (153-155) would result in increased 
conversion of oxo-ETEs into their corresponding inactive glutathione adducts (83).  
Therefore, tumor progression is associated with substantial activation of pro-proliferative 
PGE2 and metabolic inactivation of the the oxo-ETEs. 
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Figure 3.1. Oxo-ETE chemical structures and metabolic pathways. (A) Chemical 
structures of compounds used in this study, with PGE2 provided for comparison. (B) The 
currently elucidated COX-2/15-LOX and 15-PGDH dependent pathway for generation of 
11-oxo-ETE and 15-oxo-ETE. AA, Arachidonic Acid, COX, Cyclooxygenase, 15-LOX, 
15-Lipoxygenase, cPLA2, cytosolic phospholipase A2, PGH2, prostaglandin H2, HPETE, 
hydroperoxyeicosatetraenoic acid, HETE, hydroxyeicosatetraenoic acid, 15-PGDH, 15-
hydroxyprostaglandin dehydrogenase, POX, peroxidase, DH, dehydrogenase, oxo-ETE, 
oxo-eicosatetraenoic acid. 
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Figure 3.2. Disposition of oxo-ETEs in LoVo cells and HUVECs. Stable isotope 
dilution LC-SRM/ECAPCI/MS quantification of uptake and distribution of 15-oxo-ETE 
and 11-oxo-ETE by (A) LoVo cells and (B) HUVECs over time. Cells were incubated at 
37°C with 15-oxo-ETE (2µM) or 11-oxo-ETE (2µM) for 5, 30, 60, and 240 min.  For each 
time point, cellular fractions were collected, extracted and spiked with [13C20]-15-oxo-
ETE, and derivatized with PFB. Each time point is plotted as the mean of triplicates with 
SEM. 
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Figure 3.3. Anti-proliferative action of 11-oxo-ETE. BrdU incorporation measured by 
ELISA in (A) HUVECs, (B) LoVo cells, (C) HCA-7 cells, (D) A549 cells, following 24h 
treatment with indicated dose of 11-oxo-ETE in 0.25% DMSO compared to vehicle 
control.  1-way ANOVA with post-hoc Dunnett’s Multiple Comparison test versus vehicle 
control was used to access statistical significance (*  p< 0.05, ** p< 0.01, ***p < 0.001). 
Data are plotted as the means (n=3-8) with SEM bars, representative of at least two 
independent experiments.  
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Figure 3.4. Intracellular oxo-ETEs after methyl ester derivative treatment.  Stable 
isotope dilution chiral LC-SRM/ECAPCI-MS quantification of the ratio of cellular/ media 
11-oxo- and 15-oxo-ETE in (A) LoVo cells and (B) HUVECs. Cells were incubated with 
15-oxo-ETE (10 µM), 15-oxo-ME (10 µM), 11-oxo-ETE (10 µM), 11-oxo-ME (10 µM), or 
0.25% DMSO vehicle control for 60 min. Cellular and media fractions were collected, 
extracted, and spiked with [13C20]-15-oxo-ETE, and derivatized with PFB. Data are 
plotted as the means of triplicates with SEMs of the ratio of analytes in the cellular over 
media fractions. Statistical significance was assessed by 1-way ANOVA with post-hoc 
Bonferroni Multiple Comparison test (* = p<0.05). 
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 Figure 3.5. Anti-proliferative action of oxo-ETEs and their methyl esters.  Cell 
proliferation measured by MTT assay with LoVo cells over multiple days with the 
indicated compounds in 0.25% DMSO compared to vehicle control.  Treatments with the 
free acids are shown in (A), the methyl-esters are shown in (B). Data are plotted as the 
means (n=4) with SEMs, representative of at least two independent experiments. 
Statistical significance was assessed by 1-way ANOVA with post-hoc Bonferroni Multiple 
Comparison test against the respective vehicle control (* p < 0.05, ** p < 0.01, *** p < 
0.001). 
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Figure 3.6. MRP1 and MRP4 expression. Western blots of HAEC, HUVEC, MCF-7 
cells, HCA-7 cells, LoVo cells, and A549 cells for transporters MRP 4 and MRP 1, 
together with the loading control GAPDH.  Increased expression of MRP1 was observed 
in the cancer cells lines (MCF-7, HCA-7, LoVo, A549) versus the endothelial cells 
(HAEC, HUVEC).  MRP4 expression was detectable in all cell lines, with robust 
expression in A549 cells. 
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Figure 3.7. Potentiation of 11-oxo-ETE by probenacid. Cell proliferation of LoVos 
measured by MTT assay over multiple days with 2 M 11-oxo-ETE-ME and/or 1 mM 
probenecid in 0.25% DMSO compared to vehicle control.  Data are plotted as the means 
(n=4) with SEMs, representative of at least two independent experiments.  Statistical 
significance was assessed by 1-way ANOVA with post-hoc Bonferroni multiple 
comparison test (* p <0.05). 
 
 
Figure 3.8. Increased recovery of 11-oxo-ETE with probenacid treatment. Stable 
isotope dilution chiral LC-SRM/ECAPCI-MS quantification of the recovery of 11-oxo-ETE 
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in LoVo cells. Cells were incubated with either 0.25% DMSO or 1mM probenecid for 30 
min before incubation with 11-oxo-ME (10 µM) in 0.25% DMSO vehicle control for 60 
min.  Cellular and media fractions were collected, extracted, and spiked with [13C20]-15-
oxo-ETE, and derivatized with PFB. Data are plotted as the means of triplicates with 
SEMs. Statistical significance was assessed by 2-way student’s t-test (** = p<0.01). 
 
 
 
Figure 3.9. LC-ECAPCI–MS of 15-oxo-ETE internal standard. 10ng PFB-derivatized 
13
C20-15-oxo-ETE internal standard analyzed by normal phase ECAPCI-MS.  Noise levels in the 
11-oxo-ETE and 15-oxo-ETE channels are shown to establish a baseline. 
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Figure 3.10. Lack of residual oxo-ETEs after washing of the cells.  The 4th wash of the 
cellular fraction was pooled for a 11-oxo-ETE and a 15-oxo-ETE treatment, derivatized, and 
analyzed as indicated for the media fractions.  11-oxo-ETE and 15-oxo-ETE channels 
demonstrate noise levels of signal, indicating that the wash steps were sufficient to remove 
detectable 11-oxo- or 15-oxo-ETE. 
 
 
Figure 3.11. Lack of induction of oxo-ETEs by treatment with 13C20-15-oxo-ETE.   
LoVo cells were cultured and treated as indicated in the methods section, and then treated with 
10M 
13
C
20
-15-oxo-ETE.  Cell and media fractions were pooled, and derivitization and analysis 
were performed as indicated except the internal standard was ommitted.  No detectable 11-oxo-
ETE of 15-oxo-ETE was found, indicating that the 
13
C
20
-15-oxo-ETE did not induce generation 
of 11-oxo-ETE or 15-oxo-ETE.   
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Chapter 4. A Covalently Modifying Endogenous Canonical NF-B 
Inhibitor from Arachidonic Acid Metabolism 
 
In preparation for submission as: A covalently modifying endogenous canonical NF-B inhibitor 
from arachidonic acid metabolism.  Nathaniel W. Snyder, Guang Yang, Xiaojing Liu, Suhong 
Zhang, Phyllis A. Dennery, and Ian A. Blair. 
 
Background: Arachidonic acid (AA) metabolism results in the formation of eicosanoids 
including 11-oxo-eicosatetraenoic acid (11-oxo-ETE). 
Results: 11-oxo-eicosatetraenoic acid was found to inhibit canonical p50/p65 NF-B 
signaling via a covalent modification.  
Conclusion: 11-oxo-ETE is a feedback mediator for arachidonic acid metabolism and 
NF-B signaling. 
Significance: Inflammatory states involved in normal physiology and disease are 
regulated by a diverse set of mediators. 
 
Summary 
α,β-unsaturated ketone containing molecules have been shown to bind to critical 
cysteine residues of proteins.  Metabolism of arachidonic acid (AA) via 
Cyclooxygenase/15-hydroxyprostaglandin dehydrogenase (COX/15-PGDH) leads to the 
formation of 11-oxo-eicosatetraenoic acid (oxo-ETE), an α,β-unsaturated ketone 
containing eicosanoid with structural similarity to other bioactive lipids. 11-oxo-ETE has 
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no known receptor or function, but has been detected in human samples.  Here, we 
show that pre-treatment of human umbilical vein endothelial cells (HUVECs) by 11-oxo-
ETE reduced p50/p65 binding to consensus sequence DNA when activated by TNF- 
and Kdo2-Lipid A.  Inhibition of canonical NF-B signaling was confirmed through 
electrophoretic mobility shift assays, western blot for manganese super oxide dismutase 
from TNF- challenged HUVECs, and a stably expressed firefly luciferase NF-B 
reporter assay in HEK293 cells.  Western blots of phosphorylated inhibitor of kappa B 
(IkB) α and inhibitor of kappa B kinase (IKK) β revealed a decrease in phosphorylation of 
IBα, with no change in phosphorylation of IKK.  This finding was confirmed by in vitro 
kinase studies of IKK.  LC-MS/MS of tryptic peptides from the DNA binding domain of 
p50/p65 revealed a Michael addition adduct of 11-oxo-ETE to a critical cysteine residue, 
as well as a histidine adduct.  These experiments demonstrate that products of AA 
through COX/15-PGDH metabolism may serve as a negative feedback loop via a redox 
sensitive lipid mediator, 11-oxo-ETE.  Therefore, it may be of interest to design stable 
11-oxo-ETE mimetics or modulators of AA metabolism to induce 15-PGDH. 
Introduction 
Initiation, control, and resolution of inflammation are all regulated, in part, by 
arachidonic acid (AA) metabolism, and thus by the enzymes responsible for transforming the AA-
derived bioactive lipids (6).  However, the roles of several of these major downstream products 
remain to be elucidated. 
AA metabolism by the cyclooxygenase enzymes (COX) begins with abstraction of the 13 
pro-S hydrogen (26).  Formation of prostaglandin (PG) G2 occurs through insertion of molecular 
oxygen, followed by a second insertion and a cyclization reaction.  A monoxygenase type reaction 
may also occur, with insertion of molecular oxygen at either C11 or C15 resulting in 11(R)-
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hydroperoxyeicoatetaenoic acid (HPETE) or a mixture of 15(S) and 15(R)-HPETEs (156).  The 
C15 monoxygenase reaction to 15(R)-HPETE is a major pathway after acetylation by aspirin.  
The HPETEs are then reduced by peroxidases yielding stable hydroxyeicosatetraenoic acids 
(HETEs) (157).  15-HPETE can also be generated from arachidonic acid by various 
lipoxygenases (LO) with specificity for the carbon where the oxygen insertion occurs, including a 
12/15-LO and a 15-LO (33).  11- or 15-HETEs are then transformed into oxo-ETEs via a second 
level of metabolism involving 15-hydroxyprostaglandin dehydrogenase (15-PGDH), converting 
the hydroxyl group to a carbonyl (83,108,129).  This creates an electrophilic -unsaturated 
ketone that could react via a Michael addition with a nucleophilic cysteine or histidine residue. 
The metabolic pathway for generation of the 11-oxo- and 15-oxo-ETE has been 
demonstrated in cell lines expressing both COX-2 and 15-PGDH (83,108,129).  11-oxo-ETE has 
been detected in advanced human atherosclerotic plaques (122). Despite our understanding of the 
metabolism and a demonstration of the endogenous presence of 11-oxo-ETE, there is no known 
G-protein coupled receptor, or any well described signaling pathway for this molecule.  However, 
similar molecules such as the electrophilic oxo-derivatives  (EFOXs) (118) and 15-deoxy-12,14-
PGJ2 (15d-PGJ2) (12), also contain -unsaturated ketones, and have been shown to inhibit NF-
B signaling.  Therefore, we hypothesized that 11-oxo-ETE may act via a similar mechanism.  
This study was aimed at investigating the effects of 11-oxo-ETE on the canonical signaling 
pathway of NF-B mediated by the transcription factors p50/p65, and test a plausible mechanism 
based on covalent adduction to explain the inhibitory effects observed in a cell model system. 
 
Experimental Procedures 
Chemicals and Reagents–Protease inhibitor cocktail (100x), phosphatase inhibitor 
(100x) Trizma-HCl, ethacrynic acid, pentafluorobenzyl bromide (PFB), and clear flat-
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bottom streptavidin coated 96-well plates were purchased from Sigma-Aldrich (St. Louis, 
MO). Medium 200 and low serum growth supplement (LSGS) were supplied by 
Invitrogen (Carlsbad, CA). RIPA and MOPS buffers, LC-MS grade (Optima) formic acid, 
water, and acetonitrile were obtained from Fisher Scientific (Pittsburgh, PA). Gases were 
supplied by The Linde Group (Munich, Germany). Electrophoretic mobility shift assay 
(EMSA) probes were purchased from Integrated DNA Technologies (Coralville, IA).  
Unless otherwise noted, antibodies were purchased from Cell Signaling Technologies 
(Danvers, MA).  Recombinant IKK, biotin-tagged IkB- substrate peptide, ATP, and 
kinase buffer were also from Cell Signaling Technologies.   
Cell Culture–Human umbilical vein endothelial cells (HUVECs) were obtained from 
Invitrogen (Carlsbad, CA) and were cultured in Medium 200 with low serum growth 
supplement on Collagen IV coated tissue culture plates from Becton Dickinson (Bedford, 
MA).  HEK293 cells stably expressing firefly luciferase driven by a 5x-B reporter were a 
kind gift of the Hogenesch lab at University of Pennsylvania and were maintained in 
DMEM with 2% FBS and 100,000 units/L penicillin and 100 mg/L streptomycin. 
Transcription Factor Binding Assays–HUVECs  were treated with 2 M 11-oxo-ETE, 2 
M 15d-PGJ2, or vehicle control 0.25% DMSO in maintenance media.  After 15 minutes 
the cells were then challenged with 0.5 mg/mL Kdo2-Lipid A and 40 ng/mL TNF- or 
vehicle control  for 45 minutes without changing the media.  Nuclear fractions were taken 
from cells using a nuclear extraction kit from Cayman Chemical (Ann Arbor, MI) and 
p50/p65 binding was assayed using a p50/p65 binding EIA based detection kit from 
Cayman Chemical. 
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Electrophoretic Mobility Shift Assay–HUVECs were treated with 0.2 M 11-oxo-ETE, 2 
M 11-oxo-ETE, the NF-B inhibitor BAY 11-7085, or vehicle control 0.25% DMSO.  
After 15 minutes the cells were then challenged with 40 ng/mL TNF- or vehicle control 
for 45 minutes without changing the media.    Nuclear extracts were taken as described 
above.  Duplexes of oligonucleotide containing the consensus sequence (5’-GCC TGG 
GAA AGT CCC CTC AAC T-3’) or mutated sequence (5’-GCC TGG GAA ACT CGC 
CTC AAC T-3’) of NF-B were synthesized by Integrated DNA Technologies.  EMSA 
assay was performed as described previously (158) with minor modification.  Briefly, a 
32P-labeled consensus NF-B was used as a probe to evaluate NF-B binding ability.  
To identify nonspecific binding of the nuclear proteins, competition reactions were 
performed by addition of either 50-fold excess of non-radiolabeled NF-B or 50-fold 
excess of non-radiolabeled mutated NF-B to the reaction mixtures prior to 
electrophoresis.  In order to identify the NF-κB subunit proteins in the complex, 1 µL of 
p50 or p65 antibody, ab7971 or ab7970, respectively, from Abcam (Cambridge, MA) 
was incubated with the nuclear protein prior to addition of the radiolabeled probe to 
visualize any supershift-retarded bands in the NF-B complex (11). A loading control 
oligomer SP-1 (5’-ATT CGA TCG GGG CGG GGC GAG C-3’) was obtained from 
Promega (Madison, WI) (12). An AP-1 oligomer (5’-TTC CGG CTG AGT CAT CAA GCG 
C-3’) from IDT was used as an additional control.  Purity of all oligomers was checked by 
gel electrophoresis prior to use (data not shown). 
Superoxide Dismutase Western Blotting– HUVECs were treated with 2 M 11-oxo-ETE, 
2 M 11-oxo-ETE-methyl ester (11-oxo-ETE-ME), or vehicle control 0.25% DMSO in 
maintenance media.  After 15 minutes the cells were challenged with 40 ng/mL TNF- or 
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vehicle control for 6 hours without changing the media.  Cells were lysed in RIPA buffer 
with protease inhibitor cocktail and flash frozen in dry ice/ethanol then stored at -80°C 
until analysis.  Protein was quantified with a micro-BCA kit from Thermo-Pierce, and 30 
g of protein/well was loaded in a 4-12% gradient Bis-Tris gel and ran for 50 minutes at 
200 V in MOPS buffer.  Proteins were transferred to a nitrocellulose membrane in 
transfer buffer with 10% methanol at 30 V overnight at 4°C and blocked for an hour in 
5% skim milk in TBS/T.  The membrane was cut and incubated overnight at 4°C with the 
primary antibody.  After washing, the membrane was incubated for 2 hours at room 
temperature with the secondary antibody.  Visualization was performed in a digital 
analyzer (GE healthcare) with Western Lightning ECL reagent (Perkin Elmer). 
Phospho-protein Western Blotting–HUVECs were treated with 2 M 11-oxo-ETE, 2 M 
11-oxo-ETE-ME, or vehicle control 0.25% DMSO in maintenance media.  After either 5 
minutes or 6 hours the cells were challenged with 40 ng/mL TNF- or vehicle control for 
45 minutes without changing the media.  Cells were lysed in RIPA buffer with 1x 
protease and 1x phosphatase inhibitor cocktail and flash frozen in dry ice/ethanol then 
stored at -80°C until analysis.  Blotting and visualization were performed as above. 
IKK Kinase Assay–HTScan IKK Kinase assay kit (Cell Signaling) was used as 
directed with minor modification to screen for IKK inhibition.  Briefly, recombinant IKK 
was incubated with indicated compounds at the indicated concentrations for 15 minutes 
in 1x kinase buffer prepared separately from the kit using the reducing agent TCEP 
instead of DTT.  Biotin-tagged IB- and ATP were added to a final concentration of 
1.5M and 200 M respectively, and the mix was incubated for 30 minutes at room 
temperature.  The reaction was quenched with addition of 50 mM EDTA pH 8.  The 
cocktail was loaded into strepavidin coated clear 96-well plates, allowed to bind for 2 
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hours at room temperature, washed with PBS/T three times.  The plate was incubated 
with 100 mL 1:1000 anti-phospho-IB- antibody in TBS/T with 5% BSA for 2 hours, 
then washed three times with 200 mL PBS/T.  The plate was incubated with 100 mL 
1:1000 secondary anti-rabbit antibody coupled to HRP for an hour at room temperature.  
The plate was developed and read in a UV-Vis spectrometer (BioRad). 
Adduct Formation and Analysis–A synthetic peptide with a tryptic overhang of two 
residues on each terminus (FRYVCEGPSHGGLPGASSEKNK) corresponding to the 
human and mouse p50 DNA binding domain (Supplemental Fig. 1) was obtained from 
AnaSpec (Freemont, CA).  The peptide was incubated overnight with 10 m 11-oxo-ETE 
in 1 mM ammonium bicarbonate buffer pH 7.5 then digested with sequencing grade 
trypsin (Promega) for 16 hours at 37°C.  The sample was then desalted on a C18 spin 
column from The Nest Group (Southborough, MA), evaporated in a vacuum dessicator, 
and dissolved in mobile phase A for LC-MS analysis.  LC separations were conducted 
using a Waters nano-ACQUITY UPLC system (Waters Corp., Milford, MA, USA). A 
Waters BEH130 C18 column (100 m × 150 mm inner diameter, 1.7 µm pore size; 
Waters Corp) was employed for reversed phase separation (flow-rate 1.8 L/min).  
Solvent A was 98% water/2% acetonitrile with 0.1% formic acid, and solvent B was 
99.5% acetonitrile/0.5% water with 0.1% formic acid.  The gradient was as follows: 5% B 
at 0 min, 5% B at 3 min, 60% B at 35 min, 95% B at 37 min, 95% B at 43 min, 5% B at 
44 min, and 5% at 60 min.  Separations were performed at 30°C.  A LTQ XL-Orbitrap 
hybrid mass spectrometer (Thermo Fisher) was used in positive ion mode with a 
Michrom captive spray electrospray ionization (ESI) source. The operating conditions 
were: spray voltage at 4 kV; capillary temperature at 250°C; capillary voltage at 35 V; 
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collision induced dissociation (CID) was performed using helium as the collision gas in 
the ion trap (normalized collision energy [CE], 30%). 
 NF-B reporter assay–HEK293 cells stably expressing firefly luciferase driven by 
a 5x-B reporter were incubated with increasing concentrations of 11-oxo-ETE for 5 
minutes before treatment with 40 ng/mL TNF- for 6 hours.  Treatment media was the 
same as maintenance media with 0.25% DMSO. 
LC-MS Quantification of Cellular Uptake–HEK293s as above were plated at 4x105 cells / 
well in a 6-well tissue culture plate (Corning, Corning, NY) and allowed to attach for 12 
hours.  11-oxo-ETE was re-suspended in media containing 0.25% DMSO at indicated 
concentrations by serial dilution from the most concentrated treatment.   After 90 
minutes, the cells were gently scraped in the media; an aliquot of 250 L of the cell 
suspension was taken and spiked with 1 ng [13C20]-15-oxo-ETE internal standard.  
Extraction and derivatization has been described in detail elsewhere (159).  Briefly, the 
samples were extracted with dichloromethane/methanol (2:1,v/v) containing 0.5% by 
volume acetic acid with vigorous shaking, the organic phase was then removed and 
evaporated under nitrogen gas.  After evaporation of the organic phases to dryness, 
samples were suspended in 100 µL DIPEA in acetonitrile (1:9; v/v) and 200 µL of PFB 
bromide in acetonitrile (1:19; v/v) and kept at room temperature for 30 minutes.  The 
derivatized samples were dried down again under nitrogen, and then re-suspended in 
100 µL of hexane/ethanol (95:5; v/v) for stable isotope dilution chiral LC-selected 
reaction monitoring (SRM)/electron capture atmospheric pressure chemical ionization 
(ECAPCI)/MS analysis.  A Water’s Alliance 2690 HPLC system (Waters Corp.) was used 
for liquid chromatography separations. The PFB derivatives of 11-oxo-ETE and 15-oxo-
ETE were separated using normal phase Chiralpak AD-H column (250 x 4.6 mm, 5 µm; 
78 
Daicel Chiral Technologies, Westchester, PA) with a 1 mL/min flow rate. Solvent A was 
hexanes and solvent B was isopropanol/hexane (6:4; v/v). Gradient composition was: 
2% B at 0-14.5 min, 12% B at 15 min, 90% B at 17 min, 90% B at 22 min, 2% B at 22.5 
min, and 2% B at 29 min.  Seperations were performed at 30°C.  A Thermo Triple Stage 
Quadrupole (TSQ Quantum) mass spectrometer (Thermo Scientific) with an APCI 
source was operated in negative ion mode as previously described (129).  The following 
transitions corresponding to each compound were monitored; 11-oxo-ETE-PFB, m/z 
317165 (CE, 25 eV) and [13C20]-15-oxo-ETE-PFB, m/z 337120 (CE, 18 eV).  For 
absolute quantification of 11-oxo-ETE, a standard curve ranging from 0 to 2 ng was 
generated in the same matrix under identical extraction conditions with pure compound.  
Data analysis was performed using Xcalibur software (Thermo Scientific). 
 
Results 
11-oxo-ETE inhibits p50/p65 DNA Binding in HUVECs–Pretreatment of the HUVECs 
with 11-oxo-ETE or 15d-PGJ2 significantly reduced the additional p50 (Figs. 2A, 2C) and 
p65 (Figs. 2B, 2D) binding induced by treatment with Kdo2/TNF-.  These results were 
confirmed by EMSA.  Either 2 M 11-oxo-ETE (Fig. 3, lane 6) or the NF-B inhibitor BAY 
11-7085 (Fig. 3, lane 4) abolished the induced NF-B signaling in the TNF- treated 
HUVECs.  Competition assays revealed that the induced factor was in fact NF-B, and 
predominantly p65 (Fig. 3, lane 9). 
11-oxo-ETE Dose-Dependently Inhibits NF-B Driven Luciferase Activity– HEK293 cells 
stably expressing firefly luciferase driven by a 5x-B reporter were incubated with 
increasing concentrations of 11-oxo-ETE for 5 minutes before treatment of 40 ng/mL 
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TNF- for 6 h.  11-oxo-ETE reduced firefly luciferase activity in a dose-dependent 
manner versus the vehicle control (Fig. 4A).  With a 30 minute pretreatment of 100 M of 
the GST inhibitor ethacrynic acid the effect of 11-oxo-ETE on NF-B inhibition was more 
evident (Fig. 4B), and recovery of 11-oxo-ETE from the treated cells was higher at 90 
minutes (Fig 4B, 4C). 
11-oxo-ETE Inhibits Downstream of IKK in HUVECs–Pretreatment of 11-oxo-ETE for 5 
minutes before TNF- challenge for 45 minutes caused a modest reduction in TNF--
mediated elevation of phospho-IkB-α levels.  The methyl ester of 11-oxo-ETE, which 
targets the intracellular space, also caused a modest reduction in phospho-IkB-α levels 
(Fig. 5A).  However, a 6 hour pretreatment with 11-oxo-ETE or 11-oxo-ETE-ME, caused 
no inhibition of TNF--mediated phospho-IkB-α elevation (Fig. 5B). 
To exclude the possibility of effects on upstream kinases, levels of phospho-IKK 
were surveyed by Western blotting from the same cell extracts.  No reduction in 
phosphor-IKK was observed in either time point. In no cases did the 11-oxo-ETE or 11-
oxo-ETE-ME alone induce significant phosphorylation of IKK or IkB-α (Fig. 5A, 5B).  
In vitro screening of IKK activity with recombinant IKK, a biotin linked substrate, 
capture on a streptavidin coated plate, and HRP-based visualization was used to study 
the effects of ,-unsaturated ketone containing eicosanoids on IKK kinase activity.  
This experiment demonstrated dose dependent inhibition of IKK by 15d-PGJ2 and 11-
oxo-ETE (Fig. 5C).  15-oxo-ETE was much less potent (data not shown). 
11-oxo-ETE Treatment in HUVECs Inhibits the Induction of Manganese Superoxide 
Dismutase–Treatment of HUVECs with 11-oxo-ETE and 11-oxo-ETE-ME before TNF- 
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challenge strongly inhibited the induction of the NF-B target manganese superoxide 
dismutase after 6 h (Fig. 6). 
11-oxo-ETE Forms a Covalent Adduct with Amino Acids within the p50 DNA Binding 
Domain–In order to mechanistically explain the reduction in p50/p65 activity, we 
investigated the possible formation of a covalent adduct forming between the 
electrophilic ,-unsaturated ketone of 11-oxo-ETE and the nucleophilic residues of 
p50/p65.  The tryptic peptide corresponding to the cysteine and histidine containing 
DNA-binding domain of p50 was chosen because it would offer the most structural 
information for complete elucidation of the adduct (Supplemental Fig. 1A). 
The synthetic peptide with a tryptic overhang of 2 residues on each terminus was 
obtained from AnaSpec, incubated overnight with 10 M 11-oxo-ETE then digested with 
trypsin for 16 h.  The sample was then desalted using a C18 spin column (The Nest 
Group), evaporated in a vacuum desiccator, and dissolved in mobile phase A for 
chromatographic separation and mass spectrometry. 
Reversed LC-MS/MS revealed two putative covalent adducts that were isomeric. 
Positive ion mode charge state determination and high-resolution accurate mass 
determination in the Orbitrap showed that the unmodified and modified peptide was 
primarily triply charged (MH3
3+) (Supplemental Fig. 2A, 2B).  The LC retention time of the 
unmodified peptide (17.4 min; Fig 7A) was shorter than the two modified peptides (24.8 
min, 28.3 min; Fig. 7B).  This was consistent with the increased hydrophobicity derived 
from the addition of a fatty acid.  MS/MS analysis of MH4
3+ (m/z 698.35) from the later 
eluting adduct, suggested that 11-oxo-ETE had added to the peptide residue 
corresponding to cysteine-61 (Supplementary Fig. 4) of the p50 protein (Supplementary 
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Fig. 1).  Three relatively high abundance y11
+2
, y13
+2, y14
+2 ions were observed containing 
an unmodified histidine residue provided compelling evidence for a covalent modification 
on cysteine (Fig. 8, Supplemental Fig. 4).  The presence of the oxo-ETE moiety was 
confirmed by the ion at m/z 319.2258 (Calculated m/z for C20H36O3 = 319.2268). 
The earlier eluting adduct had a product ion spectrum that was consistent with 
addition of 11-oxo-ETE to the histidine moiety (Fig. 8, Supplemental Fig. 3).  The 
spectrum was quite different from that observed for the cysteine adduct.  In particular, 
there was a relatively intense y16 ion containing the oxo-ETE moiety.  Additional minor 
product ions confirmed that the attachment of oxo-ETE was at the peptide residue 
corresponding to histidine-64 (Fig. 8) of the p50 DNA binding domain. 
 
Discussion 
The specific identity and mechanism for lipid mediators of resolution remain 
controversial.  Anti-inflammatory lipids with a mechanism of action through a GPCR, 
such as the lipoxins, may constitute one family of signaling molecules.  Other molecules 
such as 15d-PGJ2, the EFOXs derived from eicosapentaenoic acid and 
docosahexaenoic acid, nitro-fatty acids, and now 11-oxo-ETE have non-G protein-
coupled receptor mechanisms of action (12,118,135,136,145,160). 
-unsaturated ketone containing fatty acids can form covalent adducts to cysteine 
and histidine residues of proteins (161).  In the case of adduction to signaling proteins, 
such as Keap1-Nrf2 (135), PPAR(12), NF-B (12), or IKK(133) this may mediate a 
cellular response as a redox sensor.  Such a system of redox-mediated feedback has 
been hypothesized to be important in the control and resolution of inflammatory 
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responses.  Alternatively, other adduct forming entities such as 4-hydroxynonenal have 
been implicated in pathological oxidative stress (162). 
The present study has unequivocally shown that 11-oxo-ETE is directly analogous to 
(and slightly more potent than) the widely studied PGD2 degradation product 15-d-PGJ2 
in its ability to inhibit the activity of NF-κB (Fig. 2).  This occurs through a pathway that 
did not appear to involve diminished phosphorylation of IKKβ (Fig. 5A) or IkB-α (Fig. 5B).  
In spite of a very modest change in the phosphorylation status of IKKβ there was a clear 
dose-dependent decrease in the activity of NF-κB (Fig. 5C). 
The structure/function relationship of electrophiles to inhibition of NF-κB is likely 
complex, especially within the wider pathological context.  This may be attributable to the 
structural properties of targets for electrophiles, as has been suggested by studies with 
PPAR (16,163).  Available structural data on the NF-κB family members examined in 
our study points to the critical nature of the contact of the cysteine binding domain 
(Supplementary Fig. 1) with the target consensus sequence DNA (164,165).  
Interactions may also be a property of the contextually dependent metabolism of the 
electrophile (166). 
Identifying 11-oxo-ETE-mediated covalent modifications to NF-κB components such 
as p50 or p65 in a cellular context would be extremely challenging because of the trace 
amounts that are present.  Furthermore, the purified proteins require substantial 
amounts of free thiols to maintain their activity.  This would prevent the covalent 
attachment of any electrophilic Michael acceptors such as 11-oxo-ETE.  Therefore, we 
used a potential tryptic peptide (with two amino acid overhangs at the trypsin sites) 
derived from the p50 component of NF-κB (Supplementary Figure 1A).  After treatment 
of the peptide with 11-oxo-ETE and trypsin digestion, an adduct was identified with a 
structure that was consistent with covalent attachment of 11-oxo-ETE to cysteine-61 
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(Fig. 8, Supplementary Fig. 4) and an adduct at histidine-66 (Fig. 8, Supplementary Fig. 
3).  Availability of these covalently modified peptides show that the 11-oxo-ETE 
modifications were a plausible hypothesis to explain the cellular responses observed 
earlier.  However, current LC-MS methodology does not have sufficient sensitivity to 
determine whether the 11-oxo-ETE modifications can also occur on the endogenous p50 
protein.  
Interestingly, 15d-PGJ2, 15-oxo-ETE, and 11-oxo-ETE also exhibit anti-proliferative 
effects (108,129).  In inflammatory states and in multiple cancers, COX-2 is up-regulated 
and 15-PDGH is down-regulated (88,115,127,167,168).  This metabolic dysregulation, 
as well as perturbation of cellular eicosanoid transporters, is hypothesized to contribute 
to a pro-inflammatory, pro-proliferative, and pro-angiogenic environment.  Therefore, the 
oxo-ETEs could potentially exert both anti-inflammatory and anti-proliferative effects that 
would be abolished by down regulation of 15-PGDH, which is required for their 
biosynthesis (83,108,129). 
Our findings indicate that therapies designed to modulate, rather than completely 
inhibit, AA metabolism into downstream products might be a more effective therapy for 
chronic inflammatory conditions and cancer.  Thus, increased COX-2 activity can be 
compensated by increased 15-PGDH activity through inactivation of pro-inflammatory 
eicosanoids such as PGE2 and increased formation of eicosanoids that can modulate 
the activity of NF-κB such as 11-oxo-ETE.  Research into the metabolism and signaling 
of other polyunsaturated lipid products, or via other signaling pathways may also provide 
valuable insight into electrophiles with therapeutic or diagnostic implications. 
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Figure 4.1. Chemical structures examined in this study. -unsaturated ketone 
containing eicosanoids used in this study and the Michael addition adduct of 11-oxo-ETE to a 
cysteine residue. 
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Figure 4.2. Inhibition of induced p50/p65 transcription factor binding in activated 
endothelial cells. (A) NF-κB p50 binding in nuclear extracts from HUVECs pre-treated with 2 
M 11-oxo-ETE. (B) p65 binding in nuclear extracts from HUVECs pre-treated with 2 M 11-
oxo-ETE. (C) p50 binding in nuclear extracts from HUVECs pre-treated with 2 M 15d-PGJ2. 
(D) p65 binding in nuclear extracts from HUVECs pre-treated with 2 M 15d-PGJ2.  Cells were 
first treated with 0.5 mg/mL Kdo2-Lipid A and 40 ng/mL TNF- for 45 minutes.  0.25 % DMS 
was used as control. 
86 
 
Figure 4.3. EMSAs from HUVEC nuclear extracts after various treatments. (1) Free 
probe for NF-kB. (2) 0.25 % DMSO control. (3) TNF-α. (4) BAY 11-7085 + TNF-α. (5) 0.2 µM 
11-oxo-ETE + TNF-α.  (6) 2 µM 11-oxo-ETE + TNF-α. (7) 50-fold excess of cold NF-kB (8) 
Mutated NF-B cold competition. (9) p50 antibody supershift. (10) p65 antibody supershift. (11) 
SP-1 cold competition. (12) AP-1 cold competition. 
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Figure 4.4. NF-B driven firefly luciferase activity with 11-oxo-ETE treatment.  (A) 
Firefly luciferase activity versus vehicle control in HEK293 cells stably transfected with a 
5x-B reporter driving firefly luciferase with pretreatment of 11-oxo-ETE for 5 minutes 
before treatment with 40 ng/mL TNF-.  B) Following an additional pre-treatment of the 
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cells with 100 M ethacrynic acid. C) LC-ECAPI/SRM/MS quantification of 11-oxo-ETE 
from HEK293 cells with or without ethacrynic acid pre-treatment. 
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Figure 4.5. IKKβ and IkBα phosphorylation in HUVECs. (A) Pretreatment with 11-
oxo-ETE or 11-oxo-ETE–ME for 5 minutes before TNF-α challenge for 45 minutes. (B) 
Pretreatment with 11-oxo-ETE or 11-oxo-ETE–ME for 6 hours before TNF-α challenge 
for 45 minutes. (C) In vitro IKKβ inhibition with 15d-PGJ2 (2 or 10 µM) and 11-oxo-ETE 
(2 or 10 µM). 
 
 
Figure 4.6. Inhibition of induced manganese superoxide dismutase by 11-oxo-ETE 
in activated endothelial cells.  Western blot of manganese superoxide dismutase from 
HUVECs pre-treated with 0.25% DMSO vehicle control, 2 M 11-oxo-ETE, or 2 M 11-
oxo-ETE-ME, and then challenged with 40 ng/mL TNF- as indicated. 
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Figure 4.7. LC-MS analysis of tryptic peptides. The LC-MS chromatogram of (A) Un-
modified peptide from binding pocket of p50. (B) 11-oxo-ETE adducts of peptides from 
the DNA binding pocket of p50. 
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Figure 4.8. Peptide fragments detected in MS2 analysis of the 698.3468 m/z 
precursor ion corresponding to the adduct of the tryptic peptide of the p50 DNA 
binding domain.  (A) Cys-61 adduct (B) His-66 adduct. Ions in bold provide differential 
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site localization of the adduct to Cys-61 versus His-66. 
 
Figure 4.9. DNA binding domain of p50 showing cysteine-61 and hsitidine-66. (A) 
Sequence homology of mammalian p50s (NFKB1) and p65. (B) Predicted protonated 
molecules from un-modified and modified tryptic peptides. 
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Figure 4.10.  Protonated molecules with charge states from high resolution LC-MS 
analysis. (A) 11-oxo-ETE-modifed peptide from DNA binding region of p50. (B) 
Unmodified peptide from DNA binding region of p50.  
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FIGURE 4.11. MS
2
 analysis of the 11-oxo-ETE modification on histidine-66 residue 
of the peptide from the binding pocket of p50.  
 
 
 
FIGURE 4.12. MS2 analysis of the 11-oxo-ETE modification on cysteine-61 residue 
of the peptide from the binding pocket of p50. 
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Chapter 5: Stable Isotope Labeling in Cell Culture for Liquid 
Chromatography-Mass Spectrometry of Mixed Length Acyl-
coenzyme A Thioesters. 
 
In preparation for submission as: Stable isotope labeling in cell culture for liquid 
chromatography mass spectrometry of mixed length acyl-coenzyme A thioesters.  
Nathaniel W. Snyder, Sankha S. Basu, Zinan Zhou, Andrew J. Worth, Ian A. Blair 
 
Abstract 
Rationale: Coenzyme A (CoA) thioesters are a critical component of cellular metabolism.  
Therefore, the measurement of CoA species is an important analytical task, and can be 
accomplished with high sensitivity, specificity, and reproducibility by the gold standard 
method of stable isotope dilution-liquid chromatography-single reaction monitoring-mass 
spectrometry (SID-LC-SRM/MS).     
Methods: Previously, we developed a strategy for producing the required array of short 
chain acyl-CoA heavy isotopic standards for SID analysis.  Here we expand our 
procedure for producing isotopically labeled CoA thioesters to include lower abundance 
medium and long chain acyl-CoAs.  A fatty acid treatment and solid phase extraction 
were adapted for acyl-CoA recovery from cell culture. Reversed phase LC-MS/MS with 
an API4000 mass spectrometer operating in positive ion mode was used for analysis. 
Results: We demonstrate induction, recovery, and analysis of low abundance medium 
and long chain acyl-CoAs.  The isotopic purity of our labeling was confirmed to be above 
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99%. Chromatographic separation of isobaric mixed length chain acyl-CoAs was 
confirmed against commercial standards. Using SID-LC-SRM/MS, we measure murine 
liver acyl-CoA levels, and absolutely quantify the induction of arachidonoyl-CoA in cell 
culture. 
Conclusions: This method should further the rigorous quantitative study of acyl-CoA 
species.  This procedure provides a simple cost-effective means of preparing acyl-CoA 
stable isotope labeled standards. 
 
 
 
Introduction 
 In prokaryotes and eukaryotes, coenzyme A is an essential cofactor for energetic 
and synthetic metabolic pathways.  CoA species are perturbed in a wide variety of 
diseases with high mortality and morbidity including metabolic dysfunction (169), 
toxicological insult (170), and a spectrum of genetic disorders (171,172).  Fatty acid 
synthesis, catabolic breakdown of long chain fatty acids, xenobiotic biotransformation, 
and post-translational modification of proteins rely on acyl-CoA intermediates (8,173-
175).  However, mammalian cells are incapable of synthesizing the essential CoA 
precursor pantothenate (vitamin B5) from precursors (176).  Previously, we have taken 
advantage of this incomplete metabolism by replacing pantothenate in cell media with a 
[13C3 
15N1]-pantothenate heavy isotope labeled analog, which is then incorporated into 
CoA, and thus, any CoA thioester (177).  We termed this methodology stable isotope 
labeling by essential nutrients in cell culture (SILEC), after the similarity to the stable 
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isotope labeling by amino acids in cell culture (SILAC) methods employed for proteins 
(178).  For acyl-CoA molecules, this imparts a +4 m/z shift to the internal standard, 
allowing distinction between the analyte and the internal standard in a mass 
spectrometer, without significant isotopic overlap or interference from biological matrices 
(179). 
 A major limitation of our earlier work was that our extraction and analysis 
methods only encompassed short chain CoA thioesters, failed to include naturally 
transient medium chain acyl-CoAs and more hydrophobic longer chain acyl-CoA 
species.  In this study we have adapted a previously reported extraction to encompass a 
wider range of CoA species (180), and demonstrate recovery of short, medium, and long 
chain CoA thioesters after an optimized induction of lower abundance species.  We 
further demonstrate a successful application of our SILEC method to create a panel of 
internal standards.  To demonstrate the utility of this method we absolutely quantify 
induction of arachidonoyl-CoA after treatment with the parent fatty acid in a cell culture 
system, and measure absolute levels of acyl-CoA species in mouse liver tissue. 
Materials and Methods 
Reagents  
Arachidonoyl-CoA, 5-sulfosalicilic acid (SSA), ammonium formate solution, 
glacial acetic acid, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich 
(St. Louis, MO).  Optima LC-MS grade methanol, acetonitrile (ACN), 2-propanol (IPA) 
and water were purchased from Fisher Scientific (Pittsburgh, PA).  2-(2-pyridyl) ethyl 
functionalized silica gel 100 mg/1 mL tubes were obtained from Supelco Analytical 
(Bellefonte, PA).  F-12K media, DMEM, medium 200, low serum growth supplement 
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(LSGS) kit, streptomycin, and penicillin were purchased from Invitrogen (Carlsbad, CA). 
Charcoal stripped fetal bovine serum (csFBS) was from Gemini Bioproducts (West 
Sacramento, CA).  [13C3 
15N1] calcium pantothenate was purchased from Isosciences 
(King of Prussia, PA).  Peroxide free arachidonic acid (AA) was purchased from Cayman 
Chemical (Ann Arbor, MI).   Human colorectal adenocarcinoma cells (LoVo) and human 
colon adenocarcinoma (HCA7) cells were obtained from ATCC (Manassas, VA).  
Cell Culture 
For SILEC labeling, Hepa1c1c7s were passaged at least 7 times in custom RPMI 
1640 media without calcium pantothenate (AthenaES, Baltimore, MD) and containing 
10% charcoal stripped-FBS, 100 units/mL penicillin, 100 mg/L streptomycin, and 2 mg/L 
[13C3 
15N1]-calcium pantothenate.  24 hours before extraction, “ultra-labeling” with media 
as above, but omitting csFBS, was carried out for to ensure optimal CoA heavy isotopic 
labeling.  For unlabeled cell culture, HCA7 cells were grown in DMEM media with 2% 
FBS and 100 units/mL penicillin and 100 mg/L streptomycin. LoVos were grown in F-12K 
media with 2% FBS and 100 units/mL penicillin and 100 mg/L streptomycin. 
Sample preparation 
For SILEC internal standards, batches were grown as above.  Upon completion 
of labeling method, cells were gently lifted, centrifuged at 500 rcf for 5 minutes and 
resuspended in 750 µL / 10cm2 plate of 3:1 ACN:IPA.  Samples were sonicated with a 
probe tip sonicator on ice 30 times for 0.5 s.  250 µL of 100 mM KH2PO4 (pH 6.7) were 
added to the samples, then vortexed and spun down for 10 min at 16,000 rcf at 4°C.  
The supernatant was pooled and stored in -80°C until use. 
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For cellular acyl-CoA analysis, cells were gently lifted, centrifuged at 500 rcf for 5 
minutes and resuspended in 750 µL / 10 cm2 plate of 3:1 ACN:IPA for extraction as 
previously described (180).  Samples were pulse sonicated with a probe tip sonicator on 
ice 30 times for 0.5 s.  250 µL of 100 mM KH2PO4 (pH 6.7) were added to the samples, 
then vortexed and spun down for 10 min at 16,000 rcf at 4°C.  The supernatant was 
transferred to a glass tube and acidified with 125 µL of glacial acetic acid.  SPE columns 
were equilibrated with 1 mL 9:3:4:4 ACN:IPA:H2O:acetic acid.  The samples were 
transferred to the column and filtrated.  The column was washed two times with 1 mL of 
the 9:3:4:4 mix.  The columns were eluted two times with 500 µL 4:1 methanol:250 mM 
ammonium formate into glass tubes.  Filtrate was evaporated to dryness under nitrogen 
gas.  The filtrate was then re-dissolved in 50 µL of 70:30 H2O:ACN with 5% SSA (w/v) 
and transferred to HPLC vials. 
Induction of arachidonoyl-CoA and measurement of mouse liver acyl-CoA 
HCA7 and LoVo cells were grown until 80% confluence as above.  25 µM 
arachidonic acid with 0.25% DMSO in DMEM media was added and at 30 min, 60 min, 
90 min and 4 h, the cells were gently scraped and collected in plastic tubes. Tubes were 
centrifuged for 5 min at 500 rcf.  Media was removed and the cell pellet was dissolved in 
550 µL 3:1 ACN:IPA and 200 µL of the internal standard mix was added to each sample.  
Then the samples were extracted and prepared as above. 
For the arachidonoyl-CoA quantification, six standard solutions of arachidonoyl-
CoA in methanol were made corresponding to 20 pmol, 2 pmol, 0.2 pmol, 20 fmol, 2 fmol 
and 0 fmol on column.  The standards were dried and then re-dissolved in 800 µL 3:1 
ACN:IPA and 200 µL of ISTD were added to each sample.  250 µL of 100 mM KH2PO4 
(pH 6.7) were added to the samples, then vortexed and spun down for 10 min. at 16,000 
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rcf.  The supernatant was transferred to a glass tube and acidified with 125 µL of glacial 
acetic acid.  Then, the samples were extracted using SPE column and the samples were 
prepared as above.  Analysis of the standard curve was performed with Excel. 
LC-MS/MS 
Samples were kept at 4°C in a Leap CTC autosampler (CTC Analytics, 
Switzerland) with 20 μL injections used for LC-MS analysis.  Chromatographic 
separation was performed using reversed phase Waters XBridge C18 column (2.1 x 150 
mm, pore size 3.5 μm) on an Agilent 1100 HPLC system using a three solvent system: 
(A) 5 mM ammonium acetate in water, (B) 5 mM ammonium acetate in 95/5 
acetonitrile/water (v/v), and (C) 80/20/0.1 (v/v/v) acetonitrile/water/formic acid, with a 
constant flow rate of 0.2 mL/min.  Gradient elution was performed as follows: 2% B 
(isocratic) for 1.5 min, 2% to 20% (linear gradient) over 3.5 min, 20% to 100% B (linear 
gradient) B over 0.5 min, 100% B (isocratic) for 8 min, 100% C for 5 min, before 
equilibration at initial conditions for 5 min.   
Samples were analyzed using an API 4000 triple quadrupole mass spectrometer 
(Applied Biosystems, Foster City, CA) in positive electrospray ionization (ESI) mode and 
data was analyzed using Analyst software as previously described (179).  The mass 
spectrometer operating conditions were as follows: ion spray voltage (5.0 kV), 
compressed air as curtain gas (15 psi) and nitrogen as nebulizing gas (8 psi), heater (15 
psi), and collision-induced dissociation (CID) gas (5 psi).  The ESI probe temperature 
was 450°C, the declustering potential was 105 V, the entrance potential was 10 V, the 
collision energy was 45 eV, and the collision exit potential was 15 V.  CoA thioesters 
were monitored using the transitions described in Table 2. 
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Results 
Mixed Acyl-CoA Extraction 
 Extracts of LoVo cells at 80% confluence were analyzed by the LC-MS method 
described above.  The neutral loss scans of 507.1 m/z are shown in Figure 2 for the 
mixed CoA solid phase extraction (Figure 2A), the short chain CoA solid phase 
extraction (Figure 2B), and a biphasic liquid-liquid Folch extraction (Figure 2C).  In our 
hands, the mixed extraction recovered the broadest range of acyl-CoA species as 
evidenced by the peaks corresponding to acyl-CoA species in the short, medium, and 
long chain range.  The short chain extraction we have previously used gave intense 
CoASH and acetyl-CoA peaks, and overall higher signal intensity, but did not recover 
significant middle or long chain CoA species.  Recovered species appeared less 
abundant in the Folch extract versus the mixed CoA SPE (Figure 2A, 2C). 
Generation of a SILEC standard 
 Hepa1c1c7 mouse hepatocellular carcinoma cells were grown in RPMI media 
with pantothenate omitted, 2% charcoal stripped FBS, and 2 mg/L [13C4 
15N1] calcium 
pantothenate added for 7 passages.   Cells were “ultra-labled” for 24 hours in the same 
media with 0% FBS.  The cells were harvested using the mixed CoA solid phase 
extraction method.  Labeling for oleoyl-CoA was determined using integration of the 
peak area for the 1032  525 and 1036  529 m/z transitions corresponding 
respectively to the unlabeled and labeled oleoyl-CoA (Figure 3A). Commercial standards 
were matched with SILEC internal standards for the following acyl-CoA species; acetyl, 
butyryl, hexanoyl, octanoyl, decanoyl, lauroyl, tetradecanoyl, palmitoyl, palmitoeloyl, 
lineolyl, steareolyl, oleoyl, and arachidonoyl-CoA (Figure  3B).  Importantly, the M2 
103 
isotopomers for overlapping species, such as oleoyl-CoA M2 and steareoyl-CoA, are 
shown to achieve baseline separation with our liquid chromatography method (Figure 
3B).  Consistent with our previous work on short-chain acyl-CoAs (170,177,179) we find 
that the distribution of species is unequal, such that certain molecules of interest may be 
insufficiently synthesized in the internal standard mix for analytical use.  To address this 
problem, we tested induction of acyl-CoAs in Hepa1c1c7 cells with various doses of fatty 
acid mixtures.  A fatty acid mix sodium butyrate, sodium hexanoate, sodium octanoate, 
sodium decanoate, and sodium dodecanoate at 100 M was found to be ideal, where 
above that concentration cellular toxicity was observed (data not shown).  A time course 
study revealed that 3 hour incubation at 100 M produced the best distribution of acyl-
CoA species (Figure 5). 
Arachidonoyl-CoA time course 
 To demonstrate the use of this method for cellular studies, we quantified the 
levels of arachidonoyl-CoA in a cell system treated with free arachidonic acid.  A special 
SILEC standard was generated by treating the SILEC cells with 25 µM arachidonic acid 
for one hour before extraction.  This provided increased arachidonoyl-CoA internal 
standard, and shows the applicability of this method for targeted long chain acyl-CoA 
quantitation.  LoVo and HCA-7 colon adenocarcinoma cells were treated with 25 µM 
arachidonic acid, and the cells were extracted and analyzed by our method at various 
time points.  The resulting standard curve was linear over 4 orders of magnitude from 20 
fmol to 20 pmol on column and allowed us to capture the entire concentration range of 
cellular induction of arachidonoyl-CoA levels in the treated cells with absolute 
quantification (Figure 4A). 
Tissue acyl-CoA quantitation 
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 A set of three mouse liver tissue samples were analyzed by our method, and 
absolute quantification of select acyl-CoA species is given.  We describe pmol/mg of 
protein levels of long chain CoA thioesters in the mouse liver tissue (Figure 4B).  This 
demonstrates the use of this method for quantitative analysis of acyl-CoA species from 
tissue samples. 
Conclusion 
 Acyl-coenzyme A species are important to cell bioenergetics metabolism, and 
play critical roles in lipid generation, cell signaling, post-translational modification of 
proteins, and metabolism of xenobiotics (170,175).  However, the variety of individual 
chemical entities making up the acyl-CoA family poses a challenge to the analytical task 
of their measurement.  LC-UV strategies for analysis of CoA species may be 
insufficiently specific due to co-eluting peaks (181).  Excellent LC-MS/MS strategies for 
the analysis of acyl-CoAs have been employed by other groups, including validated 
methods by Magnes, et al. (182) and Mauriala et al. (183). However, these 
measurements used no internal standards. 
 In this study, we expand our previous method to generate stable isotope labeled 
internal standards for short chain acyl-CoAs to include medium and long chain acyl-
CoAs.  We were able to generate standards of even the low abundance acyl-CoA 
species and demonstrate the utility of this method in measuring induction of an acyl-CoA 
species and measuring absolute levels of CoAs from mouse liver tissue. 
 
 
 
105 
 
 
 
Figure 5.1. A) Biosynthesis of long chain acyl-coenzyme A thioesters B) 
Coenzyme A MS fragmentation for neutral loss of 507 amu 
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Figure 5.2. Neutral loss 507 scans of LoVo cells. Cells were extracted by A) mixed 
acyl-CoA SPE B) Folch extraction C) short chain acyl-CoA SPE. 
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Figure 5.3. LC-SRM/MS chromatograms of acyl-CoA thioesters. Chromatograms of 
A) labeling efficiency of unlabeled and [13C3,
15N1] labeled oleoyl-CoA from Hepa1c1c7 
SILEC extracts, B) labeled SILEC acyl-CoAs and unlabeled authentic standard acyl-
CoAs.  Where isotopic overlap is observed, chromatographic separation is shown (e.g. 
the M2 of oleoyl-CoA and M0 stearoyl-CoA). 
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Figure 5.4. Application of SID-LC-MS/MS of mixed length CoAs to biological 
systems. A) Absolute quantitation of the induction of arachidonoyl-CoA in two different 
colon carcinoma cells lines from 0.5 to 4 hours. B) Absolute quantitation of acyl-CoA 
species from three different mouse liver samples taken from different animals. 
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Figure 5.5. Neutral loss of 507 amu scans of [13C3, 15N1] Hepa1c1c7 cells 
extracted at various time points.  Spectra from extracted cells of (A) baseline, (B) 30 
minutes, (C) 3 hours, (D) 6 hours, (E) 12 hours, (F) 24 hours after treatment with a 100 
M mix of fatty acids as indicated in materials and methods. 
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Chapter 6: Untargeted Metabolomics from Biological Sources 
Using Ultraperformance Liquid Chromatography- High 
Resolution Mass Spectrometry (UPLC-HRMS) 
Published as:  Snyder, N. W., Khezam, M., Mesaros, C. A., Worth, A., Blair, I. A. Untargeted 
Metabolomics from Biological Sources Using Ultraperformance Liquid Chromatography-High 
Resolution Mass Spectrometry (UPLC-HRMS). J. Vis. Exp. (75), e50433, doi:10.3791/50433 
(2013). 
 
6.1 Abstract 
Here we present a workflow to analyze the metabolic profiles for biological 
samples of interest including; cells, serum, or tissue.  The sample is first separated into 
polar and non-polar fractions by a liquid-liquid phase extraction, and partially purified to 
facilitate downstream analysis.  Both aqueous (polar metabolites) and organic (non-
polar metabolites) phases of the initial extraction are processed to survey a broad range 
of metabolites.  Metabolites are separated by different liquid chromatography methods 
based upon their partition properties.  In this method, we present microflow ultra-
performance (UP)LC methods, but the protocol is scalable to higher flows and lower 
pressures.  Introduction into the mass spectrometer can be through either general or 
compound optimized source conditions.  Detection of a broad range of ions is carried 
out in full scan mode in both positive and negative mode over a broad m/z range using 
high resolution on a recently calibrated instrument.  Label-free differential analysis is 
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carried out on bioinformatics platforms.  Applications of this approach include metabolic 
pathway screening, biomarker discovery, and drug development. 
 
6.2 Introduction 
Due to recent technological advances in the field of HRMS, untargeted, 
hypothesis-generating metabolomics approaches have become a feasible approach to 
analysis of complex samples.(184)  Mass spectrometers capable of 100,000 resolution 
facilitating routine low part per million (ppm) mass accuracy have become widely 
available from multiple vendors.(185,186)  This mass accuracy allows greater specificity 
and confidence in a preliminary assignment of analyte identity, isotopic pattern 
recognition, and adduct identification.(187)  When coupled with an appropriate 
extraction procedure and high-performance LC or UPLC, complex mixtures can be 
analyzed with additional specificity derived from retention time data.(188)  UPLC 
possesses greater chromatographic efficiency and allows greater sensitivity, resolution 
and analysis time making a greater coverage of the metabolome possible.(189)  The 
resulting large datasets can be integrated into any of multiple differential analysis 
software and mined for useful patterns or individual analytes of interest.(190-194)  
Putative hits can be initially identified using a combination of peak detection algorithms, 
accurate mass based chemical formula prediction, fragmentation prediction, and 
chemical database searching.  This approach allows prioritization of targets for time-
consuming complete structural identification or for development of more sensitive and 
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more specific stable isotope dilution UPLC/selected or multiple reaction monitoring/MS 
studies that are the current gold standard methods for quantification.(159)  
The varying nature of biological samples has led to optimization of extraction 
protocols for urine(195), cells(196), serum(197), or tissue(198).  This protocol features 
extractions for cells, serum, and tissue.  Where appropriate, comments and additional 
references have been included for modifications of the procedure to address inclusion 
of stable isotopes, or for inclusion of especially unstable metabolites.  
6.3 Protocol Text 
1.) [Sample Extraction from Cells] 
1.1) For a 10cm plate of cells: collect 1.5mL of lifted cell suspension in media into a pre-
labeled 10mL glass centrifuge tube.  For adherent lines, cells should be lifted with gentle 
scraping in 1.5mL of media kept on ice.  Optional: If internal standards are used, add an 
appropriate aliquot at this step. 
Comment: Quenching of cellular metabolism is crucial for certain metabolites.  For 
analysis of time-sensitive metabolites, procedures such as cold methanol extraction 
should be considered.(199) 
1.2) Add 6mL of chloroform (CHCl3)/methanol (CH3OH) (2:1, v/v) to each of the 10mL 
glass tubes containing the samples.  Set the samples in a shaker or multi-vortexer on low 
speed for 30 min.  After shaking, the samples are centrifuged with a low 
acceleration/deceleration setting at 1935 x g for 10 min at 4°C to completely separate 
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the phases.  Optional: To avoid using CHCl3, extractions can be conducted with 
dichloromethane (CH2Cl2).(159,200) 
1.3) Using a long stem Pasteur pipet, transfer the organic (bottom) layer to a new pre-
labeled 10mL glass centrifuge tube.  Continue to 4.1. 
1.4) Transfer the upper aqueous later into a clean plastic 2mL Eppendorf tube.  
Evaporate the sample under nitrogen gas.  Continue to 2.6.2 for aqueous phase 
desalting or continue to 4.1. 
2.) [Sample Extraction from Serum] 
2.1) Transfer 20μL of serum into a plastic 2mL Eppendorf tube.  Optional: If internal 
standards are used, add an appropriate aliquot at this step. 
2.2) Add 190μL of CH3OH and vortex for 10 sec.  
2.3) Add 380μL of CHCl3 and vortex for 10 sec. 
2.4) Add 120μL of H2O to induce phase separation. Vortex the samples for 10 sec and 
allow to equilibrate at room temperature for 10 min.  
2.5) Centrifuge the samples at 8000 x g for 10 min at 4°C to separate the phases. 
2.6) Transfer the lower organic phase into a clean plastic 2mL Eppendorf tube.  Continue 
to 4.1.  
2.6.1) Transfer the upper aqueous later into a clean plastic 2mL Eppendorf tube.  
Evaporate the sample under nitrogen gas. 
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2.6.2) Re-suspend the sample in 200L H2O.  Acid or base reagents (0.1% Acetic acid, 
formic acid or 0.1% ammonium hydroxide) may be used to preferentially extract pH 
sensitive metabolites.   Sonicate for 20 min on ice to re-suspend the sample completely. 
2.6.3) Activate the C18 spin columns with 500L CH3OH. 
2.6.4) Equilibrate the spin column with two washes of 500 H2O and then load the 
sample.  If acid/base reagents are used maintain this concentration in the wash steps. 
2.6.5) Wash with 500L H2O to desalt the sample.  Again, if acid/base reagents are used 
maintain this concentration in the wash steps. 
2.6.6) Elute with two volumes of 200L 80% CH3OH in H2O into a pre-labeled clean 2mL 
Eppendorf tube.  Again, if acid/base reagents are used maintain this concentration in 
the wash steps.  Continue to 4.1. 
3.) [Sample Extraction from Tissue] 
3.1.) Depending on the tissue, use between 10-100 mg of frozen tissue.  Add the whole 
piece of tissue to a pre-labeled 2mL low retention Eppendorf tube with 1mL of PBS (1M, 
pH 6.8) in an ice bath.  Optional: If internal standards are used, add it into the buffer, 
before adding the tissue. 
3.2.) Homogenize the tissue in ice with an electric tissue grinder for 30 sec in each 
Eppendorf. Between samples, clean the tissue grinder in two separate tubes containing 
CH3OH and H2O, respectively. 
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3.3) Transfer the tissue homogenate with a plastic pipette into a pre-labeled 10mL glass 
centrifuge tube.  After the transfer, rinse each Eppendorf tube two times with 1mL of 
CH3OH and add the washes to the tissue homogenate in the glass tubes. 
3.5) Add 4mL of CHCl3 to each of the 10mL glass tubes containing the tissue 
homogenate and CH3OH washes.  Set the samples in a shaker or multi-vortexer on low 
speed for 30 min.   
3.6) After shaking, centrifuge the samples with a low acceleration/deceleration setting 
at 1935 x g for 10 min to completely separate the phases.  Optional: To avoid using 
chloroform, extractions have been developed with CH2Cl2. 
3.7)  Using a long stem Pasteur pipette, transfer the organic (bottom) layer to a new pre-
labeled 10mL glass centrifuge tube. Continue to 4.1. 
3.8) Using a long stem Pasteur pipette, transfer the aqueous layer to a new pre-labeled 
10mL glass centrifuge tube.  Go to 2.6.2 for desalting or continue to 4.1. 
4.) [Re-suspension and filtration of samples for UPLC] 
4.1) Evaporate the samples under nitrogen gas. 
4.2) Reconstitute dried down samples in an appropriate volume of the starting solution 
for the desired UPLC method (see Table 1).  50-100L is usually a desirable re-
suspension volume.  Gently vortex and/or pipette the sample up and down to aid in 
dissolving the analytes. 
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4.3.) Transfer the sample into a 0.22m nylon tube filter and spin at up to 14000 x g 
until the sample has completely passed through the filter (~5 min).  Make sure that 
there are no visible precipitates remaining in the sample. 
4.4.) Transfer the supernatant of the filtered sample into a pre-labeled UPLC vial with 
insert.  Cap vial, then flick the vial to remove any bubbles from the bottom of the 
sample vial.  Place the sample in the chilled autosampler (4-5˚C). 
5.) [UPLC Setup] 
5.1.) Using the control software for the liquid chromatograph, create a run for the 
organic sample based off of the conditions listed in Table 1.  Then create a method for 
the aqueous phase off the conditions listed in Table 1.  Optional: If a known set of target 
analytes are of high interest, optimize the UPLC conditions using the heavy labeled 
analog of these compounds, and generate a method using these conditions. 
5.3.) Allow the UPLC to adequately equilibrate.  This should include a full priming of 
solvents before attaching a column, and following the manufacturer’s directions for 
equilibration volume of a new column (usually 3-5 column volumes). Maintain a log of 
starting back pressures to help diagnose future problems. 
6.) [Mass Spectrometer Setup] 
6.1.) Using the control software for the high resolution mass spectrometer, create a 
positive mode method using the conditions listed in Table 2.  Then using the same 
conditions, create a negative mode method.  Optional: If a known set of target analytes 
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are of high interest, optimize source and optics conditions using the heavy labeled 
analog of these compounds, and generate a method using these conditions. 
6.2) Clean and calibrate the instrument, establish a stable spray into the spectrometer, 
and allow time for the calibration solution to adequately dissipate from the source and 
optics.  Acceptable stability of spray should give a 3-5% RSD of intensity over at least 
100 scans with injection of calibration solution at the same slow rate as the LC method 
being used. 
 6.3) Set up the sequence for all the samples, set appropriate injection volume, and run 
a blank before the first sample.  If carryover or matrix effects between samples are 
suspected, run adequate blanks/washes.  Samples should be setup in a randomized 
manner using a random number generator and a key to avoid any batch effects 
introduced by analysis. 
Comment: Quality control samples including stable isotope standards or analytical 
standards of likely targets can be extremely valuable in troubleshooting and assuring 
reliable, reproducible, and valid results.  A technical replicate of a standard only sample 
followed by a solvent blank can be used to accesses deviation of signal intensity and 
retention time, as well as carryover into the blank run. 
6.4) Begin sequence and monitor periodically for problems including pressure 
fluctuations, or loss of signal intensity across the run. If severe problems are detected, 
stop the run, and repeat from 6.2. 
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7.) [Differential Analysis] 
7.1.) Two workflows are presented for this protocol.  The first is through SIEVE 2.0, 
proprietary label-free differential analysis software sold by Thermo Fisher.  The second 
workflow is through XCMS Online, a free platform through Scripps Research 
Institute.(194)  Before beginning differential analysis, manually check the TICs or look at 
filtered chromatograms for any known compound in the sample to ensure 
reproducibility of runs and injection/UPLC/spray stability throughout all the samples. 
7.2.) SIEVE 
7.2.1) Transfer the .raw data files from the mass spectrometer to the hard drive of the 
workstation where SIEVE is installed.  (Note: running SIEVE with data stored on a 
networked or USB port connected drive is not advisable as it can limit the speed of 
analysis) 
7.2.2) Open SIEVE, and begin a new experiment. 
7.2.3) Load the appropriate files into SIEVE. 
7.2.4) Assign comparison groups and select a single reference file to allow SIEVE to 
generate the parameters for analysis. 
7.2.5) Follow the prompts and adjust any parameters per requirements of any individual 
experiment.  It is often advisable to start with stringent parameters and then go back 
and loosen the parameters as more generous settings can lengthen analysis time. 
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7.2.6) Load the correct adduct list for positive or negative mode in the parameters. 
7.3.) XCMS Online 
7.3.1) Convert files into an acceptable format for XCMS Online.  In our case, we convert 
to mzXML format.(201) 
7.3.2) Open XCMS Online, and Create Job. 
7.3.3) Upload and name datasets.  Only two datasets (e.g. Control vs Treatment) can be 
uploaded as XCMS stand-alone is limited to head-to-head comparisons. 
7.3.4) Select desired settings from the drop-down list.  Pre-populated parameters are 
available for different instrumentation setups, and these can be further modified for 
experimental needs.  In our case, we use the HPLC-Orbi2 settings. 
7.3.5) Submit and confirm job. 
7.4) Data Analysis 
7.4.1) For SIEVE and XCMS a list of frames and features, respectively, will be populated 
once the analysis is finished.  Ensure that the LC alignment overlays any landmark peaks.  
If any of the unaligned LC runs show large deviation in landmark peaks this may indicate 
a problem with the sample. 
Optional: For SIEVE, if internal standards are used, locate the corresponding peak group 
and normalize to the selected frame.  For XCMS On-line, normalization can be done in a 
spreadsheet after export. 
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7.4.2) Plot the data by coefficient of variation (CV) within a like sample population (e.g. 
control samples).  Any large CV values may indicate a problem with one or more sample. 
Sort the list based on desired traits (e.g. p-value<0.05, Fold Change>1.5, low standard 
deviation within a group, etc.) 
7.4.3) Examine each peak for appropriate peak alignment across groups, peak 
integration, Gaussian peak shape, signal intensity, isotopes, and adduct assignment. 
7.4.4) Export data as desired for further analysis or to generate targeted mass lists for 
confirmation and MSn experiments. 
 
6.4 Representative Results 
The results presented show selected data from a 6-h treatment of SH-SY5Y 
glioblastoma cells with the pesticide and mitochondrial complex I inhibitor rotenone.  
For brevity, only the organic phase positive mode data is presented.  The samples were 
processed and analyzed as described above (Figure 1, Table 1, Table 2) and loaded onto 
two differential analysis platforms for label-free quantification, SIEVE and XCMS online.  
Although a large number of hits (Figure 2, Figure 3) are identified by the two programs 
used for differential analysis these features include likely artifacts, poorly integrated 
peaks, and other features of questionable analytical value (Figure 6).  This can be judged 
by screening the hits for appropriate signal intensity, low variation between samples of 
the same group, background levels, and good chromatographic peak shapes (Figure 3). 
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To demonstrate the downstream confirmation of initial hits, we isolate a feature 
with a mass corresponding to our treatment compound rotenone within 3ppm (Figure 
3, Figure 4).  We confirm the identity of this analyte with UPLC-HR/tandem mass 
spectrometry (MS/MS) of our sample and the pure compound (Figure 5).  We also 
identify a differentially abundant feature reduced in the rotenone treated group, 
tentatively identified as D-pantethine by accurate mass database searching (Figure 4). 
 
Tables and Figures:   
 
Figure 6.1. General Experimental Outline for Sample Preparation and Analysis by 
Microspray UPLC-HRMS.   
A general outline of sample preparation, including the optional introduction of internal 
standards and protein or lipid/protein content analysis.  Phase separation, liquid 
chromatography, and analysis by different ion modes in the mass spectrometer are 
outlined. 
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Table 6.1: [UPLC Conditions] 
General and compound optimized UPLC conditions.  For organic phase 1, constant flow 
rate of 1.8L/min through a Waters nanoACQUITY C18 BEH130 column kept in a heater 
at 35˚C was used. Solvent A: 99.5% water/0.5% acetonitrile with 0.1% formic acid, 
Solvent B: 98% acetonitrile/2% water with 0.1% formic acid  For organic phase 2, 
constant flow rate of 3.4L/min through an Acentis Express C8 column kept in a heater 
at 35˚C was used. Solvent A: 40% water/20% acetonitrile with 0.1% formic acid and 
10mM ammonium formate, Solvent B: 90% isopropanol/10% acetonitrile with 0.1% 
formic acid and 10mM ammonium formate  For the aqueous phase, constant flow rate 
of 1.2L/min through a Waters nanoACQUITY C18 BEH130 column kept in a heater at 
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35˚C was used. Solvent A: 95% water/5% methanol with 0.1% ammonium hydroxide, 
Solvent B: 95% methanol/5% water with 0.1% ammonium hydroxide. 
 
Figure 6.2. Mirror Plot Generated with XCMS. 
A mirror plot showing differentially abundant features as detected and quantified 
through XCMS online from the organic phase positive mode UPLC-MS analysis.  Each dot 
represents a distinct “feature.”  Green dots are features more abundant (larger 
integrated area) in the control, whereas red dots are less abundant in the treatment.  
Increasing size of the dot indicates increasing magnitude of fold change between the 
groups, and the intensity of color indicates a decreasing p-value with increasing 
saturation of color. 
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Figure 6.3. Analyte Peaks. 
Chromatograms showing the organic phase positive ion mode UPLC-MS analysis.  A) 
Corrected (aligned) Total ion current (TIC) from SIEVE 2.0. B) Extracted Ion 
Chromatogram for the feature tentatively identified as D-pantethine through XCMS. C) 
Extracted Ion Chromatogram for the feature later identified as rotenone from SIEVE. D) 
XIC for the feature later identified as rotenone from SIEVE normalized to TIC. 
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Figure 6.4. Database Search Results. 
Database hits for A) Human Metabolome Database (http://www.hmdb.ca) and B) 
ChemSpider/KEGG (via SIEVE) (ChemSpider alone can also be employed - 
http://www.chemspider.com) using accurate mass determinations for the features 
shown in Figures 3B, 3C, and 3D corresponding to the ions of m/z 555.2516 and 
395.1481 based on the identification of these ions as [MH]+ species. 
 
Figure 6.5. HR/MS/MS Structural Confirmation. 
Confirmation of identification of the feature corresponding to the ion at 395.1481 m/z 
with a retention time of 23.22 min as rotenone based on UPLC-MS/MS comparison to a 
commercial standard with A) similar retention time and B) the same m/z (395.1481, 
~0ppm error) with nearly identical fragmentation. 
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Table 6.2: [MS Settings] 
General and compound optimized mass spectrometer settings used for the LTQ XL-
Orbitrap with a Michrom Thermo Advance captive spray ESI source. 
6.5 Discussion 
Untargeted metabolomics offers a powerful tool for investigating endogenous or 
xenobiotic biotransformations, or capturing a metabolic profile from a sample of 
interest.  The output of the technique scales with the resolution and sensitivity of the 
technology used to separate and analyze the sample, the ability to deal with the large 
datasets generated, and the ability to mine the dataset for useful information (e.g. 
accurate mass database searching).  Recently, this has been facilitated by advances in 
high resolution mass spectrometers, and high- or ultra-performance liquid 
chromatography.  Differential analysis software has addressed the analysis bottleneck, 
and can accomplish peak detection adjustment for retention time shifts, filtering, and 
statistical analysis with high-throughput.(202-204)  Selection of the proper informatics 
pipeline should include considerations as to data centroiding algorithms, peak 
detection, peak integration, alignment, ability to integrate MS/MS data, and ability to 
deal with isotopes or adducts.(205)  Selection of appropriate cheminformatics databases 
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should also be considered.(206-209)  The current inadequacy of any particular database 
to comprehensively identify compounds and integrate accurate mass data, MS/MS data, 
or LC data remains a major problem in the field.  
The workflow presented here integrates liquid-liquid extraction, micro-flow 
liquid chromatography, and high resolution mass spectrometry with two different 
differential analysis software platforms demonstrated in a cell culture treatment model.  
Additionally, extraction protocols are listed for serum and tissue, as these may serve as 
useful samples for similar analysis. 
Although any method used for untargeted metabolomics should be optimized 
for repeatability, stable UPLC conditions, and source stability, some variation is 
inevitable.  Both SIEVE and XCMS allow correction for retention time shift, but special 
attention should be paid to ensure that the parameters set in the experiment are 
adequate to correct variation.  Also, stable isotope labeled internal standard(s) can be 
easily integrated into this procedure to reduce artifacts and inter-sample variation 
caused by differences in sample extractions or LC-MS analysis.(159)   As with all sensitive 
LC-MS methodology, it is crucial to use high purity reagents, and ensure that the sample 
preparation removes undesirable particulate matter or aggregate.  Artifacts can be 
generated by the normal variation in contaminants, and it may be desirable to confirm 
that putative hits are not in fact ubiquitous contaminants of the extraction or analysis 
process. 
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Lastly, although the method is labeled as “untargeted” or “unbiased” 
metabolomics, this is a partial misnomer.  The nature of the extraction, separation, and 
analysis will favor metabolites with certain characteristics including stability during 
extraction, interaction with stationary and mobile phases during separation, and 
ionization at the source of the mass spectrometer.(210-212)  Depending on the 
available instrumentation, this procedure can be adapted to different extractions, flow 
rates, LC pressures, ion sources, or mass spectrometers.  Therefore, we have included 
notes in the procedure where certain conditions can be optimized based on general 
knowledge or internal standards representative of a class of molecules of interest. 
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Name of the 
reagent 
Company Catalogue 
number 
Comments 
(optional) 
Phosphate 
Buffered Saline 
Mediatech 21-031-CM  
Water (H2O) Fisher Scientific W7-4 (optima) 
Acetonitrile 
(CH3CN) 
Fisher Scientific A996-4 (optima) 
Methanol (CH3OH) Fisher Scientific A454-4 (optima) 
Isopropanol Fisher Scientific A464-4 (optima) 
Chloroform 
(CH3Cl) 
Sigma-Aldrich  366927 Hazard 
Dichloromethane 
(CH2Cl2) 
Acros Organics 61030-1000 To replace 
chloroform 
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Diethyl Ether Sigma-Aldrich 346136 To replace 
chloroform 
Formic Acid (FA) Fisher Scientific  (optima) 
NH4OH Fisher Scientific A470-250 (optima) 
Ammonium 
formate 
(HCOONH4) 
Sigma-Aldrich 78314  
MicroSpin C18 
Columns 
Nest Group Inc SS18V  
Pasteur Pipets Fisher Scientific 13-678-200  
10mL Glass 
Centrifuge Tubes 
Kimble Chase 73785-10  
10mL Plastic 
Centrifuge Tubes 
CellTreat CLS-4301-015  
LC Vials (glass) Waters 60000751CV  
LC Inserts (glass) Waters WAT094171  
LC Vials (plastic) Waters 186002640  
0.22m Filters Corning 8169 nylon 
2mL Eppendorf 
Tubes 
BioExpress C-3229-1 Low Retention 
  
Name of 
equipment 
Company Catalogue 
number 
Comments 
(optional) 
High Resolution 
Mass 
Spectrometer 
Thermo Scientific LTQ XL-Orbitrap  
HPLC/UPLC Waters nanoACQUITY 
UPLC 
 
Source Michrom Thermo Advance 
Source 
 
Differential 
Analysis Software 
Thermo Scientific SIEVE 2.0  
nanoACQUITY C18 
BEH130 
Waters 186003546 1.7 μm particle 
size, 150 mm x 
100 μm 
Acentis Express C8 Sigma-Aldrich 54262 2.7 μm particle 
size, 15 cm × 
200 μm 
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Table 6.3. Specific reagents and equipment  
 
Chapter 7. Saturation and Coenzyme A Thioester Formation of 
11- and 15-oxo-eicosatetraenoic Acid 
 
In preparation for submission as:  Saturation and coenzyme A thioester formation of 11- 
and 15-oxo-eicosatetraenoic acid. Nathaniel W. Snyder, Alejandro D. Arroyo,  
Clementina A. Mesaros, Suhong Zhang, Xiaojing Liu, Ian A. Blair 
Abstract 
Arachidonic acid metabolism by cyclooxygenase-2 (COX-2) and 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) results in the formation of 11-oxo- and 
15-oxo-eicosatetraenoic acid (oxo-ETE).  Both 11-oxo- and 15-oxo-ETE have been 
found in human specimens; however their further metabolism remains unknown.  This 
lack of understanding limits the biological measurement of these metabolites, as well as 
hindering elucidation of their function.  In this study, we describe metabolic pathways for 
both 11-oxo- and 15-oxo-ETE including reduction of double bonds and thioester 
formation.  Using an untargeted liquid chromatography mass spectrometry (LC-MS) 
approach we identify a mono-saturated product of both 11-oxo- and 15-oxo-ETE. We 
also identify a di-saturated product of 11-oxo-ETE.  We confirm these findings using LC-
MS/MS and treatment with aracidonic acid, [13C20]-15-oxo-ETE, as well as the methyl-
ester of 11-oxo-ETE.   Time course experiments show that these metabolites 
accumulate after treatment with the parent compounds.  Examination of the Michael 
addition adducts of the parent compounds and metabolites showed that the -
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unsaturated ketone moiety was absent in the doubly saturated product.  With a targeted 
LC-MS/MS approach we also describe the formation of CoA thioesters of both 11-oxo- 
and 15-oxo-ETE.  Subsequently, we demonstrate that these acyl-CoA species undergo 
up to 4 double bond reductions. These findings should facilitate the further study of poly-
unsaturated fatty acid metabolism in inflammatory diseases and cancer. 
 
Introduction 
Cyclooxygenases are major enzymes responsible for the generation of bioactive 
lipids from the preferred precursor arachidonic acid (AA) (22).  The resulting products 
are responsible for a vast array of cellular responses through families of G-coupled 
protein receptors (GPCRs) (6).  Evidence for non-GPCR mediated signaling exists 
(12,16,17,136,145,163), but is still controversial for some mediators (11).  The diversity 
of physiological responses therefore stems from relatively small alterations in the 
structure of the parent molecule.  Oxidation, reduction, cyclization, isomerization, and 
conjugation can fundamentally alter the function of eicosanoids.  Certain transformation 
result in changing of the affinity for receptors, increasing clearance, or effectively 
inactivating a functionality of a given molecule (40). 
The AA oxidation product 11-oxo-eicosatetraenoic acid (11-oxo-ETE) is 
generated by the sequential action of cyclooxygenases (COX), peroxidases, and 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) on free AA (129).  The known 
intermediates of this pathway are the unstable 11-hydroperoxyeicosatetraenoic aicd (11-
HPETE) and the stable product 11- hydroxyeicosatetraenoic acid (11-HETE) (27).  15-
oxo-ETE can be generated by a COX/15-PGDH pathway from free AA or a 15-LOX/15-
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PGDH or 12/15-LOX/15-PGDH pathway from free or esterified AA (83,108).  The further 
metabolism of these molecules however remains poorly described. 
In human cancers and inflammatory conditions, COX-2 and 15-PGDH are 
counter-regulated, whereby COX-2 expression is increased and 15-PGDH levels are 
reduced (42,88,142).  Electrophilic -unsaturated ketone containing fatty acids derived 
from -6 and -3 polyunsaturated fatty acids have anti-proliferative, anti-inflammatory, 
and redox signaling properties (12,108,118,129,136).  The involvement of oxidized 
phospholipids in atherosclerosis and inflammation also warrant interest in the 
metabolism of oxidized lipids (213).   
A more complete understanding of the metabolism of these molecules is needed 
to understand the roles such lipids may play in normal and pathological function.  
Understanding the exact biotransformation will facilitate identification of the responsible 
enzyme(s).  A variety of distinct fatty acid metabolizing enzymes exist with varying 
specificity for substrate and reaction (40).  Furthermore, the lack of an identified GPCR 
for either 11-oxo- or 15-oxo-ETE complicates the elucidation of their biological function.  
The possibility that the terminal signaling metabolite generated through 11-oxo- or 15-
oxo-ETE is not in fact the oxo-eicosatetraenoic acid cannot yet be discounted. 
Due to the involvement of endothelial cells in eicosanoid metabolism, 
atherosclerosis, tumor angiogenesis, inflammatory responses, and relevance to redox 
signaling we chose to study the metabolism of 11-oxo- and 15-oxo-ETE in human 
umbilical vein endothelial cells (HUVECs).  We also employ a COX-2/15-PGDH stably 
expressing human colon adenocarcinoma cell line (LoVo) that was used in previous 
studies of 11-oxo- and 15-oxo-ETE (129).  Through a combination of targeted and 
untargeted approaches, we examined 11-oxo- and 15-oxo-ETE metabolism.  
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Specifically, we investigated the interdependent saturation and CoA thioester formation 
of 11-oxo- and 15-oxo-ETE. 
 
Materials and Methods 
Reagents.  11-oxoeicosatetranoic acid (11-oxo-ETE), 15-oxoeicosatetranoic acid (15-
oxo-ETE), 11-oxo-eicosatetranoic acid methyl ester (11-oxo-ETE-ME), 15-oxo-
eicosatetranoic acid methyl ester (15-oxo-ETE-ME) and the [13C20]-labeled 15-oxo-ETE 
internal standard were synthesized in-house as previously reported (129).  Peroxide free 
arachidonic acid (AA) was purchased from Cayman Chemical (Ann Arbor, MI).  5-
sulfosalicilic acid (SSA), ammonium formate solution, glacial acetic acid, and dimethyl 
sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO).  HPLC grade 
chloroform and ammonium acetate as well as Optima LC-MS grade methanol, 
acetonitrile, water, isopropanol, ammonium acetate, ammonium formate, and formic acid 
were purchased from Fisher Scientific (Pittsburgh, PA).  2-(2-pyridyl) ethyl functionalized 
silica gel (100 mg/mL) tubes were obtained from Supelco Analytical (Bellefonte, PA).  F-
12K media, medium 200, low serum growth supplement (LSGS) kit, human umbilical 
vein endothelial cells (HUVECs), streptomycin, and penicillin were purchased from 
Invitrogen (Carlsbad, CA).  Fetal bovine serum (FBS) was from Gemini Bioproducts 
(West Sacramento, CA).  Human colorectal adenocarcinoma cells (LoVo and HCA-7) 
were obtained from ATCC (Manassas, VA). 
Untargeted discovery.  HUVECs were grown until 80% confluence on Collagen IV 
coated plates from Becton Dickinson (Bedford, MA), and maintained in medium 200 
supplemented with low serum growth supplement (LSGS) kit (Invitrogen).  Cells were 
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treated with 10 M 11-oxo-ETE, 11-oxo-ETE-ME, 15-oxo-ETE, or 15-oxo-ETE-ME in 
0.25% DMSO containing media.  An initial treatment time of 90 minutes at 37˚C was 
chosen based on previously published uptake data (129,214).  Extraction was performed 
as previously described with minor modifications (137). Cells were gently lifted, mixed, 
and an aliquot of the resulting suspension was transferred to a glass tube.  Folch 
extractions were performed with 2:1 chloroform:methanol with 0.1% acetic acid.  The 
organic phase was evaporated to dryness under N2.  The samples were dissolved in 
70:30 water:acetonitrile with 0.1% formic acid then filtered using 0.22 m nylon 
centrifuge filters (Costar) and transferred into HPLC vials for LC-HRMS analysis. 
Metabolic time course.  HUVECs were grown as above.  Media containing 0.25% 
DMSO with 10 M 11-oxo-ETE, 11-oxo-ETE-ME, 15-oxo-ETE, or 15-oxo-ETE-ME was 
added.  Cells were incubated at 37˚C for 5 min, 30 min, 1.5 h, 3 h, 6 h or 9 h.  At each 
time point, 450 L of the supernatant media was collected and transferred to a glass 
tube.  The cells were gently scraped in the remaining 450 L of media and transferred to 
a glass tube.  2.5 ng of [13C20]-15-oxo-ETE was added as an internal standard and, 
subsequently, Folch extractions were performed as previously described with minor 
modifications (215). The organic phase was evaporated to dryness under N2.  The 
samples were dissolved in 100 M70:30 water:acetonitrile with 0.1% formic acid then 
filtered using 0.22 m nylon centrifuge filters and transferred into HPLC vials for LC-
HRMS analysis. 
Acyl-CoA analysis.  Human colorectal adenocarcinoma cells (LoVo) were grown to 
80% confluence in F-12K media with 2% FBS and 100,000 units/L penicillin and 100 
mg/L streptomycin.  HUVECs were grown as above.  Extraction and analysis were 
performed as previously described (177,180). Briefly, cells were gently lifted, and the 
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resulting suspension was centrifuged at 500 x g at 4˚C.  The supernatant was removed, 
and the pellet was suspended in 750 L of 3:1 acetonitrile:isopropanol (ACN:IPA).  The 
suspension was sonicated with a probe tip sonicator to disrupt the cellular membranes.  
250 L of 100 mM KH2PO4 (pH 6.7) was added, the suspension was vortexed, and then 
centrifuged at 16000 x g at 4˚C.  The resulting supernatant was transferred to a glass 
tube and acidified with 125 L glacial acetic acid for solid phase extraction.  100 mg 2-
(2-pyridyl)ethyl-functionalized silica gel solid phase extraction columns (Sigma) were 
equilibrated with 1 mL 9:3:4:4 ACN:IPA:H2O:acetic acid.  Supernatants were transferred 
to the column and filtrated.  The columns were washed two times with 1 mL of the 
9:3:4:4 mixture.  The columns were eluted two times with 500 µL 4:1 methanol:250 mM 
ammonium formate into glass tubes.  Filtrate was evaporated to dryness under N2.  The 
dry samples were dissolved in 50 µL of 70:30 water:acetonitrile with 5% SSA (w/v) and 
transferred to HPLC vials. 
Liquid chromatography.  For LC-HRMS analysis, LC separations were conducted as 
previously described (215) using a Waters nano-ACQUITY UPLC system (Waters Corp., 
Milford, MA, USA). A Waters XBridge BEH130 C18 column (100 m × 150 mm, 1.7 m 
pore size; Waters Corp) was employed for reversed phase separation (flow-rate 1.8 
L/min) with a 3 L injection.  For gradient 1,  solvent A was 98/2 water/acetonitrile (v/v) 
with 0.1% formic acid, and solvent B was 99.5/0.5 acetonitrile/water (v/v) with 0.1% 
formic acid.  The gradient was as follows: 2% B at 0 min, 2% B at 3 min, 3.6% B at 11 
min, 8% B at 15 min, 8% B at 27 min, 50% B at 30 min, 50% at 35 min, and 2% B at 37 
min.  Separations were performed at 30 °C.  For gradient 2, Solvent A was 4/6 
water/acetonitrile (v/v) with 0.1% formic acid, 10 mM ammonium formate and solvent B 
was 1/9 acetonitrile/isopropanol (v/v) with 0.1% formic acid, 10 mM ammonium formate.  
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The gradient was as follows: 30% B at 0 min, 30% B at 6 min, 60% B at 11 min, 60% B 
at 15 min, 80% B at 27 min, 80% B at 30 min, 85 % at 35 min, 85 % at 45 min, 30 % at 
47 min, and 30% B at 55 min.  Separations were performed at 50 °C. 
For targeted acyl-CoA analysis, samples were maintained at 4°C in a Leap CTC 
autosampler (CTC Analytics, Switzerland) during sample batch runs.  10 L injections 
were used for LC-MS analysis.  Chromatographic separation was performed using a 
reversed phase Waters XBridge BEH130 C18 column (2.1 x 150 mm, 3.5 m pore size) 
on an Agilent 1100 HPLC system using a three solvent system: (A) 5 mM ammonium 
acetate in water, (B) 5 mM ammonium acetate in 95/5 acetonitrile/water (v/v), and (C) 
80/20/0.1 (v/v/v) acetonitrile/water/formic acid, with a constant flow rate of 0.2 mL/min.  
Solvent C was used after analysis to wash the column.  The gradient was as follows: 2% 
B at 0 min, 2% B at 1.5 min, 20% B at 5 min, 100% B at 5.5 min, 100% B at 13.5 min, 
100% C at 14 min, 100% C at 19 min, 2% B at 20 min and 2% B at 25 min. 
Mass spectrometry.  For LC-HRMS analysis, an LTQ XL-Orbitrap hybrid mass 
spectrometer (Thermo Fisher) was used in positive ion mode with a Michrom captive 
spray ESI source as previously described (215). For gradient 1 from above, the 
operating conditions were: spray voltage at 4 kV; capillary temperature at 250°C; 
capillary voltage at 35 V, tube lens 60 V.  For gradient 2, the operating conditions were: 
spray voltage at 1.5 kV; capillary temperature at 200°C; capillary voltage at 0 V, tube 
lens 80 V. 
For targeted acyl-CoA analysis, samples were analyzed using an API 4000 triple 
quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) in the positive 
electrospray ionization (ESI) mode and analyzed using Analyst software as previously 
described (177).  The column effluent was diverted to waste before 8 min and after 18 
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min.  The mass spectrometer operating conditions were as follows: ion spray voltage 
(5.0 kV), compressed air as curtain gas (15 psi) and nitrogen as nebulizing gas (8 psi), 
heater (15 psi), and collision-induced dissociation (CID) gas (5 psi).  The ESI probe 
temperature was 450°C, the declustering potential was 105 V, the entrance potential 
was 10 V, the collision energy was 45 eV, and the collision exit potential was 15 V.  CoA 
thioesters were monitored using SRM (selected reaction monitoring mode) as previously 
published (179). 
 
Results 
Untargeted discovery reveals distinctive patterns of biotransformation of the oxo-
ETEs in HUVECs.  To determine possible routes of biotransformation of 11-oxo-ETE 
and 15-oxo-ETE, HUVECs were treated for 90 minutes with 10 M of the parent 
compound in 0.25% DMSO.  A biphasic Folch extraction was then performed on the 
lifted cell suspension to capture a broad range of intra- and extra-cellular metabolites.  
LC-HRMS was carried out in an untargeted manner on the extracted lipid and aqueous 
fractions.  Analysis of differential abundant features was carried out by SIEVE 2.0, 
metaboanalyst 2.0, and XCMS (194,216).  Metabolic discovery experiments conducted 
in HUVEC cells revealed a diversity of differentially abundant features from the lipid 
fraction, with markedly less features in the aqueous fraction as demonstrated by the 
respective cloud plots generated with XCMS (S Fig. 1).  A ranked list by fold change 
versus control using a t-test (Welch’s unpaired) p-value cut-off of p < 0.01 was 
generated. Top hits from both programs were manually inspected; chromatograms were 
extracted from representative raw data samples (Fig. 1). 
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Two sequential mass shifts of +2 amu and an increased retention time were 
chosen for follow up targeted analysis for 11-oxo-ETE (Fig. 1A).  Only one +2 amu shift 
was observed for 15-oxo-ETE (Fig. 1B).  Interestingly, the free acid of 11-oxo-ETE 
demonstrated one major saturation and one minor second saturation, however, the 
methyl-ester of 11-oxo-ETE showed only one +2 amu shift (Fig. 1D).  These putative 15-
oxo-ETE metabolites were confirmed by treatment with [13C20]-15-oxo-ETE, and a 
resulting heavy isotope labeled metabolite was found with the same pattern of mass and 
retention time shift (Fig. 1C).   This pattern of retention time and mass shift seems 
logically indicative of a reduction in double bonds.  Accurate mass and isotope patterns 
matched predicted values for both parent and saturated compounds for 11-oxo-ETE and 
15-oxo-ETE in positive and negative ion mode (Supplemental Figure 3 and data not 
shown). 
Time course studies reveal accumulation of reduced metabolites.  To further 
describe the dysregulated features, time course studies were carried out using a 
targeted approach.  Cells were treated as above, using 11-oxo-ETE, 15-oxo-ETE, and 
their methyl esters.  Extractions were done over a multi-hour time course to examine the 
change in levels of targeted metabolites.  [13C20]-15-oxo-ETE stable isotope standard 
was spiked into all extractions to allow quantitation of the metabolites (Fig. 2).  The 
internal standard co-eluted with 15-oxo-ETE (Fig. 2).  The area of the target peak was 
integrated and quantified as a ratio over the area of the internal standard peak.  Values 
were expressed as a fold change log10 for each time point in order to cover the range of 
observed change in signal (Fig. 3).  The methyl-ester treated cells showed an order of 
magnitude amplification in the accumulation of metabolites compared to cells treated 
without the methyl ester derivatives of 11- and 15-oxo-ETE (Figs. 3B, 3D).  This was in 
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line with our previous work demonstrating that treatment with the methyl esters 
increased the intracellular pool of the free acid (214). 
MS/MS of parent oxo-ETEs and saturated metabolites.  MS/MS experiments were 
carried out in both positive and negative mode. (Supplemental Figure 3) Under negative 
ESI conditions, both mono-saturated oxo-ETEs exhibited an intense parent ion at m/z 
319.2270 (δ = 2.8ppm). (Supplemental Figure 3) The bis-saturated metabolite 
corresponding to 11-oxo-ETE+4 amu showed m/z 321.2424 (δ = 3.4ppm). The 11-oxo-
ETE MS/MS spectrum exhibited m/z 165.1283 (δ = 0.6ppm) that is formed by α-
cleavage to the carbonyl at position 11, and thus it retains the original double bonds from 
C12 and C14. In the MS/MS spectrum of the mono-saturated 11-oxo-ETE, the fragment 
corresponding to one double bond being reduced in the same fragment was found at 
m/z 167.1442 (δ = 0.4ppm) (Supplemental Figure 3). This indicates that the first 
saturation happens to positions C12 or C14. Consistent with this finding, the molecular 
fragment m/z 167.1076 (δ = 0.4ppm)  from 11-oxo-ETE, that corresponds to the 
fragment containing the initial double bonds at C 5 and C8, did not have a corresponding 
ion in the MS/MS spectrum of the 11-oxo-ETE mono-unsaturated  (m/z 169.1234). This 
further indicated that the first reduction did not occur at the position C5 or C8.  The 
hypothesis that the first reduction happens to positions C12 or C14, was supported by 
the MS/MS data in positive mode. The m/z 217.1587 fragment, that contained the two 
double bonds at position C12 and C14, had a similar ion m/z 219.1742 in the mono-
saturated 11-oxo-ETE, indicating a similar first reduction at one of these positions. 
The negative ion MS/MS spectrum of 15-oxoETE was identical with published 
CID spectrum by Murphy, et. al (217). The MS/MS spectrum of the monosaturated 15-
oxoETE contained multiple different fragments that showed a mass increase of 2 amu. 
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Unfortunately, the best described fragmentation of oxo-ETEs is due to the breaking of 
the double bond allylic to the carbonyl moiety. This generates the fragments 113.0977, 
corresponding to the part of the molecule without any double bond, and 219.1394, 
corresponding to the part of the molecule containing all the double bonds. The MS/MS 
spectrum of the mono-saturated 15-oxoETE showed the same fragment 113.0977 
indicating that the first reduction did not occur at C13.  The fragment corresponding to 
219.1394 shifted to 221.1549 consistent with the first reduction taking place to one of the 
initial double bonds at C5, C8 or C11. As discovered by the use of deuterium and 
oxygen labeled compounds there are simultaneous mechanisms of ion formation in the 
MS/MS spectra of oxo-ETEs, resulting in isobaric fragments derived from different 
fragmentation (217).  Even if different fragment ions from the MS/MS spectrum of 15-
oxo-ETE showed the corresponding ions + 2 amu in the monounsaturated spectrum 
(Supplemental Figure 3), would be highly speculative to propose the place of the double 
bond reduction just based on the MS/MS data.    
 
Michael addition adducts of the parent and saturated products reveal position of 
double bond reduction.  In order to examine the position of the double bond reductions 
in the metabolites, the formation of 1,4-Michael adducts was monitored by LC-HRMS.  
Lipid extracts from treated HUVECs were treated overnight with 5% (v/v) BME at 37°C to 
adduct any -unsaturated ketone containing compounds (Figs. 4B, 4D).  Control 
treated extracts were treated with 5% (v/v) water and treated identically overnight (Figs. 
4A, 4C).  Treatment of the 11-oxo-ETE containing extracts reduced the parent and 
mono-saturated products by over one order of magnitude (Figs. 4A, 4B).  In contrast, the 
doubly saturated product gave a strong peak in both control and BME treated samples 
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(Figs. 4B, 4D).  These findings indicate that the parent and monosaturated product still 
contain the -unsaturated ketone with the double bond at carbon 12.  This is in 
contrast to the disaturated product of 11-oxo-ETE where one of the two reduced double 
bonds appears to occur at C12 resulting in the loss of the -unsaturated ketone 
moiety. 
 The formation of GSH-adducts from treated HUVECs was also examined by LC-
HRMS.  GSH-adducts were observed for the parent and monosaturated 11-oxo-ETE 
(Figs. 5A), as well as the parent and monosaturated 15-oxo-ETE (Figs. 5B).   The same 
pattern was observed for the GSH-adduct of [13C20]-15-oxo-ETE (Figs. 5C).  Agreeing 
with the BME adduction, no GSH-adduct was observed for the doubly saturated 11-oxo-
ETE metabolite (Figs. 5A).  These data agree with the BME adduction results and 
indicate a second reduction of a double bond in 11-oxo-ETE abolishes the -
unsaturated ketone. 
Targeted acyl-CoA analysis reveals thioester formation and saturation.  The 
observation of a second reduction in 11-oxo-ETE prompted further experiments to 
understand the nature of this biotransformation.  A cytosolic prostaglandin reductase has 
been described for prostanoids with a double bond between carbons 13 and 14.  
However, description of a second saturation is to the author’s knowledge unknown.  The 
possibility of mitochondrial metabolism for the oxo-ETEs was therefore raised.  Using a 
previously described method for analysis of acyl-coenzyme A thioesters, we investigated 
the possibility of a oxo-ETE-coenzyme A thioester as had been described for similar 
oxidized fatty acids (166). 
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 A proof-of-principle experiment was conducted using LoVo cells treated with 
DMSO vehicle control or 25 M AA (Fig. 6).  LC-MS experiments using the CoA 
stereotypical neutral loss of 507 DA revealed an induction of acyl-CoA species.  A strong 
peak at 1054 m/z corresponding to arachidonoyl-CoA was induced in the treatment 
versus the control.  Interestingly, a peak at 1068 m/z was also observed, which would 
correspond to a oxo-ETE-CoA thioester (Fig. 6B). 
To confirm this initial observation and test if the saturated products previously 
observed also formed CoA thioesters we treated LoVo cells with 25 M AA, 10 M 11-
oxo-ETE, 10 M 11-oxo-ETE-ME, or 10 M 15-oxo-ETE.  Using our previously 
described extraction methodology, we used LC-SRM/MS with transitions corresponding 
to the distinct CoA neutral loss of 507 amu fragmentation for the oxo-ETE-thioester with 
zero to four saturations (Fig. 7).  In contrast to the free acid, we observed peaks in more 
than two channels. 
To further investigate the nature of the saturation, we treated two human colon 
adenocarcinoma lines, LoVo and HCA-7, with 11-oxo-ETE and observed the saturation 
of the 11-oxo-ETE-CoA thioesters over time.  In order to provide a semi-quantitative 
analysis, heavy labeled arachidonoyl-CoA was generated as previously described (179) 
and used as an internal standard for normalization and spiked into the sample before 
extraction.  The patterns of saturation observed was different between the two cell lines, 
where detectable amounts of all four saturations were seen in the LoVo cells, with only 2 
saturations at maximum seen in the HCA-7 cells. 
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Discussion 
The study of metabolism of eicosanoids has mostly focused on the generation of 
bioactive lipids.  The transformation of the initial products remains less well described.   
Existing literature on eicosanoid metabolism for COX/15-PGDH products has focused on 
PGE2 and its 15-PGDH dependent product 15-keto-PGE2.  A second level of 
transformation via a double bond reduction forms the product 13,14-dihydro-15-keto-
PGE2.  However, the COX/PGDH pathway also produces 11-oxo- and 15-oxo-ETE.  15-
oxo-ETE can also be generated by 15-LOX/PGDH metabolism.  Existing work on the 
metabolism of 15-oxo-ETE has described the generation and signaling of complex lipids 
integrating 15-oxo-ETE (218).  In this work, we expand the knowledge of these pathways 
to include additional downstream products.  
Our untargeted metabolomics approach revealed a distinct pattern of limited 
saturation for 11-oxo- and 15-oxo-ETE.  The similar metabolism of [13C20]-15-oxo-ETE, 
as well as time course studies support the identification of the metabolites are 
derivatives of the parent oxo-ETEs.  By examining the formation of Michael adducts, 
including BME and GSH adducts, we were able to discern the status of the double bond 
proximal to the carbonyl in the -unsaturated ketone moiety of the oxo-ETEs.  The 
parent and predominant first saturation of 11-oxo- and 15-oxo-ETE maintain the -
unsaturated ketone moiety.  However, the second saturation of 11-oxo-ETE no longer 
forms a BME or GSH adduct, indicating the double bond at C12 adjacent to the carbonyl 
has been reduced.  The enzymatic basis of this transformation warrants investigation as 
the -unsaturated ketone moiety has been associated with bioactivity in related 
molecules. 
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Saturation of mono- or poly-unsaturated fatty acids has been described through 
mitochondrial metabolism.  However, description of eicosanoid thioesters is lacking in 
the literature. Although we extended our discovery method to specifically look for CoA 
thioesters of PGE2 and the proximal metabolites 15-keto-PGE2 and 13,14-dihydro-15-
keto-PGE2, we could not detect any of these products (Figure 6B and data not shown).  
We also fail to detect the CoA thioester of the 11-oxo-ETE-methyl ester (data not 
shown).  This further supports the hypothesis that the identified product is in fact a 
thioester via the carboxylic acid group.  This distinction is important since the -
unsaturated ketone moiety could result in a 1,4-Michael addition product as identified in 
our previous work on covalent adduction to a nucleophilic amino acid.  
The limited saturation of free 11-oxo-ETE and 15-oxo-ETE and the pattern 
observed for the CoA thioesters may be relevant to wider metabolism.  For the 
saturation of the CoA thioester we detect up to the full four possible saturation events, 
which may indicate a difference in mitochondrial versus cytosolic enzyme activity or 
substrate specificity for only the CoA thioester. 
Ultimately, design of therapeutic interventions to modulate or mimic the effects of 
these molecules could be enabled by a complete elucidation of the pathways of 
metabolism.  This could facilitate the discovery of inhibitors or for the design of stable 
derivatives.  As additional benefit, identification of these novel metabolites may 
contribute to the ongoing efforts in untargeted metabolomics and an increased 
appreciation of specificity in lipidomics experiments. 
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Figure 7.1.  Extracted ion chromatograms of LC-HRMS analysis of lipid extract 
from oxo-ETE treated HUVECs.  Mass spectral features from the discovery experiment 
were extracted from representative chromatograms with a 5 ppm mass window from the 
given m/z from positive ion mode LC-HRMS analysis of lipid extracts of HUVECs treated 
with (A) 11-oxo-ETE, (B) 15-oxo-ETE, (C) [13C20]-15-oxo-ETE, or (D) 11-oxo-ETE-ME.  
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Peaks putatively corresponding to reductions in double bonds (saturations) were 
apparent for one and two saturations in 11-oxo-ETE.  Only one saturation was 
detectable for 15-oxo-ETE and [13C20]-15-oxo-ETE.  11-oxo-ETE-ME treatment revealed 
a similar pattern of saturation as observed for 11-oxo-ETE, except the methyl ester itself 
was only mono-saturated. 
 
Figure 7.2. Representative stable isotope dilution-LC-HRMS chromatograms of 
parent and putative metabolites.  Co-elution of 15-oxo-ETE and [13C20]-15-oxo-ETE 
was observed as well as baseline separation of 11-oxo-ETE from [13C20]-15-oxo-ETE. 
Extracted ion chromatograms within a 5 ppm window of (A) 11-oxo-ETE and the 
suspected monosaturated and disaturated products (B) 15-oxo-ETE and the suspected 
monosaturated product.   
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Figure 7.3. Time course of accumulation of free oxo-acid metabolites in lipid 
extracts from HUVECs. Accumulation of putative metabolites after treatment with 10M 
(A) 11-oxo-ETE, (B) 11-oxo-ETE-ME, (C) 15-oxo-ETE, or (D) 15-oxo-ETE-ME. Area 
under the curve was calculated from XICs of metabolites.  [13C20]-15-oxo-ETE was used 
as the internal standard and to normalize for extraction and ionization efficiency for 
relative quantitation.  Values are expressed in Log Area under the peak for 
(Analyte/ISTD) to capture the full range of values over the timecourse. 
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Figure 7.4.  LC-HRMS chromatograms of mock and BME treated oxo-ETE samples 
for parent oxo-ETEs and metabolites.  Lipid extracts of treated HUVECs were treated 
with or without 5% volume/volume BME overnight at 37°C.  (A) 11-oxo-ETE treated 
samples without BME, (B) 11-oxo-ETE with BME, (C) 15-oxo-ETE without BME (D) 15-
oxo-ETE with BME.  Panel (E) shows the reaction of 11-oxo-ETE with BME and the 
resulting adduct. 
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Figure 7.5.  LC-HRMS chromatograms of GSH-adducts from parent and saturated 
products of oxo-ETEs. Aqueous phase of Folch extraction from treated HUVECs were 
analyzed by LC-HRMS after desalting.  A 5 ppm mass window around the GSH-adduct 
is shown for  (A) 11-oxo-ETE and saturated products (B) 15-oxo-ETE and its 
monosaturated product, (C) [13C20]-15-oxo-ETE and its monosaturated product. 
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Figure 7.6.  Neutral loss of 507 Da scans show inducible acyl-CoA species. Neutral 
loss scans of 507 Da of (A) DMSO (B) 25 M AA treated LoVo cells. 
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Figure 7.7. LC-MS/MS chromatograms for oxo-ETE-acyl-CoA species and reduced 
metabolites. Extracted ion chromatograms of acyl-CoA LC-MS/SRM analysis from 
LoVo Cells treated with (A) 25 M AA treated LoVo cells (B)  10 M 11-oxo-ETE (C) 10 
M 15-oxo-ETE (D) 10 M 11-oxo-ETE-ME.  The m/z transitions corresponding to the 
reduction of 0-4 double bonds were monitored (1068561, 1070563, 1072565, 
1074567, 1076569).  Panel (E) shows the structures of 11-oxo-ETE-CoA and 15-
oxo-ETE-CoA. 
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Figure 7.8. Time course of 11-oxo-ETE-CoA thioesters. Quantification over 4 h of the 
parent and saturated products of 11-oxo-ETE-CoA in (A) LoVo cells (B) HCA-7 cells. 
SID-LC-MS/SRM were performed using [13C3 
15N1]-arachidonoyl-CoA as an internal 
standard for quantitation.  Values are expressed in Log Area under the peak for 
(Analyte/ISTD) to capture the full range of values over the timecourse. 
Supplemental Figures 
 
 S Fig 
7.1.  Mirror plots from XCMSonline differential analysis of untargeted LC-HRMS of 
(A) organic phase and (B) aqueous phase from 11-oxo-ETE-ME treated HUVECs. 
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S Fig 7.2.  Background of LC-HRMS analysis of Folch extraction from HUVEC lipid 
extract for DMSO treated cells.  XICs for a 5 ppm mass window corresponding to the 
parent and reduced oxo-ETEs are shown.  
 
155 
 
156 
S Fig 7.3. MS/MS determination of reduced double bond positions. (A) Negative ion 
mode ESI fragmentation of 11-oxo-ETE.  (B) Chromatograms of diagnostic product ions 
for 11-oxo-ETE parent and metabolite structural elucidation. (C) Chromatograms of 
diagnostic product ions for 11-oxo-ETE parent and metabolite structural elucidation 
confirmed by a second LC gradient. (D) LC-CID-MS/HRMS negative ion product ion 
scan of 11-oxo-ETE. (E) LC-CID-MS/HRMS negative ion product ion scan of 
monosaturated 11-oxo-ETE. (F) LC-CID-MS/HRMS negative ion product ion scan of 
disaturated 11-oxo-ETE.  (G) LC-CID-MS/HRMS negative ion and LC-HCD-MS/HRMS 
product ion scan of 15-oxo-ETE.  (H) LC-CID-MS/HRMS negative ion and LC-HCD-
MS/HRMS product ion scan of monosaturated 15-oxo-ETE.  (I) LC-CID-MS/HRMS 
negative ion and LC-HCD-MS/HRMS product ion scan of disaturated 15-oxo-ETE. 
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Chapter 8: Conclusion and future directions 
 
8.1 Conclusions 
The work presented above describes the discovery of a new set of lipid metabolites of 
11-oxo-ETE as well as description of the bioactivity and possible mechanistic function of the 
parent 11-oxo-ETE.  The methodology used for metabolite characterization and quantification 
was then applied to the specific public health problem of asbestos exposure.  The metabolic 
pathway under investigation in this work begins when COX-2 converts the substrate arachidonic 
acid into PGG2, 11(R)-HPETE, 15(S)-HPETE and 15(R)-HPETE.  The subsequent action of 
POXs reduces the unstable hydroperoxide precursors to PGH2, 11(R)-HETE, 15(S)-HETE, and 
15(R)-HETE, respectively.  From these resulting metabolites, a plethora of other eicosanoids is 
generated in an enzyme and/or context dependent manner. 
In Chapter 2, the ability of 15-PGDH to oxidize 11(R)-HETE into anti-proliferative 11-oxo-
ETE is described.  The LoVo colon cancer adenocarcinoma cell model was used to clearly 
demonstrate that 11-oxo-ETE was rapidly secreted or metabolized by the LoVo cells. Chapter 3 
describes an elaboration of the initial findings of rapid export and anti-proliferative action of 11-
oxo-ETE by design of potent “pro-drug” methyl-ester forms of 11-oxo-ETE and 15-oxo-ETE that 
showed increased concentration in the intracellular space and more potent anti-proliferative 
effects.  Furthermore, these effects were increased by pharmacological blockade of MRP 
exporters, which further implicates these exporters in modulating the biological effects of 11-oxo-
ETE.  Using the tools described in Chapter 3, the signaling, bioactivity, and mechanistic cellular 
action of 11-oxo-ETE on the NF-κB pathway were examined.  The findings of these studies are 
described in Chapter 4.  Inhibition of NF-κB signaling was demonstrated in HUVECs and with a 
luciferase reporter assay.  A plausible mechanism was elucidated through the characterization of 
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an 11-oxo-ETE adduct on the cysteine or histidine residue of the DNA binding domain of a NF-κB 
transcription factor protein.  
Chapter 5 describes a targeted approach to acyl-CoA analysis, whereby the novel 11-
oxo-ETE-CoA thioester was discovered.  Chapter 6 describes the methodology used for 
untargeted metabolomic analysis through nanoflow-ultraperformance liquid chromatography-high 
resolution accurate mass-mass spectrometry.  The methods described in Chapters 5 and 6 were 
applied to the study of 11-oxo-ETE and 15-oxo-ETE metabolism to reveal distinct pathways of 
biotransformation.  The results of these metabolic studies are described in Chapter 7. 
Overall, this thesis reports the evolution of studies that initially involved the specific 
problem of understanding how an endogenous metabolite exerted its anti-proliferative effects on 
cancer cells.  When existing methodologies failed to further the understanding of the problem, 
new methodologies were developed.  Untargeted and targeted LC-MS based approaches for 
sensitive discovery and rigorous quantitation of AA metabolites were developed.  The power of 
these methodologies was then realized in the elucidation of novel metabolism. 
Initial studies involved the targeting a specific metabolite of AA, 11-oxo-ETE, together 
with an investigation of its mechanism of formation.  Although 11-oxo-ETE belongs to a 
physiologically critical and pharmacological important pathway, little previous work had focused 
on the specific metabolite itself.  Through understanding of the exact enzymology of formation, 
the relevance of 15-PGDH as a pharmacological target was supported.  The initial kinetic 
description of 11-oxo-ETE formation prompted further work to examine its disposition and 
bioactivity.  This required the generation and testing of specific chemical tools, which might be 
useful to the study of related molecules, or for therapeutic uses.  The chemical tools developed in 
the initial study of 11-oxo-ETE then served as a useful probe in the examination the mechanistic 
signaling of 11-oxo-ETE in an inflammatory context.  This mechanistic understanding expanded a 
broader scientific understanding of the electrophilic fatty acids, and will further the study of other 
related molecules for therapeutic and biomarker use.  Through use of the most rigorous SID-LC-
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MS/MS, the investigation of the formation and disposition of 11-oxo- and 15-oxo-ETE remained 
internally consistent across studies, and externally consistent with existing literature. 
In order to examine the further metabolism of 11-oxo-ETE, specific methodological tools 
had to be developed.  Both untargeted and targeted liquid chromatography-mass spectrometry 
approaches were created to study pathways of 11-oxo-ETE metabolism.  The application of these 
approaches led to identification of novel metabolites.  Pathways of biotransformation discovered 
for 11-oxo- and 15-oxo-ETE may also play roles in the metabolism of a wide variety of important 
lipid mediators. 
 
8.2 Future directions 
Considering the complexity of human metabolism, a major limitation of current 
methodology is that it focuses on limited numbers of metabolites within a specific context without 
consideration of the broader metabolic context (i.e. the other changes within the system). Mass 
spectrometry platforms, such as LTQ-Orbitrap, Q-exactive, Tribrid, TripleTOF 5600, Synapt, and 
12T FT-ICR all provide high resolution capacity that can facilitate good mass accuracy 
(69,152,185,219-221). Expanded dynamic range, and increased sensitivity afforded by such 
technological innovation will also drive metabolism research.  Supplementing studies with 
targeted analysis or complementary techniques such as NMR will also provide increased 
coverage and validity to studies (222).  The growth of metabolomics software (e.g. XCMS and 
SIEVE), bioinformatics platforms with integrated statistical tools (e.g. R and metaboanalyst), and 
metabolite databases (e.g. METLIN, ChemSpider, LipidMAPS, and HMDB), together with HRMS, 
will make it possible to begin addressing these issues (190,193,194,207,209,216).  Improvements 
in LC systems, including 2D-LC, and retention time database matching with references standards 
will also improve metabolomics. 
For metabolic studies of lipids, the current small molecule metabolite databases provide 
incomplete coverage (Chapter 8). Therefore, compared to proteomics studies (with more 
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sophisticated databases), it is more challenging to assign specific structures to unknown features 
observed in an LC-MS chromatogram (Chapter 7 and 8). This is an inherent property of the 
enormous diversity of structures that can be encountered with small molecule metabolites 
(Chapter 7 and 8), which is also paradoxically what makes global metabolite profiling 
(metabolomics) such a necessary tool when confronted with such biochemical complexity.  
HRMS based analysis of small molecule metabolites should not be expected to provide accurate 
quantitation, complete specificity, or complete structural information in all cases and no single tool 
that is currently available is applicable to every experimental design.  Besides LC-MS, NMR is 
also crucial for unknown metabolite structure elucidation, but suffers from limitations of sensitivity 
and capital costs (223).  Thus, more basic discovery research into human metabolism (Chapters 
1-8) will be required to attain the goal of high confidence assignments from broad coverage 
metabolomics data sets on a routine basis.  Ultimately, validation with targeted analysis using 
rigorous analytical methodology suited for the task (Chapter 5) will still be required (81). 
Importantly, the integration of genomics, transcriptomics, and proteomics/post-
translational modifications experiments may provide the complex and enriched data necessary for 
understanding feedback relationships and the fine tuning of metabolites in physiology and 
disease.  In this thesis research, no specific G-coupled protein receptors were identified for any 
product along the 11-oxo-ETE or 15-oxo-ETE pathway.  Although the first steps in this process 
were laid in Chapter 1-7, assignment of an unknown receptor/ligand pair is still one of the most 
difficult problems of pharmacology.  The integration of multi-dimensional (gene, RNA, protein, 
modification, metabolite) –omics data may facilitate this type of identification by virtue of providing 
a systems biology approach to narrow down candidate receptors.  Additionally, increasing power 
of LC-MS platforms may facilitate better chemical probe approaches (224). 
Ultimately, the future directions of the work in this thesis are two-fold: the top-down 
approach informed from metabolomics driving identification of differentially abundant metabolites 
from experimental studies and the bottom-up investigation of newly discovered pathways with 
rigorous validation.  Both approaches are complimentary, necessary, and scientifically valid when 
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conducted with due acknowledgement of the inherent limitations.  The historic and ongoing use of 
metabolites as putative biomarkers, therapeutics in their own right, and receptor or enzyme drug 
targets makes metabolism an attractive area of study for the betterment of human knowledge and 
health. 
BIBLIOGRAPHY 
Reference List 
 
 1.  Zubarev, R. A. and Makarov, A. 2013. Orbitrap Mass Spectrometry. Analytical 
Chemistry. 85: 5288-5296. 
 2.  Domon, B. and Aebersold, R. 2006. Mass spectrometry and protein analysis. Science. 
312: 212-217. 
 3.  Pawlosky, R., Barnes, A., and Salem, N. 1994. Essential fatty acid metabolism in the 
feline: relationship between liver and brain production of long-chain polyunsaturated 
fatty acids. Journal of lipid research. 35: 2032-2040. 
 4.  Van Deemter, J., Zuiderweg, F. J., and Klinkenberg, A. v. 1956. Longitudinal diffusion 
and resistance to mass transfer as causes of nonideality in chromatography. Chemical 
Engineering Science. 5: 271-289. 
 5.  Fahy, E., Subramaniam, S., Brown, H. A., Glass, C. K., Merrill, A. H., Murphy, R. C., 
Raetz, C. R., Russell, D. W., Seyama, Y., and Shaw, W. 2005. A comprehensive 
classification system for lipids. Journal of lipid research. 46: 839-862. 
 6.  Smyth, E. M., Grosser, T., Wang, M., Yu, Y., and FitzGerald, G. A. 2009. Prostanoids in 
health and disease. Journal of Lipid Research. 50: S423-S428. 
 7.  Gardner, H. W. 1989. Oxygen radical chemistry of polyunsaturated fatty acids. Free 
Radical Biology and Medicine. 7: 65-86. 
 8.  Robishaw, J. D. and Neely, J. R. 1985. Coenzyme A metabolism. American Journal of 
Physiology-Endocrinology And Metabolism. 248: E1-E9. 
 9.  Van Meer, G., Voelker, D. R., and Feigenson, G. W. 2008. Membrane lipids: where they 
are and how they behave. Nature reviews molecular cell biology. 9: 112-124. 
 10.  Simmons, D. L., Botting, R. M., and Hla, T. 2004. Cyclooxygenase isozymes: the 
biology of prostaglandin synthesis and inhibition. Pharmacological reviews. 56: 387-437. 
162 
 11.  Bell-Parikh, L. C., Ide, T., Lawson, J. A., McNamara, P., Reilly, M., and FitzGerald, G. 
A. 2003. Biosynthesis of 15-deoxy-12,14-PGJ2 and the ligation of PPAR. J. Clin. Invest. 
112: 945-955. 
 12.  Scher, J. U. and Pillinger, M. H. 2005. 15d-PGJ2: The anti-inflammatory prostaglandin? 
Clin. Immunol. 114: 100-109. 
 13.  Wang, D. and DuBois, R. N. 2010. The role of COX-2 in intestinal inflammation and 
colorectal cancer. Oncogene. 29: 781-788. 
 14.  Wu, W. K., Sung, J. J., Lee, C. W., Yu, J., and Cho, C. H. 2010. Cyclooxygenase-2 in 
tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. 
Cancer Lett. 295: 7-16. 
 15.  Reader, J., Holt, D., and Fulton, A. 2011. Prostaglandin E2 EP receptors as therapeutic 
targets in breast cancer. Cancer Metastasis Rev. 30: 449-463. 
 16.  Waku, T., Shiraki, T., Oyama, T., Fujimoto, Y., Maebara, K., Kamiya, N., Jingami, H., 
and Morikawa, K. 2009. Structural Insight into PPAR gamma Activation Through 
Covalent Modification with Endogenous Fatty Acids. Journal of Molecular Biology. 385: 
188-199. 
 17.  Na, H. K. and Surh, Y. J. 2003. Peroxisome proliferator-activated receptor  (PPAR) 
ligands as bifunctional regulators of cell proliferation. Biochem. Pharmacol. 66: 1381-
1391. 
 18.  Clark, J. D., Lin, L. L., Kriz, R. W., Ramesha, C. S., Sultzman, L. A., Lin, A. Y., Milona, 
N., and Knopf, J. L. 1991. A novel arachidonic acid-selective cytosolic PLA2 contains a 
Ca2+-dependent translocation domain with homology to PKC and GAP. Cell. 65: 1043-
1051. 
 19.  Kennerly, D. A., Sullivan, T. J., Sylwester, P. A. T. R., and Parker, C. W. 1979. 
Diacylglycerol metabolism in mast cells: a potential role in membrane fusion and 
arachidonic acid release. The Journal of experimental medicine. 150: 1039-1044. 
 20.  Kennerly, D. A. 1987. Diacylglycerol metabolism in mast cells. Analysis of lipid 
metabolic pathways using molecular species analysis of intermediates. Journal of 
Biological Chemistry. 262: 16305-16313. 
 21.  Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, 
M. C., Ward, A. M., Hahn, Y. K., Lichtman, A. H., and Conti, B. 2011. Endocannabinoid 
hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 334: 
809-813. 
 22.  Funk, C. D. 2001. Prostaglandins and leukotrienes: advances in eicosanoid biology. 
Science. 294: 1871-1875. 
163 
 23.  Fu, J. Y., Masferrer, J. L., Seibert, K., Raz, A., and Needleman, P. 1990. The induction 
and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. 
Journal of Biological Chemistry. 265: 16737-16740. 
 24.  Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., and Simmons, D. L. 1991. 
Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by 
mRNA splicing. Proceedings of the National Academy of Sciences. 88: 2692-2696. 
 25.  Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., and Herschman, H. R. 1991. 
TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a 
novel prostaglandin synthase/cyclooxygenase homologue. Journal of Biological 
Chemistry. 266: 12866-12872. 
 26.  Rouzer, C. A. and Marnett, L. J. 2009. Cyclooxygenases: structural and functional 
insights. J. Lipid Res. 50: S29-S34. 
 27.  Bailey, J. M., Bryant, R. W., Whiting, J., and Salata, K. 1983. Characterization of 11-
HETE and 15-HETE, together with prostacyclin, as major products of the 
cyclooxygenase pathway in cultured rat aorta smooth muscle cells. Journal of Lipid 
Research. 24: 1419-1428. 
 28.  Song, I., Ball, T. M., and Smith, W. L. 2001. Different suicide inactivation processes for 
the peroxidase and cyclooxygenase activities of prostaglandin endoperoxide H synthase-
1. Biochemical and biophysical research communications. 289: 869-875. 
 29.  Salvo, F., Fourrier-Reglat, A., Bazin, F., Robinson, P., Riera-Guardia, N., Haag, M., 
Caputi, A. P., Moore, N., Sturkenboom, M. C., and Pariente, A. 2011. Cardiovascular and 
gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized 
clinical trials. Clinical Pharmacology & Therapeutics. 89: 855-866. 
 30.  Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, 
B., Vyas, S. N., and FitzGerald, G. A. 2001. Cyclooxygenase inhibitors and the 
antiplatelet effects of aspirin. New England Journal of Medicine. 345: 1809-1817. 
 31.  Wood, A. J. and Patrono, C. 1994. Aspirin as an antiplatelet drug. New England Journal 
of Medicine. 330: 1287-1294. 
 32.  Wood, A. J., FitzGerald, G. A., and Patrono, C. 2001. The coxibs, selective inhibitors of 
cyclooxygenase-2. New England Journal of Medicine. 345: 433-442. 
 33.  Brash, A. R. 1999. Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of 
Substrate. Journal of Biological Chemistry. 274: 23679-23682. 
 34.  Sigal, E., Craik, C. S., Highland, E., Grunberger, D., Costello, L. L., Dixon, R. A., and 
Nadel, J. A. 1988. Molecular cloning and primary structure of human 15-lipoxygenase. 
Biochemical and biophysical research communications. 157: 457-464. 
164 
 35.  Nadel, J. A., Conrad, D. J., Ueki, I. F., Schuster, A., and Sigal, E. 1991. 
Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, 
leukocytes, and airway cells. Journal of Clinical Investigation. 87: 1139. 
 36.  Brash, A. R., Boeglin, W. E., and Chang, M. S. 1997. Discovery of a second 15S-
lipoxygenase in humans. Proceedings of the National Academy of Sciences. 94: 6148-
6152. 
 37.  Kuhn, H., Walther, M., and Kuban, R. J. 2002. Mammalian arachidonate 15-
lipoxygenases: Structure, function, and biological implications. Prostaglandins & other 
lipid mediators. 68: 263-290. 
 38.  Milne, G. L., Musiek, E. S., and Morrow, J. D. 2005. F2-isoprostanes as markers of 
oxidative stress in vivo: an overview. Biomarkers. 10: 10-23. 
 39.  Mesaros, C., Lee, S. H., and Blair, I. A. 2009. Targeted quantitative analysis of 
eicosanoid lipids in biological samples using liquid chromatographytandem mass 
spectrometry. Journal of Chromatography B. 877: 2736-2745. 
 40.  Tai, H. H. 2011. Prostaglandin catabolic enzymes as tumor suppressors. Cancer 
Metastasis Rev. 30: 409-417. 
 41.  Backlund, M. G., Mann, J. R., Holla, V. R., Buchanan, F. G., Tai, H. H., Musiek, E. S., 
Milne, G. L., Katkuri, S., and DuBois, R. N. 2005. 15-Hydroxyprostaglandin 
Dehydrogenase Is Down-regulated in Colorectal Cancer. J. Biol. Chem. 280: 3217-3223. 
 42.  Liu, Z., Wang, X., Lu, Y., Du, R., Luo, G., Wang, J., Zhai, H., Zhang, F., Wen, Q., Wu, 
K., and Fan, D. 2010. 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of 
human gastric cancer. Cancer Biol. Ther. 10: 780-787. 
 43.  Na, H. K., Park, J. M., Lee, H. G., Lee, H. N., Myung, S. J., and Surh, Y. J. 2011. 15-
Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer 
chemoprevention and therapy. Biochem. Pharmacol. 82: 1352-1360. 
 44.  Cha, Y. I. and DuBois, R. N. 2007. NSAIDs and cancer prevention: targets downstream 
of COX-2. Annu. Rev. Med. 58: 239-252. 
 45.  Tai, H. H., Ensor, C. M., Tong, M., Zhou, H., and Yan, F. 2002. Prostaglandin 
catabolizing enzymes. Prostaglandins & other lipid mediators. 68: 483-493. 
 46.  Lee, S. C. and Levine, L. 1975. Prostaglandin metabolism. II. Identification of two 15-
hydroxyprostaglandin dehydrogenase types. Journal of Biological Chemistry. 250: 548-
552. 
 47.  Agins, A. P., Zipkin, R. E., and Taffer, I. M. 1987. Metabolism of cyclooxygenase and 
lipoxygenase products by 15-prostaglandin dehydrogenase from human HL-60 leukemia 
cells. Agents and Actions. 21: 397-399. 
 48.  Blair, I. A. 2006. Endogenous glutathione adducts. Current drug metabolism. 7: 853-872. 
165 
 49.  Hipfner, D. R., Deeley, R. G., and Cole, S. P. 1999. Structural, mechanistic and clinical 
aspects of MRP1. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1461: 359-376. 
 50.  Holla, V. R., Backlund, M. G., Yang, P., Newman, R. A., and DuBois, R. N. 2008. 
Regulation of Prostaglandin Transporters in Colorectal Neoplasia. Cancer Prevention 
Research. 1: 93-99. 
 51.  MIKKAICHI, T., SUZUKI, T., TANEMOTO, M., ITO, S., and ABE, T. 2004. The 
organic anion transporter (OATP) family. Drug metabolism and pharmacokinetics. 19: 
171-179. 
 52.  Reid, G., Wielinga, P., Zelcer, N., van der Heijden, I., Kuil, A., de Haas, M., Wijnholds, 
J., and Borst, P. 2003. The human multidrug resistance protein MRP4 functions as a 
prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. 
Proceedings of the National Academy of Sciences. 100: 9244-9249. 
 53.  Creek, D. J., Jankevics, A., Breitling, R., Watson, D. G., Barrett, M. P., and Burgess, K. 
E. 2011. Toward global metabolomics analysis with hydrophilic interaction liquid 
chromatography-mass spectrometry: improved metabolite identification by retention time 
prediction. Analytical Chemistry. 83: 8703-8710. 
 54.  Lee, S. H., Williams, M. V., and Blair, I. A. 2005. Targeted chiral lipidomics analysis. 
Prostaglandins & other lipid mediators. 77: 141-157. 
 55.  Yuan, M., Breitkopf, S. B., Yang, X., and Asara, J. M. 2012. A positive/negative ion-
switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, 
cells, and fresh and fixed tissue. Nature protocols. 7: 872-881. 
 56.  Bruins, A. P., Covey, T. R., and Henion, J. D. 1987. Ion spray interface for combined 
liquid chromatography/atmospheric pressure ionization mass spectrometry. Analytical 
Chemistry. 59: 2642-2646. 
 57.  Whitehouse, C. M., Dreyer, R. N., Yamashita, M., and Fenn, J. B. 1985. Electrospray 
interface for liquid chromatographs and mass spectrometers. Analytical Chemistry. 57: 
675-679. 
 58.  Singh, G., Gutierrez, A., Xu, K., and Blair, I. A. 2000. Liquid chromatography/electron 
capture atmospheric pressure chemical ionization/mass spectrometry: analysis of 
pentafluorobenzyl derivatives of biomolecules and drugs in the attomole range. 
Analytical Chemistry. 72: 3007-3013. 
 59.  Tolley, L., Jorgenson, J. W., and Moseley, M. A. 2001. Very high pressure gradient 
LC/MS/MS. Analytical Chemistry. 73: 2985-2991. 
 60.  Zhou, S. and Hamburger, M. 1996. Application of liquid chromatography-atmospheric 
pressure ionization mass spectrometry in natural product analysis evaluation and 
optimization of electrospray and heated nebulizer interfaces. Journal of chromatography 
A. 755: 189-204. 
166 
 61.  Marshall, A. G. and Hendrickson, C. L. 2008. High-resolution mass spectrometers. Annu. 
Rev. Anal. Chem. 1: 579-599. 
 62.  Marshall, A. G., Hendrickson, C. L., and Jackson, G. S. 1998. Fourier transform ion 
cyclotron resonance mass spectrometry: a primer. Mass spectrometry reviews. 17: 1-35. 
 63.  Johnson, J. V., Yost, R. A., Kelley, P. E., and Bradford, D. C. 1990. Tandem-in-space 
and tandem-in-time mass spectrometry: triple quadrupoles and quadrupole ion traps. 
Analytical Chemistry. 62: 2162-2172. 
 64.  Yost, R. A. and Enke, C. G. 1979. Triple quadrupole mass spectrometry for direct 
mixture analysis and structure elucidation. Analytical Chemistry. 51: 1251-1264. 
 65.  Schwartz, J. C., Senko, M. W., and Syka, J. E. 2002. A two-dimensional quadrupole ion 
trap mass spectrometer. Journal of the American Society for Mass Spectrometry. 13: 659-
669. 
 66.  Hager, J. W. 2002. A new linear ion trap mass spectrometer. Rapid Communications in 
Mass Spectrometry. 16: 512-526. 
 67.  Hsieh, Y. 2008. HPLC-MS/MS in drug metabolism and pharmacokinetic screening. 
Expert. Opin. Drug Metab Toxicol. 4: 93-101. 
 68.  Brown, S. C., Kruppa, G., and Dasseux, J. L. 2005. Metabolomics applications of FT-
ICR mass spectrometry. Mass Spectrom. Rev. 24: 223-231. 
 69.  Hu, Q. Z., Noll, R. J., Li, H. Y., Makarov, A., Hardman, M., and Cooks, R. G. 2005. The 
Orbitrap: a new mass spectrometer. J. Mass Spectrom. 40: 430-443. 
 70.  Whalen, K., Gobey, J., and Janiszewski, J. 2006. A centralized approach to tandem mass 
spectrometry method development for high-throughput ADME screening. Rapid 
Commun. Mass Spectrom. 20: 1497-1503. 
 71.  Taylor, C. F., Paton, N. W., Garwood, K. L., Kirby, P. D., Stead, D. A., Yin, Z., Deutsch, 
E. W., Selway, L., Walker, J., Riba-Garcia, I., Mohammed, S., Deery, M. J., Howard, J. 
A., Dunkley, T., Aebersold, R., Kell, D. B., Lilley, K. S., Roepstorff, P., Yates, J. R., III, 
Brass, A., Brown, A. J., Cash, P., Gaskell, S. J., Hubbard, S. J., and Oliver, S. G. 2003. A 
systematic approach to modeling, capturing, and disseminating proteomics experimental 
data. Nat. Biotechnol. 21: 247-254. 
 72.  Cox, J., Matic, I., Hilger, M., Nagaraj, N., Selbach, M., Olsen, J. V., and Mann, M. 2009. 
A practical guide to the MaxQuant computational platform for SILAC-based quantitative 
proteomics. Nat. Protoc. 4: 698-705. 
 73.  Madalinski, G., Godat, E., Alves, S., Lesage, D., Genin, E., Levi, P., Labarre, J., Tabet, J. 
C., Ezan, E., and Junot, C. 2008. Direct introduction of biological samples into a LTQ-
Orbitrap hybrid mass spectrometer as a tool for fast metabolome analysis. Anal. Chem. 
80: 3291-3303. 
167 
 74.  Wu, C. C. and Yates, J. R., III. 2003. The application of mass spectrometry to membrane 
proteomics. Nat. Biotechnol. 21: 262-267. 
 75.  Jemal, M. 2000. High-throughput quantitative bioanalysis by LC/MS/MS. Biomed. 
Chromatogr. 14: 422-429. 
 76.  Remane, D., Wissenbach, D. K., Meyer, M. R., and Maurer, H. H. 2010. Systematic 
investigation of ion suppression and enhancement effects of fourteen stable-isotope-
labeled internal standards by their native analogues using atmospheric-pressure chemical 
ionization and electrospray ionization and the relevance for multi-analyte liquid 
chromatographic/mass spectrometric procedures. Rapid Commun. Mass Spectrom. 24: 
859-867. 
 77.  Prakash, C., Shaffer, C. L., and Nedderman, A. 2007. Analytical strategies for identifying 
drug metabolites. Mass Spectrom. Rev. 26: 340-369. 
 78.  Bonfiglio, R., King, R. C., Olah, T. V., and Merkle, K. 1999. The effects of sample 
preparation methods on the variability of the electrospray ionization response for model 
drug compounds. Rapid Commun. Mass Spectrom. 13: 1175-1185. 
 79.  King, R., Bonfiglio, R., Fernandez-Metzler, C., Miller-Stein, C., and Olah, T. 2000. 
Mechanistic investigation of ionization suppression in electrospray ionization. J. Am. Soc. 
Mass Spectrom. 11: 942-950. 
 80.  Matuszewski, B. K. 2006. Standard line slopes as a measure of a relative matrix effect in 
quantitative HPLC-MS bioanalysis. J. Chromatogr. B. 830: 293-300. 
 81.  Ciccimaro, E. and Blair, I. A. 2010. Stable-isotope dilution LC-MS for quantitative 
biomarker analysis. Bioanalysis. 2: 311-341. 
 82.  Ciccimaro, E. and Blair, I. A. 2010. Stable-isotope dilution LC-MS for quantitative 
biomarker analysis. Bioanalysis. 2: 311-341. 
 83.  Hwa Lee, S., Rangiah, K., Williams, M. V., Wehr, A. Y., DuBois, R. N., and Blair, I. A. 
2007. Cyclooxygenase-2-Mediated Metabolism of Arachidonic Acid to 15-Oxo-
eicosatetraenoic Acid by Rat Intestinal Epithelial Cells. Chem. Res. Toxicol. 20: 1665-
1675. 
 84.  Ouyang, W., Zhang, D., Ma, Q., Li, J., and Huang, C. 2007. Cyclooxygenase-2 induction 
by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in 
mouse epidermal Cl41 cells. Environ. Health Perspect. 115: 513-518. 
 85.  Matsumura, F. 2009. The significance of the nongenomic pathway in mediating 
inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects. 
Biochem. Pharmacol. 77: 608-626. 
 86.  Ouyang, W., Ma, Q., Li, J., Zhang, D., Ding, J., Huang, Y., Xing, M. M., and Huang, C. 
2007. Benzo[a]pyrene diol-epoxide (B[a]PDE) upregulates COX-2 expression through 
168 
MAPKs/AP-1 and IKKbeta/NF-kappaB in mouse epidermal Cl41 cells. Mol. Carcinog. 
46: 32-41. 
 87.  Huang, R. Y. and Chen, G. G. 2011. Cigarette smoking, cyclooxygenase-2 pathway and 
cancer. Biochim. Biophys. Acta. 1815: 158-169. 
 88.  Tai, H. H., Tong, M., and Ding, Y. 2007. 15-Hydroxyprostaglandin dehydrogenase (15-
PGDH) and lung cancer. Prostaglandins Other Lipid Mediat. 83: 203-208. 
 89.  Hughes, D., Otani, T., Yang, P., Newman, R. A., Yantiss, R. K., Altorki, N. K., Port, J. 
L., Yan, M., Markowitz, S. D., Mazumdar, M., Tai, H. H., Subbaramaiah, K., and 
Dannenberg, A. J. 2008. NAD+-Dependent 15-Hydroxyprostaglandin Dehydrogenase 
Regulates Levels of Bioactive Lipids in NonSmall Cell Lung Cancer. Cancer 
Prevention Research. 1: 241-249. 
 90.  Chou, W. L., Chuang, L. M., Chou, C. C., Wang, A. H. J., Lawson, J. A., FitzGerald, G. 
A., and Chang, Z. F. 2007. Identification of a novel prostaglandin reductase reveals the 
involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-
activated receptor gamma activation. Journal of Biological Chemistry. 282: 18162-
18172. 
 91.  Celis, J. E., Gromov, P., Cabezen, T., Moreira, J. M., Friis, E., Jirstrom, K., Llombart-
Bosch, A., Timmermans-Wielenga, V., Rank, F., and Gromova, I. 2008. 15-prostaglandin 
dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of 
the apocrine molecular subtype of breast carcinoma. Molecular & Cellular Proteomics. 
7: 1795-1809. 
 92.  Pham, H., Chen, M., Li, A., King, J., Angst, E., Dawson, D. W., Park, J., Reber, H. A., 
Joe, H. O., and Eibl, G. 2010. Loss of 15-hydroxyprostaglandin dehydrogenase increases 
prostaglandin E2 in pancreatic tumors. Pancreas. 39: 332. 
 93.  Hughes, D., Otani, T., Yang, P., Newman, R. A., Yantiss, R. K., Altorki, N. K., Port, J. 
L., Yan, M., Markowitz, S. D., Mazumdar, M., Tai, H. H., Subbaramaiah, K., and 
Dannenberg, A. J. 2008. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase 
regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev. Res. 
(Phila Pa). 1: 241-249. 
 94.  Tai, H. H., Tong, M., and Ding, Y. 2007. 15-hydroxyprostaglandin dehydrogenase (15-
PGDH) and lung cancer. Prostaglandins Other Lipid Mediat. 83: 203-208. 
 95.  Thiel, A., Ganesan, A., Mrena, J., Junnila, S., Nyknen, A., Hemmes, A., Tai, H. H., 
Monni, O., Kokkola, A., Haglund, C., Petrova, T. V., and Ristimki, A. 2009. 15-
Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Gastric Cancer. Clin. Canc. 
Res. 15: 4572-4580. 
 96.  Tseng-Rogenski, S., Gee, J., Ignatoski, K. W., Kunju, L. P., Bucheit, A., Kintner, H. J., 
Morris, D., Tallman, C., Evron, J., and Wood, C. G. 2010. Loss of 15-
hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer 
progression. The American journal of pathology. 176: 1462-1468. 
169 
 97.  Markowitz, S. D. and Bertagnolli, M. M. 2009. Molecular basis of colorectal cancer. New 
England Journal of Medicine. 361: 2449-2460. 
 98.  Rangachari, P. K. and Betti, P. A. 1993. Biological activity of metabolites of PGD2 on 
canine proximal colon. American Journal of Physiology-Gastrointestinal and Liver 
Physiology. 264: G886-G894. 
 99.  Fitzpatrick, F. A. and Wynalda, M. A. 1983. Albumin-catalyzed metabolism of 
prostaglandin D2. Identification of products formed in vitro. Journal of Biological 
Chemistry. 258: 11713-11718. 
 100.  Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., and Evans, R. M. 
1995. 15-Deoxy-12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor 
PPARg. Cell. 83: 803-812. 
 101.  Xin, X., Yang, S., Kowalski, J., and Gerritsen, M. E. 1999. Peroxisome proliferator-
activated receptor g ligands are potent inhibitors of angiogenesis in vitro and in vivo. 
Journal of Biological Chemistry. 274: 9116-9121. 
 102.  Bishop-Bailey, D. and Hla, T. 1999. Endothelial cell apoptosis induced by the 
peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-12,14-prostaglandin 
J2. Journal of Biological Chemistry. 274: 17042-17048. 
 103.  Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C. H., 
Sengchanthalangsy, L. L., Ghosh, G., and Glass, C. K. 2000. 15-deoxy-12, 14-
prostaglandin J2 inhibits multiple steps in the NF-kB signaling pathway. Proceedings of 
the National Academy of Sciences. 97: 4844-4849. 
 104.  Scher, J. U. and Pillinger, M. H. 2009. The anti-inflammatory effects of prostaglandins. 
Journal of Investigative Medicine. 57: 703-708. 
 105.  Ho, T. C., Chen, S. L., Yang, Y. C., Chen, C. Y., Feng, F. P., Hsieh, J. W., Cheng, H. C., 
and Tsao, Y. P. 2008. 15-deoxy-(12, 14)-prostaglandin J2 induces vascular endothelial 
cell apoptosis through the sequential activation of MAPKS and p53. Journal of 
Biological Chemistry. 283: 30273-30288. 
 106.  Lee, S. H., Silva Elipe, M. V., Arora, J. S., and Blair, I. A. 2005. Dioxododecenoic acid: 
a lipid hydroperoxide-derived bifunctional electrophile responsible for etheno DNA 
adduct formation. Chem. Res. Toxicol. 18: 566-578. 
 107.  Blair, I. A. 2008. DNA-adducts with lipid peroxidation products. J. Biol. Chem. 283: 
15545-15549. 
 108.  Wei, C., Zhu, P., Shah, S. J., and Blair, I. A. 2009. 15-oxo-Eicosatetraenoic Acid, a 
Metabolite of Macrophage 15-Hydroxyprostaglandin Dehydrogenase That Inhibits 
Endothelial Cell Proliferation. Molecular Pharmacology. 76: 516-525. 
 109.  Ide, T., Egan, K., Bell-Parikh, L. C., and FitzGerald, G. A. 2003. Activation of nuclear 
receptors by prostaglandins. Thromb. Res. 110: 311-315. 
170 
 110.  Lee, S. H., Rangiah, K., Williams, M. V., Wehr, A. Y., DuBois, R. N., and Blair, I. A. 
2007. Cyclooxygenase-2-mediated metabolism of arachidonic acid to 15-oxo-
eicosatetraenoic acid by rat intestinal epithelial cells. Chem. Res. Toxicol. 20: 1665-1675. 
 111.  Dixon, D. A., Tolley, N. D., King, P. H., Nabors, L. B., McIntyre, T. M., Zimmerman, G. 
A., and Prescott, S. M. 2001. Altered expression of the mRNA stability factor HuR 
promotes cyclooxygenase-2 expression in colon cancer cells. Journal of Clinical 
Investigation. 108: 1657-1665. 
 112.  Shao, J., Sheng, H., Inoue, H., Morrow, J. D., and DuBois, R. N. 2000. Regulation of 
constitutive cyclooxygenase-2 expression in colon carcinoma cells. Journal of Biological 
Chemistry. 275: 33951-33956. 
 113.  Mesaros, C., Lee, S. H., and Blair, I. A. 2009. Targeted quantitative analysis of 
eicosanoid lipids in biological samples using liquid chromatography-tandem mass 
spectrometry. J. Chromatogr. B. 877: 2736-2745. 
 114.  Meijerman, I., Beijnen, J. H., and Schellens, J. H. 2008. Combined action and regulation 
of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. 
Cancer treatment reviews. 34: 505-520. 
 115.  Liu, Z., Wang, X., Lu, Y., Han, S., Zhang, F., Zhai, H., Lei, T., Liang, J., Wang, J., Wu, 
K., and Fan, D. 2008. Expression of 15-PGDH is downregulated by COX-2 in gastric 
cancer. Carcinogenesis. 29: 1219-1227. 
 116.  Ciucci, A., Gianferretti, P., Piva, R., Guyot, T., Snape, T. J., Roberts, S. M., and Santoro, 
M. G. 2006. Induction of apoptosis in estrogen receptor-negative breast cancer cells by 
natural and synthetic cyclopentenones: role of the IkB kinase/nuclear factor-kB pathway. 
Molecular pharmacology. 70: 1812-1821. 
 117.  Piva, R., Belardo, G., and Santoro, M. G. 2006. NF-kB: a stress-regulated switch for cell 
survival. Antioxidants & redox signaling. 8: 478-486. 
 118.  Groeger, A. L., Cipollina, C., Cole, M. P., Woodcock, S. R., Bonacci, G., Rudolph, T. K., 
Rudolph, V., Freeman, B. A., and Schopfer, F. J. 2010. Cyclooxygenase-2 generates anti-
inflammatory mediators from omega-3 fatty acids. Nat. Chem. Biol. 6: 433-441. 
 119.  Grant, G. E., Gravel, S., Guay, J., Patel, P., Mazer, B. D., Rokach, J., and Powell, W. S. 
2011. 5-oxo-ETE is a major oxidative stress-induced arachidonate metabolite in B 
lymphocytes. Free Radical Biology and Medicine. 50: 1297-1304. 
 120.  O'Flaherty, J. T., Cordes, J. F., Lee, S. L., Samuel, M., and Thomas, M. J. 1994. 
Chemical and biological characterization of oxo-eicosatetraenoic acids. Biochimica et 
Biophysica Acta (BBA)-General Subjects. 1201: 505-515. 
 121.  Grant, G. E., Rokach, J., and Powell, W. S. 2009. 5-Oxo-ETE and the OXE receptor. 
Prostaglandins Other Lipid Mediat. 89: 98-104. 
171 
 122.  Waddington, E., Sienuarine, K., Puddey, I., and Croft, K. 2001. Identification and 
Quantitation of Unique Fatty Acid Oxidation Products in Human Atherosclerotic Plaque 
Using High-Performance Liquid Chromatography. Analytical Biochemistry. 292: 234-
244. 
 123.  Harizi, H., Corcuff, J. B., and Gualde, N. 2008. Arachidonic-acid-derived eicosanoids: 
roles in biology and immunopathology. Trends Mol. Med. 14: 461-469. 
 124.  Wolf, I., O'Kelly, J., Rubinek, T., Tong, M., Nguyen, A., Lin, B. T., Tai, H. H., Karlan, 
B. Y., and Koeffler, H. P. 2006. 15-Hydroxyprostaglandin Dehydrogenase Is a Tumor 
Suppressor of Human Breast Cancer. Cancer Res. 66: 7818-7823. 
 125.  Tong, M., Ding, Y., and Tai, H. H. 2006. Histone deacetylase inhibitors and transforming 
growth factor-B induce 15-hydroxyprostaglandin dehydrogenase expression in human 
lung adenocarcinoma cells. Biochem. Pharmacol. 72: 701-709. 
 126.  Tatsuwaki, H., Tanigawa, T., Watanabe, T., Machida, H., Okazaki, H., Yamagami, H., 
Shiba, M., Watanabe, K., Tominaga, K., Fujiwara, Y., Oshitani, N., Muguruma, K., 
Sawada, T., Hirakawa, K., Higuchi, K., and Arakawa, T. 2010. Reduction of 15-
hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor 
survival associated with enhanced cell proliferation in gastric adenocarcinoma. Cancer 
Sci. 101: 550-558. 
 127.  Moore, A. E., Greenhough, A., Roberts, H. R., Hicks, D. J., Patsos, H. A., Williams, A. 
C., and Paraskeva, C. 2009. HGF/Met signalling promotes PGE2 biogenesis via 
regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis. 
30: 1796-1804. 
 128.  Yang, L., Amann, J. M., Kikuchi, T., Porta, R., Guix, M., Gonzalez, A., Park, K. H., 
Billheimer, D., Arteaga, C. L., Tai, H. H., DuBois, R., Carbone, D. P., and Johnson, D. 
H. 2007. Inhibition of Epidermal Growth Factor Receptor Signaling Elevates 15-
Hydroxyprostaglandin Dehydrogenase in NonSmall-Cell Lung Cancer. Cancer Res. 67: 
5587-5593. 
 129.  Liu, X., Zhang, S., Arora, J. S., Snyder, N. W., Shah, S. J., and Blair, I. A. 2011. 11-
Oxoeicosatetraenoic Acid Is a Cyclooxygenase-2/15-Hydroxyprostaglandin 
Dehydrogenase-Derived Antiproliferative Eicosanoid. Chemical Research in Toxicology. 
24: 2227-2236. 
 130.  Gulliksson, M., Brunnstrom, Johannesson, M., Backman, L., Nilsson, G., Harvima, I., 
Dahlon, B., Kumlin, M., and Claesson, H. E. 2007. Expression of 15-lipoxygenase type-1 
in human mast cells. Biochim. Biophys. Acta. 1771: 1156-1165. 
 131.  Bergholte, J. M., Soberman, R. J., Hayes, R., Murphy, R. C., and Okita, R. T. 1987. 
Oxidation of 15-hydroxyeicosatetraenoic acid and other hydroxy fatty acids by lung 
prostaglandin dehydrogenase. Arch. Biochem. Biophys. 257: 444-450. 
172 
 132.  Rosolowsky, M., Falck, J. R., Willerson, J. T., and Campbell, W. B. 1990. Synthesis of 
lipoxygenase and epoxygenase products of arachidonic acid by normal and stenosed 
canine coronary arteries. Circ. Res. 66: 608-621. 
 133.  Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., and Santoro, M. G. 
2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB 
kinase. Nature. 403: 103-108. 
 134.  Motohashi, H. and Yamamoto, M. 2004. Nrf2/Keap1 defines a physiologically important 
stress response mechanism. Trends Mol. Med. 10: 549-557. 
 135.  Villacorta, L., Zhang, J., Garcia-Barrio, M. T., Chen, X. l., Freeman, B. A., Chen, Y. E., 
and Cui, T. 2007. Nitro-linoleic acid inhibits vascular smooth muscle cell proliferation 
via the Keap1/Nrf2 signaling pathway. Am J Physiol. 293: H770-H776. 
 136.  Baker, P. R. S., Schopfer, F. J., ODonnell, V. B., and Freeman, B. A. 2009. Convergence 
of nitric oxide and lipid signaling: Anti-inflammatory nitro-fatty acids. Free Radical 
Biology and Medicine. 46: 989-1003. 
 137.  Gelhaus, S. L., Mesaros, A. C., and Blair, I. A. 2011. Cellular lipid extraction for targeted 
stable isotope dilution liquid chromatography-mass spectrometry analysis. J. Vis. Exp. 
57:  e3399. 
 138.  Kool, M., de, H. M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J., Juijn, J. A., Baas, F., 
and Borst, P. 1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and 
MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in 
human cancer cell lines. Cancer Res. 57: 3537-3547. 
 139.  Wang, D. and DuBois, R. N. 2006. Prostaglandins and Cancer. Gut. 55: 115-122. 
 140.  Backlund, M. G., Mann, J. R., Holla, V. R., Shi, Q., Daikoku, T., Dey, S. K., and DuBois, 
R. N. 2008. Repression of 15-Hydroxyprostaglandin Dehydrogenase Involves Histone 
Deacetylase 2 and Snail in Colorectal Cancer. Cancer Res. 68: 9331-9337. 
 141.  Wang, D. and DuBois, R. N. 2010. Eicosanoids and cancer. Nat. Rev. Cancer. 10: 181-
193. 
 142.  Bai, J. W., Wang, Z., Gui, S. B., and Zhang, Y. Z. 2012. Loss of 15-
hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary 
adenomas. Oncol. Rep. 28: 714-720. 
 143.  Cherukuri, D. P., Chen, X. B., Goulet, A. C., Young, R. N., Han, Y., Heimark, R. L., 
Regan, J. W., Meuillet, E., and Nelson, M. A. 2007. The EP4 receptor antagonist, L-
161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in 
HCA-7 colon cancer cells. Exp. Cell Res. 313: 2969-2979. 
 144.  Hull, M. A., Ko, S. C., and Hawcroft, G. 2004. Prostaglandin EP receptors: targets for 
treatment and prevention of colorectal cancer? Mol. Cancer Ther. 3: 1031-1039. 
173 
 145.  Migita, H. and Morser, J. 2005. 15-Deoxy-12,14-Prostaglandin J2 (15d-PGJ2) Signals 
Through Retinoic Acid Receptor Related Orphan Receptor but Not Peroxisome 
Proliferator Activated Receptor in Human Vascular Endothelial Cells. Art. Thromb. Vasc. 
Biol. 25: 710-716. 
 146.  Chinery, R., Coffey, R. J., Graves-Deal, R., Kirkland, S. C., Sanchez, S. C., Zackert, W. 
E., Oates, J. A., and Morrow, J. D. 1999. Prostaglandin J2 and 15-Deoxy-delta12,14-
prostaglandin J2 Induce Proliferation of Cyclooxygenase-depleted Colorectal Cancer 
Cells. Cancer Res. 59: 2739-2746. 
 147.  Lin, S., Wang, W., Wilson, G. M., Yang, X., Brewer, G., Holbrook, N. J., and Gorospe, 
M. 2000. Down-Regulation of Cyclin D1 Expression by Prostaglandin A2 Is Mediated by 
Enhanced Cyclin D1 mRNA Turnover. Mol. Cell. Biol. 20: 7903-7913. 
 148.  Basu, S. S., Mesaros, C., Gelhaus, S. L., and Blair, I. A. 2011. Stable Isotope Labeling by 
Essential Nutrients in Cell Culture for Preparation of Labeled Coenzyme A and Its 
Thioesters. Anal. Chem. 83: 1363-1369. 
 149.  Deeley, R. G. and Cole, S. P. 2006. Substrate recognition and transport by multidrug 
resistance protein 1 (ABCC1). FEBS letters. 580: 1103-1111. 
 150.  Marquez, B. and Van Bambeke, F. 2011. ABC multidrug transporters: target for 
modulation of drug pharmacokinetics and drug-drug interactions. Current drug targets. 
12: 600-620. 
 151.  Akanuma, S. i., Hosoya, K. i., Ito, S., Tachikawa, M., Terasaki, T., and Ohtsuki, S. 2010. 
Involvement of multidrug resistance-associated protein 4 in efflux transport of 
prostaglandin E2 across mouse blood-brain barrier and its inhibition by intravenous 
administration of cephalosporins. Journal of Pharmacology and Experimental 
Therapeutics. 333: 912-919. 
 152.  Gelhaus, S. L., Gilad, O., Hwang, W. T., Penning, T. M., and Blair, I. A. 2012. Multidrug 
resistance protein (MRP) 4 attenuates benzo[a]pyrene-mediated DNA-adduct formation 
in human bronchoalveolar H358 cells. Toxicol. Lett. 209: 58-66. 
 153.  Di Pietro, G., Magno, L. A., and Rios-Santos, F. 2010. Glutathione S-transferases: an 
overview in cancer research. Expert. Opin. Drug Metab Toxicol. 6: 153-170. 
 154.  Tew, K. D. and Townsend, D. M. 2011. Regulatory functions of glutathione S-transferase 
P1-1 unrelated to detoxification. Drug metabolism reviews. 43: 179-193. 
 155.  Singh, S., Khan, A. R., and Gupta, A. K. 2012. Role of glutathione in cancer 
pathophysiology and therapeutic interventions. Journal of experimental therapeutics & 
oncology. 9: 303. 
 156.  Bailey, J. M., Bryant, R. W., Whiting, J., and Salata, K. 1983. Characterization of 11-
HETE and 15-HETE, together with prostacyclin, as major products of the 
cyclooxygenase pathway in cultured rat aorta smooth muscle cells. J. Lipid Res. 24: 
1419-1428. 
174 
 157.  Liu, J., Seibold, S. A., Rieke, C. J., Song, I., Cukier, R. I., and Smith, W. L. 2007. 
Prostaglandin Endoperoxide H Synthases: Peroxidase hydroperoxide specificity and 
cyclooxygenase activation. J. Biol. Chem. 282: 18233-18244. 
 158.  Yang, G., Madan, A., and Dennery, P. A. 2000. Maturational differences in hyperoxic 
AP-1 activation in rat lung. American Journal of Physiology - Lung Cellular and 
Molecular Physiology. 278: L393-L398. 
 159.  Gelhaus, S. L., Mesaros, A. C., and Blair, I. A. 2011. Cellular Lipid Extraction for 
Targeted Stable Isotope Dilution Liquid Chromatography-Mass Spectrometry Analysis. 
JoVE e3399. 
 160.  Woodcock, S. R., Bonacci, G., Gelhaus, S. L., and Schopfer, F. J.Nitrated fatty acids: 
synthesis andmeasurement. Free Radical Biology and Medicine 
 161.  Shiraki, T., Kamiya, N., Shiki, S., Kodama, T. S., Kakizuka, A., and Jingami, H. 2005. 
a,b-unsaturated ketone is a core moiety of natural ligands for covalent binding to 
peroxisome proliferator-activated receptor g. Journal of Biological Chemistry. 280: 
14145-14153. 
 162.  Blair, I. A. 2008. DNA Adducts with Lipid Peroxidation Products. J. Biol. Chem. 283: 
15545-15549. 
 163.  Shiraki, T., Kamiya, N., Shiki, S., Kodama, T. S., Kakizuka, A., and Jingami, H. 2005. 
alpha,beta-Unsaturated Ketone Is a Core Moiety of Natural Ligands for Covalent Binding 
to Peroxisome Proliferator-activated Receptor gamma. Journal of Biological Chemistry. 
280: 14145-14153. 
 164.  Chen, F. E., Huang, D. B., Chen, Y. Q., and Ghosh, G. 1998. Crystal structure of p50/p65 
heterodimer of transcription factor NF-kappaB bound to DNA. Nature. 391: 410-413. 
 165.  Ghosh, G., van Duyne, G., Ghosh, S., and Sigler, P. B. 1995. Structure of NF-kappa B 
p50 homodimer bound to a kappa B site. Nature. 373: 303-310. 
 166.  Rudolph, V., Schopfer, F. J., Khoo, N. K. H., Rudolph, T. K., Cole, M. P., Woodcock, S. 
R., Bonacci, G., Groeger, A. L., Golin-Bisello, F., Chen, C. S., Baker, P. R. S., and 
Freeman, B. A. 2009. Nitro-fatty Acid Metabolome: Saturation, Desaturation, -
Oxidation, and Protein Adduction. Journal of Biological Chemistry. 284: 1461-1473. 
 167.  Chi, X., Freeman, B. M., Tong, M., Zhao, Y., and Tai, H. H. 2009. 15-
Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and 
other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch. 
Biochem. Biophys. 487: 139-145. 
 168.  Quidville, V., Segond, N., Lausson, S., Frenkian, M., Cohen, R., and Jullienne, A. 2006. 
15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-
steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid 
carcinoma cell line. Prostaglandins Other Lipid Mediat. 81: 14-30. 
175 
 169.  Ellis, B. A., Poynten, A., Lowy, A. J., Furler, S. M., Chisholm, D. J., Kraegen, E. W., and 
Cooney, G. J. 2000. Long-chain acyl-CoA esters as indicators of lipid metabolism and 
insulin sensitivity in rat and human muscle. American Journal of Physiology-
Endocrinology And Metabolism. 279: E554-E560. 
 170.  Basu, S. S. and Blair, I. A. 2011. Rotenone-mediated changes in intracellular coenzyme 
A thioester levels: implications for mitochondrial dysfunction. Chemical research in 
toxicology. 24: 1630-1632. 
 171.  Hale, D. E., Batshaw, M. L., Coates, P. M., Frerman, F. E., Goodman, S. I., Singh, I., and 
Stanley, C. A. 1985. Long-chain acyl coenzyme A dehydrogenase deficiency: an 
inherited cause of nonketotic hypoglycemia. Pediatric research. 19: 666-671. 
 172.  Amendt, B. A., Greene, C., Sweetman, L., Cloherty, J., Shih, V., Moon, A., Teel, L., and 
Rhead, W. J. 1987. Short-chain acyl-coenzyme A dehydrogenase deficiency. Clinical and 
biochemical studies in two patients. Journal of Clinical Investigation. 79: 1303. 
 173.  El-Husseini, A. E.-D. and Bredt, D. S. 2002. Protein palmitoylation: a regulator of 
neuronal development and function. Nature Reviews Neuroscience. 3: 791-802. 
 174.  Pfanner, N., Orci, L., Glick, B. S., Amherdt, M., Arden, S. R., Malhotra, V., and 
Rothman, J. E. 1989. Fatty acyl-coenzyme A is required for budding of transport vesicles 
from Golgi cisternae. Cell. 59: 95-102. 
 175.  Tracy, T. S., Wirthwein, D. P., and Hall, S. D. 1993. Metabolic inversion of (R)-
ibuprofen. Formation of ibuprofenyl-coenzyme A. Drug metabolism and disposition. 21: 
114-120. 
 176.  Webb, M. E., Smith, A. G., and Abell, C. 2004. Biosynthesis of pantothenate. Natural 
product reports. 21: 695-721. 
 177.  Basu, S. S., Mesaros, C., Gelhaus, S. L., and Blair, I. A. 2011. Stable Isotope Labeling by 
Essential Nutrients in Cell Culture for Preparation of Labeled Coenzyme A and Its 
Thioesters. Analytical chemistry. 83: 1363-1369. 
 178.  Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., and 
Mann, M. 2002. Stable isotope labeling by amino acids in cell culture, SILAC, as a 
simple and accurate approach to expression proteomics. Molecular & cellular 
proteomics. 1: 376-386. 
 179.  Basu, S. S. and Blair, I. A. 2011. SILEC: a protocol for generating and using isotopically 
labeled coenzyme A mass spectrometry standards. Nature Protocols. 7: 1-11. 
 180.  Minkler, P. E., Kerner, J., Ingalls, S. T., and Hoppel, C. L. 2008. Novel isolation 
procedure for short-, medium-, and long-chain acyl-coenzyme A esters from tissue. 
Analytical biochemistry. 376: 275-276. 
176 
 181.  Deutsch, J., Grange, E., Rapoport, S. I., and Purdon, A. D. 1994. Isolation and 
quantitation of long-chain acyl-coenzyme A esters in brain tissue by solid-phase 
extraction. Analytical biochemistry. 220: 321-323. 
 182.  Magnes, C., Sinner, F. M., Regittnig, W., and Pieber, T. R. 2005. LC/MS/MS method for 
quantitative determination of long-chain fatty acyl-CoAs. Analytical chemistry. 77: 2889-
2894. 
 183.  Mauriala, T., Herzig, K. H., Heinonen, M., Idziak, J., and Auriola, S. 2004. 
Determination of long-chain fatty acid acyl-coenzyme A compounds using liquid 
chromatographyelectrospray ionization tandem mass spectrometry. Journal of 
Chromatography B. 808: 263-268. 
 184.  Pluskal, T., Nakamura, T., Villar-Briones, A., and Yanagida, M. 2010. Metabolic 
profiling of the fission yeast S. pombe: quantification of compounds under different 
temperatures and genetic perturbation. Mol Biosyst. 6: 182-198. 
 185.  Makarov, A., Denisov, E., Kholomeev, A., Balschun, W., Lange, O., Strupat, K., and 
Horning, S. 2006. Performance Evaluation of a Hybrid Linear Ion Trap/Orbitrap Mass 
Spectrometer. Anal. Chem. 78: 2113-2120. 
 186.  Timischl, B., Dettmer, K., Kaspar, H., Thieme, M., and Oefner, P. J. 2008. Development 
of a quantitative, validated capillary electrophoresis-time of flight-mass spectrometry 
method with integrated high-confidence analyte identification for metabolomics. 
Electrophoresis. 29: 2203-2214. 
 187.  Katajamaa, M. and Oresic, M. 2007. Data processing for mass spectrometry-based 
metabolomics. J Chromatogr A. 1158: 318-328. 
 188.  Katajamaa, M. and Oresic, M. 2005. Processing methods for differential analysis of 
LC/MS profile data. BMC Bioinformatics. 6: 179. 
 189.  Wilson, I. D., Nicholson, J. K., Castro-Perez, J., Granger, J. H., Johnson, K. A., Smith, B. 
W., and Plumb, R. S. 2005. High resolution Ç£ultra performanceÇ¥ liquid 
chromatography coupled to oa-TOF mass spectrometry as a tool for differential 
metabolic pathway profiling in functional genomic studies. Journal of proteome 
research. 4: 591-598. 
 190.  Benton, H. P., Wong, D. M., Trauger, S. A., and Siuzdak, G. 2008. XCMS2: processing 
tandem mass spectrometry data for metabolite identification and structural 
characterization. Anal Chem. 80: 6382-6389. 
 191.  Katajamaa, M., Miettinen, J., and Oresic, M. 2006. MZmine: toolbox for processing and 
visualization of mass spectrometry based molecular profile data. Bioinformatics. 22: 634-
636. 
 192.  Pluskal, T., Castillo, S., Villar-Briones, A., and Oresic, M. 2010. MZmine 2: Modular 
framework for processing, visualizing, and analyzing mass spectrometry-based molecular 
profile data. BMC Bioinformatics. 11: 395. 
177 
 193.  Smith, C. A., Want, E. J., O'Maille, G., Abagyan, R., and Siuzdak, G. 2006. XCMS: 
Processing Mass Spectrometry Data for Metabolite Profiling Using Nonlinear Peak 
Alignment, Matching, and Identification. Anal. Chem. 78: 779-787. 
 194.  Tautenhahn, R., Patti, G. J., Rinehart, D., and Siuzdak, G. 2012. XCMS Online: A Web-
Based Platform to Process Untargeted Metabolomic Data. Anal. Chem. 84: 5035-5039. 
 195.  Want, E. J., Wilson, I. D., Gika, H., Theodoridis, G., Plumb, R. S., Shockcor, J., Holmes, 
E., and Nicholson, J. K. 2010. Global metabolic profiling procedures for urine using 
UPLCÇôMS. Nature protocols. 5: 1005-1018. 
 196.  Sellick, C. A., Hansen, R., Stephens, G. M., Goodacre, R., and Dickson, A. J. 2011. 
Metabolite extraction from suspension-cultured mammalian cells for global metabolite 
profiling. Nature protocols. 6: 1241-1249. 
 197.  Dunn, W. B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., 
Brown, M., Knowles, J. D., Halsall, A., and Haselden, J. N. 2011. Procedures for large-
scale metabolic profiling of serum and plasma using gas chromatography and liquid 
chromatography coupled to mass spectrometry. Nature protocols. 6: 1060-1083. 
 198.  Masson, P., Alves, A. C., Ebbels, T. M. D., Nicholson, J. K., and Want, E. J. 2010. 
Optimization and evaluation of metabolite extraction protocols for untargeted metabolic 
profiling of liver samples by UPLC-MS. Anal. Chem. 82: 7779-7786. 
 199.  Shaham, O., Slate, N. G., Goldberger, O., Xu, Q., Ramanathan, A., Souza, A. L., Clish, 
C. B., Sims, K. B., and Mootha, V. K. 2010. A plasma signature of human mitochondrial 
disease revealed through metabolic profiling of spent media from cultured muscle cells. 
Proceedings of the National Academy of Sciences. 107: 1571-1575. 
 200.  Cequier-Saünchez, E., Rodriüguez, C., Ravelo, A. G., and Zaürate, R. 2008. 
Dichloromethane as a Solvent for Lipid Extraction and Assessment of Lipid Classes and 
Fatty Acids from Samples of Different Natures. J. Agric. Food Chem. 56: 4297-4303. 
 201.  Keller, A., Eng, J., Zhang, N., Li, X. J., and Aebersold, R. 2005. A uniform proteomics 
MS/MS analysis platform utilizing open XML file formats. Mol Syst Biol. 1: 2005. 
 202.  Cleveland, W. S. and Devlin, S. J. 1988. Locally weighted regression - an approach to 
regression-analysis by local fitting. J Am Stat Assoc. 83: 596-610. 
 203.  Lange, E., Tautenhahn, R., Neumann, S., and Gropl, C. 2008. Critical assessment of 
alignment procedures for LC-MS proteomics and metabolomics measurements. BMC 
Bioinformatics. 9: 375. 
 204.  Tautenhahn, R., Bottcher, C., and Neumann, S. 2008. Highly sensitive feature detection 
for high resolution LC/MS. BMC Bioinformatics. 9: 504. 
 205.  Kuhl, C., Tautenhahn, R., Bottcher, C., Larson, T. R., and Neumann, S. 2012. CAMERA: 
An Integrated Strategy for Compound Spectra Extraction and Annotation of Liquid 
Chromatography/Mass Spectrometry Data Sets. Anal. Chem. 84: 283-289. 
178 
 206.  Kanehisa, M. and Goto, S. 2000. KEGG: kyoto encyclopedia of genes and genomes. 
Nucleic Acids Res. 28: 27-30. 
 207.  Smith, C. A., O'Maille, G., Want, E. J., Qin, C., Trauger, S. A., Brandon, T. R., Custodio, 
D. E., Abagyan, R., and Siuzdak, G. 2005. METLIN: a metabolite mass spectral 
database. Ther Drug Monit. 27: 747-751. 
 208.  Wang, Y., Xiao, J., Suzek, T. O., Zhang, J., Wang, J., and Bryant, S. H. 2009. PubChem: 
a public information system for analyzing bioactivities of small molecules. Nucleic Acids 
Res W623-W633. 
 209.  Wishart, D. S., Knox, C., Guo, A. C., Eisner, R., Young, N., Gautam, B., Hau, D. D., 
Psychogios, N., Dong, E., Bouatra, S., Mandal, R., Sinelnikov, I., Xia, J., Jia, L., Cruz, J. 
A., Lim, E., Sobsey, C. A., Shrivastava, S., Huang, P., Liu, P., Fang, L., Peng, J., 
Fradette, R., Cheng, D., Tzur, D., Clements, M., Lewis, A., De Souza, A., Zuniga, A., 
Dawe, M., Xiong, Y., Clive, D., Greiner, R., Nazyrova, A., Shaykhutdinov, R., Li, L., 
Vogel, H. J., and Forsythe, I. 2009. HMDB: a knowledgebase for the human 
metabolome. Nucleic Acids Res D603-D610. 
 210.  Bligh, E. G. and Dyer, W. J. 1959. A rapid method of total lipid extraction and 
purification. Can. J. Biochem. Physiol. 37: 911-917. 
 211.  Folch , J. 1957. A simple method for the isolation and purification of total lipids from 
animal tissues. J Biol Chem. 226: 497-509. 
 212.  Avery, M. J. 2003. Quantitative characterization of differential ion suppression on liquid 
chromatography/atmospheric pressure ionization mass spectrometric bioanalytical 
methods. Rapid Commun. Mass Spectrom. 17: 197-201. 
 213.  O'Donnell, V. B. and Murphy, R. C. 2012. New families of bioactive oxidized 
phospholipids generated by immune cells: identification and signaling actions. Blood. 
120: 1985-1992. 
 214.  Snyder, N. W., Revello, S. D., Liu, X., Zhang, S., and Blair, I. A. 2013. Cellular uptake 
and anti-proliferative effects of 11-oxo-eicosatetraenoic acid. Journal of lipid research 
 215.  Snyder, N. W., Khezam, M., Mesaros, C. A., Worth, A., and Blair, I. A. 2012. Untargeted 
Metabolomics from Biological Sources Using Ultraperformance Liquid 
Chromatography-High Resolution Mass Spectrometry (UPLC-HRMS). Journal of 
visualized experiments: JoVE 
 216.  Xia, J., Mandal, R., Sinelnikov, I. V., Broadhurst, D., and Wishart, D. S. 2012. 
MetaboAnalyst 2.0Çöa comprehensive server for metabolomic data analysis. Nucleic 
acids research. 40: W127-W133. 
 217.  MacMillan, D. K. and Murphy, R. C. 1995. Analysis of lipid hydroperoxides and long-
chain conjugated keto acids by negative ion electrospray mass spectrometry. Journal of 
the American Society for Mass Spectrometry. 6: 1190-1201. 
179 
 218.  Hammond, V. J., Morgan, A. H., Lauder, S., Thomas, C. P., Brown, S., Freeman, B. A., 
Lloyd, C. M., Davies, J., Bush, A., and Levonen, A. L. 2012. Novel keto-phospholipids 
are generated by monocytes and macrophages, detected in Cystic Fibrosis, and activate 
peroxisome proliferator-activated receptor-gamma. Journal of Biological Chemistry. 287: 
41651-41666. 
 219.  Makarov, A., Denisov, E., Lange, O., and Horning, S. 2006. Dynamic Range of Mass 
Accuracy in LTQ Orbitrap Hybrid Mass Spectrometer. Journal of the American Society 
for Mass Spectrometry. 17: 977-982. 
 220.  Michalski, A., Damoc, E., Hauschild, J. P., Lange, O., Wieghaus, A., Makarov, A., 
Nagaraj, N., Cox, J., Mann, M., and Horning, S. 2011. Mass spectrometry-based 
proteomics using Q Exactive, a high-performance benchtop quadrupole Orbitrap mass 
spectrometer. Molecular & Cellular Proteomics. 10: 
 221.  Tolmachev, A. V., Robinson, E. W., Wu, S., Kang, H., Lourette, N. M., Ptía-Toli-
Ljiljana, and Smith, R. D. 2008. Trapped-ion cell with improved DC potential 
harmonicity for FT-ICR MS. Journal of the American Society for Mass Spectrometry. 19: 
586-597. 
 222.  Wishart, D. S. 2008. Quantitative metabolomics using NMR. TrAC Trends in Analytical 
Chemistry. 27: 228-237. 
 223.  Reo, N. V. 2002. NMR-based metabolomics. Drug and chemical toxicology. 25: 375-
382. 
 224.  Liu, Y., Patricelli, M. P., and Cravatt, B. F. 1999. Activity-based protein profiling: the 
serine hydrolases. Proceedings of the National Academy of Sciences. 96: 14694-14699. 
 
 
